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ABSTRACT 
Disease progression in Multiple Sclerosis (MS), an autoimmune disease of the CNS, is widely 
accepted to be due to persistent myelin loss (demyelination) coinciding with lost nerve cells and 
nerve fibres (neuroaxonal loss). Current treatments are immunomodulatory and do not address the 
neuroaxonal or demyelinating pathology of the disease. It is hypothesised that a lack of growth 
factors within the CNS may result in the failure of remyelination. Therefore, biologics such as 
recombinant therapeutic proteins used for gene therapy offer a promising therapeutic intervention 
to the progressive stages of the disease. However, due to the short half-lives of these therapeutics 
and their pleiotropic effects, there is cause for concern over their safety and efficacy. Using LAP 
technology (the fusion of the therapeutic protein with the latent associated peptide [LAP] of TGFβ), 
the half-life of the therapeutic protein can be increased and can be targeted to sites of inflammation 
and disease.  
This study aimed to investigate the potential neuroprotective, remyelinating and anti-inflammatory 
effects of latent versions of the growth factors erythropoietin (EPO), insulin-like growth factor 1 
(IGF1) and transforming growth factor beta (TGF) respectively. Firstly, using molecular cloning 
techniques, these growth factors were individually fused and linked to the LAP of TGF via a matrix 
metalloproteinase (MMP) cleavage site resulting in three latent growth factors. Secondly, these 
latent growth factors were shown to be expressed, and to be biologically active in vitro when 
released by MMP cleavage. Finally, syngeneic fibroblasts were engineered to express the latent 
growth factors. It was found that, in CREAE, the fibroblasts engineered to produce latent TGF 
significantly reduced the disease clinical score as compared to controls whilst latent EPO produced 
by transduced fibroblasts failed to exert a statistically significant effect on disease progression. 
Nonetheless, this study demonstrates the feasibility of the latency platform technology to generate 
latent therapeutics with the ability to act as an intervention to disease progression in MS.  
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 THE CNS IS ‘IMMUNOPRIVILEGED’ 
The term immunological privilege was originally coined in 1953 (Billingham and Boswell) but was 
observed as early on as 1921 by a group in Japan (Galea et al., 2007). These and other groups 
(Byrnes et al., 1996, Stevenson et al., 1997) observed the lack of a systemic immune response when 
antigens were transplanted and retained within the brain parenchyma. Initially, this ‘immunological 
privilege’ was thought to be absolute and pertain wholly to the CNS. However, today it is agreed to 
be confined to the CNS parenchyma (and not to the CNS in its entirety) as the immune response in 
the ventricles and meninges is similar to that of a peripheral response (i.e. it is not absolute), and is 
mostly a result of the specialisation of the afferent arm of the adaptive immune response (Carson et 
al., 2006, Galea et al., 2007). Adaptive privilege of the afferent arm involves the development of 
antigen presentation to naïve T cells in the form of antigen presenting cells (APCs) that result in T cell 
priming and activation, and the ensuing emigration of these APCs to the lymph nodes—an important 
process in the transport of antigen (Galea et al., 2007). The loss of immune privilege is the 
consequence of increased permeability of the endothelial blood brain barrier (BBB) junctions, a 
dilution in the immunosuppressive effects of the cellular microenvironment, and the local activation 
of APCs resulting in an up-regulation of immunostimulatory growth factors and chemokines. 
Immune Homeostasis 
The immune system protects its host from a diverse variety of foreign antigens and pathogens, as 
well as transformed cells that could prove to be harmful. The identification and removal of these 
antigens, is mediated by immune cells (such as T and B cells). It occurs through several processes 
such as immunological tolerance formation, lymphocyte recirculation and immune surveillance. 
Once a potential threat (such as an antigen or virus) is recognised, the immune system elicits a 
response that eliminates the threat.  
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There are two types of immune response that occur: innate and adaptive responses. Innate 
responses are fleeting singular events in which macrophages (Mø), natural killer cells (NK cells), 
complement proteins, mast cells, dendritic cells (DCs) and neutrophils respond immediately and 
directly to pathogen-specific compounds, ‘molecular signatures’ and types of biological molecules, 
and eradicate any foreign antigen or infection. Conversely, adaptive immunity is a slow but effective 
long term response to foreign antigens that involves the generation of clonal memory B- or T 
lymphocytes (B- or T cells respectively) that are antigen-specific and result in the formation of 
‘immune memory’. Lymphocytes are generated in the bone marrow of the primary or central 
lymphoid system before maturing in the thymus, generating T cells; or remain within the bone 
marrow, generating B-cells. Naïve lymphocytes recirculate through lymphoid organs such as lymph 
nodes where they encounter antigen, proliferate and become activated.  
Like T cells (discussed later on), B cell activation requres two signals: an initial signal provided by an 
APC and a second signal provided by helper T cell. The initial stages of activation occur when antigen 
binds to the B cell receptor (BCR), a transmembrane receptor consisting of α and β Ig signalling 
subunits and an antigen-binding membrane immunoglobulin subunit. Once bound to the BCR, the 
antigen is internalised, processed into antigenic peptides, and loaded onto MHC Class II molecules to 
be presented on the B cell surface. If the B cell fails to receive a second signal, it is either eliminated 
or becomes functionally inactivated. The second signal is given by effector helper T cells. In a primary 
antibody response, naive T cells are activated in a peripheral lymphoid organ by binding to a specific 
antigen loaded onto MHC Class II peptides displayed by an APC. Only once this particular 
antigen:MHC Class II complex is encountered again on a particular B cell, will it be able to fully 
activate that B cell. This binding send the second signal to activate the B cell and initiate its 
differentiation and proliferation into either antibody secreting plasma cells, or memory B cells that 
do not secrete antibody. Once the foreign antigen has been eradicated, the majority of the plasma 
cells die leaving behind mainly memory B cells. If these memory B cells encounter that specific 
antigen again, they respond more rapidly than naïve B cells. As memory B cells they are able to act 
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as direct APCs and display that particular antigen:MHC Class II complex and activate helper T cells, of 
which they are the subsequent targets of. This mutual reinforcement of helper T cell and B cell 
action leads to an immune response that is highly specific and very intense. Once fully activated, 
plasma B cells proliferate to produce antibodies that opsonize (identify) foreign antigen for 
destruction by cells such as Mø (Alberts et al., 2008). 
Additionally, antibodies can bind to viruses and neutralize them before they are able to infect a cell. 
Although B cells are very successful at defending against foreign antigen and viruses, their antibodies 
are only effective in the exterior environment of the cell or on its cell surface. Once a virus has 
gained entry into the cell, another type of defence is required i.e. T cells. T cells are similar to B cells 
in that they originate from the bone marrow, have a surface receptor (the remarkable T cell receptor 
(TCR)) and undergo clonal selection once activated. The TCR is made from small snippets of DNA that 
are randomly scrambled and rearranged yielding around 1010 variations of the TCR, enough 
variations to recognise practically anything including self-antigen, but the body has several crucial 
checkpoints to remove potentially devastating self-reactive T cells. T cells mature in the thymus and 
can only recognise antigen if it is properly presented by another cell, an antigen-presenting cell (APC) 
such as DCs, B cells, Mø or microglia. T cells are subdivided into CD8+ cytotoxic cells (also known as 
the killer T cells), or into CD4+ cells. CD8+ T cells detect virus infected T cells and initiate the cells 
apoptotic pathways. CD4+ T cells on the other hand, further differentiate into either T helper cells 
(Th cells) or into regulatory T cells (TReg).  
Th cells (such as Th1, Th2 and Th17 classes) are involved in directing and activating other immune 
cells, such as activating and (in some cases) determining B cell Ig class switching and in the activation 
of CD8+ T cells (Martin-Orozco et al., 2009, Mitsdoerffer et al., 2010). The Th phenotype is 
determined by the type of T-cell activating growth factors secreted by APCs, with IL-12 (along with T-
bet and IFN-γ) inducing Th1 cells; IL-4 and GATA-3 inducing Th2 T cells; and the retinoic acid 
receptor-related orphan nuclear receptor (RORγt) along with IL-17 inducing Th17 cells. Th1 T cells 
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are preferentially stimulated by Mø and DCs and secrete pro-inflammatory growth factors such as 
IFNγ, IL-2, TNFα and TNFβ, and promote cell mediated immunity, such as delayed hypersensitivity 
reactions (Murphy and Reiner, 2002, Fabry et al., 2003, Takatori et al., 2008). Conversely, Th2 cells 
are preferentially stimulated by B cells and secrete anti-inflammatory growth factors such as IL-4, IL-
5, IL-10, IL-13 and TGFβ, growth factors known to inhibit cell-mediated immunity, including 
responses to autoantigens which lead to immunopathology in MS. As discussed earlier, helper T cells 
need to bind to a particular antigen:MHC Class II complex displayed by B cells in order to activate 
them. Secreted signals from helper T cells can also help B cells to proliferate and differentiate, and 
as mentioned above, to switch Ig class. For example interleukin 4 (IL-4) enables the switch to IgE 
antibody production (Alberts et al., 2008).  
TRegs have a lower antigen activation threshold than conventional T cells, they supress the immune 
response by supressing the function of activated T cells, and mediate peripheral tolerance (Takatori 
et al., 2008, Stockis et al., 2009, Tran et al., 2009b), playing a crucial role in immune homeostasis and 
in the prevention of inflammatory disease (Gao et al., 2012). Natural TRegs (nTRegs) develop in the 
thymus during positive and negative selection, whereas inducible or adaptive TRegs (iTRegs) are non-
regulatory CD4+ FOXP3+ T cells that acquire their CD25 expression upon maturation in the periphery, 
possibly through interaction with latent TGFβ , cell–cell contact with neurons, or through unknown 
soluble factors secreted by astrocytes (Trajkovic et al., 2004, Takatori et al., 2008, Tran et al., 2009a). 
FOXP3 (forkhead box P3) a transcription factor is a master regulator for the development and the 
function of Treg cells, ultimately modulating the destiny of Tregs by possibly interacting with 
transcription factors which define the polarization of other Th subsets such as FOXP3 binding with 
the T-box transcription factor T-bet (Tbx21), to drive Th1 differentiation; or through reprogramming 
of Treg cells such as the generation of non-suppressive cells such as Th17 cells through induction by 
IL-6 to FOXP3+ T cells; or even the differentiation of Th2 cells through the loss of FOXP3 which may 
lead to the induction of IL-4 (Haiqi et al., 2011). Recently, studies have shown these FOXP3+ Treg cells 
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can be reprogrammed into proinflammtory cells for example in patients with relapsing remitting 
multiple sclerosis who exhibit Th1-like FOXP3+ cells(Dominguez-Villar et al., 2011).  
As mentioned before, T cells cannot directly interact with or recognise antigen. As in the case of 
antigen presentation on B cells, antigen must be presented in the form of antigen complexed to 
MHC molecules on APCs such as DCs, before it can interact with the TCR. The involvement of the 
glycoprotein co-receptors, CD4 and CD8, with the antigen: MHC complex allows for the activation of 
naïve T cells, and their subsequent differentiation and proliferation. CD8+ and CD4+ T cells recognise 
MHC Class I and Class II molecules respectively. Signalling from this trimolecular complex and in the 
presence of costimulatory molecules such as CD40L, CD2, CD28, and CTLA-4; integrins such as VLA-4; 
and certain adhesion molecules such as CD44, B7, ICAM-1, lymphocyte function-associated antigen 1 
(LFA-1) and LFA-3, and vascular cell adhesion molecule 1 (VCAM-1), activates the T cell. In the 
absence of costimulatory molecules the T cells fail to produce IL-2, do not proliferate, become 
anergic and fail to elicit an immune response to antigen. Only when fully activated, can they 
recognise any cells that present its specific antigen: MHC complex.  
The interaction between blood borne naïve T cells expressing homing receptors (such as CD62L) and 
cell adhesion molecules (such as CD54 or CD102) found on high endothelial venules (HEV), leads to 
tethering and rolling of the T cell along the endothelial wall. Once engaged, the chemokine receptor 
CCR7 binds the ligands CCL21 and/or CCL19 inducing a conformational change that promotes firm 
adhesion and transmigration of the naïve T cells into the lymph node. Lymphocytes are then able to 
leave the lymph node by either transcellular (piercing the cellular membrane) or by paracellular 
(migrating around the HEV cells) routes.  
The two types of memory T cells that arise from naïve T cells have distinct homing patterns and 
effector functions. Effector memory T cells (TEM) cells are a readily available pool of antigen-primed 
T cells lacking CCR7 and CD62L that act immediately after activation expressing growth factors such 
as IL-4, IL-5, IFN-γ and perforin (a cytolytic protein); whereas central memory T cells (TCM)  express 
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CCR7 and CD62L, are able to travel to lymphoid organs, can stimulate DCs when challenged and help 
B cells in generating new effector cells but lack immediate effector functions (Elgert, 2009). Memory 
T cells differentiate from naïve T cells in a stepwise manner in which effector differentiation—the 
proliferation and differentiation of antigen-activated T cells into effector T cells—is not, as originally 
thought, a prerequisite (Manjunath et al., 2001). 
Most mature T cells continuously circulate through the body via the lymphoid organs from blood to 
tissue into lymph and back to blood. This lymphocyte recirculation ensures the effective recognition 
of the vastly dynamic repertoire of foreign antigens at all the possible sites of infection. Tumour 
immunoediting (also known as immune surveillance (Dunn et al., 2002)) is the ability of the immune 
system to detect and eradicate cancerous and precancerous cells. It plays an important role in 
immune homeostasis and in the control of cancer. It is mediated by lymphocytes looking specifically 
for tumour antigens or molecules expressed on cancerous or pre-cancerous cells and involve three 
phases: elimination, equilibrium and escape. During the elimination phase, the immune system 
either totally eliminates all potential cancerous cells, or only partially eliminates them. If the latter is 
true, the immune system proceeds to exert selective pressure on the progression of the tumour cells 
by eliminating cells where possible, whilst the tumour cells themselves continue to accumulate 
further changes such as DNA mutations. Although this selective pressure is sufficient to keep the 
tumour from progressing rapidly, if the immune system continues to fail in eliminating the entire 
population of cancerous cells, tumour cells that are able to resist, avoid or suppress the immune 
systems antitumor response will proliferate and escape.  
The immune system is highly adept at initiating an immune response against pathogens. But in order 
to maintain the boundaries between antigens that are actually foreign and those that are self-
antigens, lymphocytes undergo positive and negative selection at critical checkpoints, allowing a cell 
to be ‘tolerant of self-antigens’. Tolerance to self-antigens is an essential feature of the immune 
system, as loss of tolerance results in the development of autoimmune diseases. Within T cell 
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development, tolerance to self-antigens is achieved through central (utilizing negative and positive 
selection) and peripheral tolerance (including immunological ignorance, deletion, inhibition and 
suppression).  
A critical checkpoint during thymic development of T cells occurs when the thymocytes are dubbed 
‘double positive’ (DP) for CD4CD8. Those thymocytes that exhibit weak interaction to self-MHC 
complexes, expressed by thymic cortical epithelial cells, are selected to differentiate further into 
single-positive (SP) thymocytes expressing either CD4 or CD8. These SP thymocytes then undergo 
negative selection (another critical checkpoint in maintaining immune homeostasis)—those 
thymocytes that exhibit strong self antigen:MHC complex interactions to antigen expressed by DC’s 
and thymic medullary epithelial cells, are made funtionally inactive or are deleted. Thymocytes that 
exhibit only intermediate reactivity mature in the thymus before exiting to the periphery (positive 
selection). The elimination of the majority of autoantigen i.e. pathogenic cells bearing high affinity 
for self-reactive TCRs, constitutes a major checkpoint in immune homeostasis called central 
tolerance. However, not all autoantigens are expressed in the thymus thus mechanisms are required 
in the periphery to maintain self-tolerance (Curiel, 2007, Kim and Rudensky, 2006).  
Autoreactive T cells circulating within the peripheral lymphoid tissues are observed within normal 
individuals without autoimmune attack and are maintained through a form of self-tolerance known 
as immunological ignorance. Several mechanisms can induce immunological ignorance: the antigen 
threshold may be too low to induce reactivity, the antigens may be physically separated from T cells 
(e.g. by the BBB) or antigens are presented in the absence of co-stimulatory molecules thus 
rendering them anergic. Peripheral tolerance through T cell deletion can occur through inadequate 
amounts of vital growth factors, or through T cell death mediated by Fas and its ligand—engagement 
of the Fas receptor induces apoptosis in Fas-positive cells. As T cells express both Fas and its ligand 
when activated, apoptosis can be induced if they engage. Full T cell activation can also be inhibited 
through the interaction of the transiently expressed adhesion receptor CTLA-4 (also known as 
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CD152) found on Th cells, and the adhesion molecules B7-1 (CD80) and B7-2 (CD86) found on APCs 
and B cells. Normally CD80 and CD86 interact with the T cell costimulatory molecule CD28, but CTLA-
4 has a higher affinity for these adhesion molecules and its interaction with B cells inhibits the full 
activation of T cells and renders them anergic.   
AUTOIMMUNITY 
Autoimmunity is an immune response to self-antigens. It arises from the breakdown of tolerance 
within the body through the triggering of receptors directly by self-antigen, through the breakdown 
of the BBB, or by virtue of cross reaction between a foreign and a self-antigen. Autoimmune diseases 
can be autoantibody mediated (such as in celiac disease), or T cell mediated (such as in rheumatoid 
arthritis (RA), insulin-dependent diabetes mellitus and Multiple Sclerosis (MS)). Autoaggressive T 
cells that have evaded tolerance and are pathogenic, participate in the development of autoimmune 
diseases. 
The Blood Brain Barrier 
The BBB is a physical barrier created by the close association of the cerebral endothelial cells (CEC) 
that form the capillaries in the brain, and the BBB interactions with pericytes, astrocytes, microglia 
and neurons make up the CNS microenvironment. The BBB is developed during foetal life and by 
birth is well formed. Under normal physiological conditions, the BBB maintains CNS integrity through 
the strict control of leukocyte entry, the exclusion of macromolecules such as pro-thrombin, albumin 
and plasminogen which could cause damage to the neural tissue, the regulatation of glutamate 
levels (a neuroexcitatory amino acid within the brain), the prevention of ‘cross-talk’ between 
neurotransmitter pools within the PNS and CNS, and the regulation of the ions K+, Ca2+ and Mg2+ 
through specific ion channels and transport systems, thus maintaining a microenvironment that is 
conducive to efficient synaptic signalling. The phenotype of the BBB is created by the endothelial 
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cells lining the microvasculature to maintain and regulate homeostasis of the brain and to prevent 
neural disruption by circulating toxins (Abbott, 2002). This phenotype is strictly regulated by the CNS 
microenvironment as ex vivo culture of these cells results in its loss until the addition of astrocytes or 
their incubation in astrocyte-conditioned medium (cited in Abbott et al., 2006).  
The BBB is both structurally and functionally supported by astrocytes, pericytes, microglia and nerve 
terminals through the release of soluble factors such as basic fibroblast growth factor (bFGF), 
vascular endothelial growth factor (VEGF), angiopoietin-1 and transforming growth factor 1β 
(TGFβ1). The CNS microenvironment also regulates the trafficking of leukocytes into the CNS across 
the BBB through the suppression of selectins and the secretion of bFGF and VEGF. bFGF tightens the 
adherens junctions (AJs) and tight junctions (TJs) and induces the expression of the multidrug 
resistance proteins involved in ABC transporters. VEGF increases BBB permeability by lowering the 
expression of occludin and VE-cadherin. Both are produced by and released from pericytes (Rucker 
et al., 2000). 
The BBB is formed during foetal life and maintained in adult life by the interactions of several cell 
types and the expression of junction proteins and transporter proteins. The junctional complexes 
between the endothelial cells comprise AJs and TJs. AJs span the intercellular space with cadherins 
that are attached to the scaffolding proteins α, β and γ catenin. AJs are essential for the formation of 
TJs and act as structural support for the tissue. TJs are sites where the cellular membranes of 
endothelial cells come into close association with one another. TJs are responsible for the severe 
restriction of the paracellular diffusional pathway that would otherwise allow for the entry of ions 
and other molecules, as well as for blocking the penetration of macromolecules into the brain. The 
TJ complex spans the intercellular cleft and consists of occludin and the claudins 3 and 5 that are 
linked to the scaffolding proteins ZO-1, ZO-2 and ZO-3, as well as cingulin and junctional adhesion 
molecules (JAMs). The scaffolding proteins regulate the effectiveness of TJs by linking the occludin 
and the claudins of the separate tight junctional complexes via cingulin and the actin cytoskeleton. 
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TJs also generate a high in vivo electrical resistance to the BBB (~ 1800 Ω/cm2) (Butt et al., 1990) 
resulting in a low conductance of the barrier, thus reducing the movement of ions such as K+, Ca2+ 
and Mg2+. Additionally, the TJs function to segregate the transport proteins in the membranes from 
the lipid rafts thus preventing them from moving freely and therefore maintain barrier polarity. The 
BBB is regulated by changes in the TJs or by changes in the expression and activity of transporter 
proteins, thus matching the activities of the BBB with the requirements of the brain. 
The BBB does not exclude all macromolecules from entering the brain as many essential amino acids 
and nutrients are needed for neural metabolism, therefore several transporter systems expressed by 
the endothelial cells are available to these molecules. They include solute carriers (SLCs), ATP-
binding cassette (ABC) transcytosis transporters (such as the efflux transporters P-glycoprotein (Pgp) 
and multidrug resistance-associated proteins (MRPs)), and transcytosis. As the TJs confer the 
properties of a continuous cell membrane on the BBB, the entry and exit of polar molecules is 
dependent on its lipophilicity (the molecules ability to move through the lipid rafts), and the 
orientation of the transport proteins in the luminal or abluminal membranes of the endothelial cell 
allows for preferential transportation of these substrates from blood to brain, or from brain to 
blood. Similarly, SLCs such as GLUT1 for glucose or MCT8 for thyroid hormone allow the endothelial 
cells to mediate the flux of nutrients into or away from the brain. ABC transporters function mainly 
as efflux transporters of potentially neurotoxic endogenous or xenobiotic molecules and are thus 
neuroprotective and detoxifying. Molecules that are greater than 450 Daltons are generally 
restricted from entering the brain by the BBB. Large macromolecules such as glycosylated proteins 
and cationic molecules are transported across the BBB by endocytotic mechanisms such as receptor-
mediated transcytosis (RMT) and adsorptive-mediated transport (AMT) respectively. During RMT, 
the binding of ligands to specific receptors initialises their endocytosis where they are internalised, 
and then exocytosed on the opposite pole of the cell. This transcytosis of intact peptides and 
macromolecules is achieved by avoiding the degradative lysosomal compartment, and as this type of 
routing does not occur in peripheral endothelial cells, it is considered to be a specialised feature of 
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the BBB. During AMT, a molecule displaying excess positive charges (cationic) interacts with a cell 
surface binding site, in turn inducing endocytosis and subsequent transcytosis. 
Wnt signalling is a very important signalling pathway not only in the development and maturation of 
the BBB, but also in its maintenance. Wnt proteins are glycosylated proteins that bind to the frizzled 
family of transmembrane proteins as well as other heterologous receptors such as PDGFRα (Fancy et 
al., 2009). The Wnt signal is transduced to the cytoplasmic protein ‘dishevelled’ following receptor 
binding. Dishevelled inhibits the activity of glycogen synthase kinase-3β (GSK-3β), a serine-threonine 
kinase involved in neural cell development. In the absence of Wnt signalling, GSK-3β phosphorylates 
β-catenin (a protein involved in the makeup of AJs as well as an anchor for the actin cytoskeleton) 
resulting in its degradation. β-catenin regulates Wnt gene transcription by translocating to the 
nucleus and associating with the T cell factor (TCF) and lymphoid enhancer factor (LEF) family of 
transcription factors, which in turn bind to enhancers of T cell specific genes. In a normal 
noninflammed barrier, Wnt signalling down-regulates the expression of plasmalemma vesicle 
associated protein-1 (Plvap), a marker of leaky brain vessels, whilst under pathological conditions it 
is up-regulated by BBB microvessels. An increase in Wnt signalling results in an increase in 
expression of the junctional protein claudin-3 in a β-catenin dependent manner. A loss of β-catenin 
results in an increase in paracellular permeability and a deficit in cell-cell contact allowing the entry 
of activated lymphocytes into the CNS, an intangible beginning to MS.  
The breakdown of the BBB is a major hallmark of MS. Indeed, one of the earliest events in the 
formation of a MS lesion, is the deposition of the serum protein fibrinogen through the rupture of 
the BBB. Fibronogen is a serum glycoprotein involved in blood clot formation, and has been shown 
to be a key regulator of inflammation (Davalos and Akassoglou, 2012). Interestingly it is also able to 
activate microglia, even without activated T cells. Additionally, the ECM proteins fibronectin and 
vitronectin are found within MS lesions, proteins that have similar functions to fibrinogen i.e. they 
bind to integrins and are able to induce the activation and expression of microglia and MMP-9 
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(Watzlawik et al., 2010). The disruption of the BBB also allows for the activation of OPCs and 
therefore the facilitation of remyelination as several factors have been shown an increase in 
expression following BBB breakdown i.e. NG2, the transcription factors Olig2 and Nkx2.2, and 
chondroitin sulfate proteoglycans, factors involved in oligodengrogenesis (Watzlawik et al., 2010).   
MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is an autoimmune, demyelinating disease characterised by the breakdown of 
the BBB, the infiltration and accumulation of inflammatory cells in the CNS and the destruction of 
the myelin sheath, a process known as demyelination. The areas of destruction are termed lesions 
and occur most commonly in the periventricular white matter (such as the cerebellum, the brain 
stem, the spinal cord and the optic nerves) and it is the location of these lesions that dictates the 
symptoms that a patient experiences. The aetiology of the disease is, as yet, unclear.  
History 
Arguably, the first documented case of MS was of Saint Lidwina of Schiedam (1380–1433) who 
presented symptoms consistent with MS following an ice-skating fall in 1396. The first illustrations of 
MS plaques were documented by Robert Carswell (1793–1857) in 1838 in his collection Pathological 
Anatomy: Illustrations of the Elementary Forms of Disease. The term “sclérose en plaque 
disséminée” was coined by the physician-scientist Edmé Vulpian (1826–1887) in 1866. He later 
worked with the neurologist Jean-Martin Charcot (1825–1893) who, in 1868, was the first to 
systematically describe MS from his observations on the deceased. Jean-Martin Charcot also 
provided the first evidence of CNS damage and identified features for diagnosis and pathology. He 
also outlined the disease progression and noted the destruction of the myelin sheaths and the 
preservation of the axon (Herndon, 2003, Iezzoni, 2010).  
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Epidemiology 
MS is the most common neurological condition that affects young adults today. In the general UK 
population, MS affects more females than males (2:1), has an incidence of seven per 100 000 every 
year, a prevalence of 83–120 per 100 000 (Compston and Coles, 2002, Pugliatti et al., 2006), and it 
presents between the ages 15 and 60 years.  
There are four clinical stages of MS defined by their clinical course and not on known differences in 
genetics or pathogenesis (Figure 1.1, Rudick, 2003). The most commonly observed stage, relapsing-
remitting MS (RRMS), affects around 85% of patients confirmed with MS and is characterised by 
distinct attacks or relapses that are followed by periods of remission or improvement. Primary-
progressive MS (PPMS), affecting around 10% of patients confirmed with MS, shows deterioration 
from the start with no obvious clinical relapses or periods of improvement. Secondary-progressive 
MS (SPMS), to which the majority of RRMS patients progress, is characterised by a slow and 
gradually progressive deterioration that accounts for most of the disease impact. Finally, the 
relatively rare progressive-relapsing MS (PRMS) falls within PPMS in that some relapses may occur, 
but do little for the long term outcome (Keegan and Noseworthy, 2002).  
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Figure 1.1. The stages of MS.  
The clinical course of MS is indicated with a black line with stepwise increases in disability in early disease caused by 
relapses (RRMS) and, later, by gradual progression of disability in SPMS and from disease onset in PPMS. Early in the 
disease, peripherally-initiated activation and infiltration of lymphocytes drives the inflammatory processes that manifest 
clinical relapses and remissions (pink shading). As the disease progresses, the accumulation of disability becomes apparent 
in the form of continual disability with no remissions and degeneration and/or CNS inflammation predominates (blue 
shading). RRMS=relapsing-remitting multiple sclerosis, SPMN=secondary-progressive multiple sclerosis, PPMS=primary-
progressive multiple sclerosis.  
Diagnosis of MS 
The current acceptable diagnostic criteria for MS are the McDonald criteria (McDonald et al., 2001). 
It essentially dictates that an individual must have a minimum of two or more neurological attacks, 
which correspond to two or more different sites of lesions within the CNS, thus providing evidence 
of dissemination in both time and space. Supporting clinical evidence in the absence of this 
dissemination in time and space can be provided by radiological and laboratory investigations such 
as magnetic resonance imaging and the analysis of the cerebrospinal fluid (CSF). The CSF is tested for 
increased IgG antibody production and oligoclonal banding (as compared to serum controls) 
(Anderson et al., 1992) as studies have shown that in over 90% of clinically definite MS patients, 
elevated levels of the CSF IgG antibody and the appearance of discreet oligoclonal bands have been 
found.  
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Possible Causes of MS? 
MS is the result of complex interactions between genetics and environmental factors but its 
aetiology is, as yet, unknown (Compston and Coles, 2002, Ascherio and Munger, 2007a, Ascherio and 
Munger, 2007b). The support for a genetic component is significant. Twin studies have shown an 
increased risk of 30% for identical twins but only 4% for fraternal twins. First degree siblings show an 
increased risk of 3% which is significant when compared to the risk of 0.1% in the general population 
(Sadovnick and Ebers, 1993). The likely genes involved in contributing to the development of MS 
have been narrowed down to the DR15 and DQ6 markers of the MHC gene complex, with a 
protective effect conferred by the HLA-C5 allele (reviewed in Compston and Coles, 2008).  
However, the distribution of MS cannot be explained by population genetics alone as there is a 
distinctive geographic distribution of MS. MS occurs mainly in individuals of north European ancestry 
where persons of Caucasian decent are twice as likely to develop the disease. Interestingly, 
migration of large numbers of people also alters the distribution of MS. Migration from a high risk 
region to a low risk region during childhood is associated with a reduced risk, and vice versa. 
Conversely, if migration occurs after childhood, the risk of the previous region is retained (reviewed 
by Ebers and Sadovnick, 1993). However, conflicting data has been recently published stating that 
although a geographical gradient of incidence does exist for Australia and New Zealand, it doesn’t 
exist for Europe and North America (Koch-Henriksen and Sorensen, 2010).  
Environmental components to MS are “strongly presumed but not yet proven” and remain 
enigmatic (Iezzoni, 2010). During the 1980’s, it was discovered that lymphocytes in MS patients 
produced subnormal amounts of the warning proteins IFN-α and IFN-β, which are usually secreted 
by cells that have encountered viruses, leading researchers to investigate the involvement of viruses 
as acute viral infection has been shown to result in an impairment in the lymphocyte response to 
viral antigens (Haahr et al., 1983). Since then many viruses have been implicated in the development 
of MS and several including measles, mumps, rubella, rabies, herpes simplex virus, parainfluenza 1 
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and human retrovirus (Iezzoni, 2010) have been investigated to no avail. A possible exception is that 
of Epstein Barr Virus which might be involved in early MS pathogenesis (Salvetti et al., 2009).  
Other factors and theories have been thought to influence the development of MS including sunlight 
levels (as UV radiation has demonstrated a suppressive effect), the effect vitamin D has on 
regulatory T cells, and the lack of vitamin D correlating to the gradient of incidence observed in MS 
cases (reviewed in Smolders et al., 2008).  
Whatever the initial cause may be, it is the migration of activated T cells across an impaired BBB that 
initiates the pathway of autoimmune neuroinflammation.  
PATHWAY OF AUTOIMMUNE NEUROINFLAMMATION  
The pathway of autoimmune T cell neuroinflammation is thought to occur in two phases (Flugel et 
al., 2001, Platten and Steinman, 2005): the first phase occurs with the priming and activation of 
naïve CD4+ T cells by DCs in the periphery; the second involves the transendothelial migration and 
entry of these activated CD4+ T cells into the CNS through a process called the leukocyte adhesion 
cascade, and their subsequent reactivation by activated microglia (Figure 1.2). The leukocyte 
adhesion cascade comprises several distinct stages: tethering and rolling, arrest, intravascular 
crawling, and paracellular and transcellular transmigration that allows the activated lymphocytes to 
gain entry across the BBB.  
The tethering and rolling of leukocytes along the blood vessel wall can be mediated through either 
selectins (a family of cell adhesion molecules) or through integrins. Leukocytes interact with E-, L-, 
and P-selectins (expressed by endothelial, leukocyte, and platelet cells respectively) via the cell 
surface ligands P-selectin glycoprotein ligand 1 (PSGL1) or other glycosylated ligands such as CD44 
and E-selectin ligand (ESL1). However, CEC do not express either E- or P-selectin, neither do they 
store P- nor E-selectin in their Weibel-Palade bodies (cell-specific storage granules). Presumably, 
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leukocyte tethering and rolling in CECs occurs through the interactions of the leukocyte integrins 
α4β1 (also known as very late antigen-4 or VLA-4) and α4β7, and the endothelial ligands VCAM-1 and 
mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) respectively (Baron et al., 1993, 
Engelhardt et al., 1997).  
During inflammation, endothelial cells are induced to express chemokine receptors (such as CCR3 
and CXCR4) and chemoattractants (such as CCL5, CXCL4 and CXCL5) on their luminal surface by 
activated platelets and Mø. Arrest is rapidly triggered by these chemokines and chemoattractants 
and is mediated through leukocyte rolling. Following arrest, the final process of transendothelial 
migration involves intravascular crawling and either paracellular or transcellular migration into 
inflamed tissue.  
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Figure 1.2: Diagrammatic representation of the pathway of autoimmune inflammation in MS.  
The pathway of autoimmune inflammation is thought to occur in two stages: a priming stage in which antigen presenting cells (APC) activate naïve CD4+ T cells via the T cell receptor (TCR) and 
through the expression of T cell activating growth factors such as IL-12. The activated T cells, in turn, induce the endothelial cells of the blood brain barrier (BBB) to express cell adhesion 
molecules, such as ICAM1, VCAM1, PECAM1, and MAdCAM-1. The migration of the activated T cell through the BBB involves a cascade of tethering, crawling, rolling and transmigration across 
or through the cell using cell-cell interactions such as α4β7 and Very-late antigen 4 (VLA-4; also known as α7β1) with their respective ligands MAdCAM1 and VCAM1 on the endothelial cells. 
Additionally, activated macrophages induce endothelial cells to express chemokine receptors (such as CCR3 and CXCR4) and chemoattractants (such as CCL5, CXCL4 and CXCL5) which trigger 
leukocyte rolling. Once these interactions occur, the leukocytes form projections that allow it entry through the BBB and into the CNS. Once they have entered the CNS, they are reactivated 
resulting in a phenotypic change and an upregulation of receptors and markers such as OX-40, and CD25, as well as the expression of pro-inflammatory molecules such as IFNγ, TNFα and IL-2. 
The exposure of endothelial cells to IFNγ and TNFα results in their release of nitric oxide (NO) and other oxygen radicals. This leads to an overall decrease in BBB integrity. During the initial 
wave of infiltrating leukocytes, macrophages (Mø) down regulate T cell growth factor production through its expression of the B7-H1 protein whose interaction with T cell programmed death 
proteins results in either immunological ignorance or anergy. However, following a second wave of infiltrating leukocytes, these Mø become activated and act as APCs expressing the T cell 
activating growth factors IL-12, IL-23 and NO thus propagating the autoimmune reaction. 
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Role of adaptive immunity 
Prior to crossing the BBB, the activated T cells undergo alterations with a down-regulation in the 
activation markers IL-2 receptor α-chain (CD25) and OX-40. The cells then acquire surface bound 
MHC class II antigens and up-regulate the chemokine receptors CCR-1, CCR-2b, CCR-3, CCR5 and 
CXCR4 expressed on various cell types (such as endothelial, Mø, microglia, astrocytes, B cells, T cells 
and DCs) with a resulting phenotype called ‘migratory membrane phenotype’. This increase in 
chemokines results in the alteration of selectin-mediated leukocyte interactions with endothelial 
cells to one that is integrin-mediated with high affinity that leads to transcellular migration of 
monocytes, lymphocytes and Mø (Ley et al., 2007).  
Once in the CNS, the majority of these CD4+ T cells are reactivated as suggested by the upregulation 
of OX-40, CD25 and the pro-inflammatory growth factors IFNγ, TNFα, and IL-2, and a down-
regulation in the TCR/CD3 complex. Exposure of endothelial cells and astrocytes to IFNγ and TNFα 
respectively results in a decrease in occludin expression and its dissociation from the Z0-1 complex. 
This dissociation through increased tyrosine phosphorylation, the phosphorylation of the junction-
associated protein vasodilator-stimulated phosphoprotein (VASP) and of VE-cadherin through 
induction of nitric oxide (NO) by TNFα, all result in a decrease in BBB integrity by increasing 
endothelial permeability. 
Microglia are the resident Mø of the brain parenchyma and during the initial wave of T cell 
infiltration through the BBB, they negatively regulate the T cell growth factor production. They do 
this by expressing B7-H1 (a homologue of the co-stimulatory protein B7 found on activated APCs), 
which interacts with the T cell programmed death proteins, resulting in either immunological 
ignorance or anergy. During the autocrine feedback loop created, the microglial cells themselves 
become activated and act as APCs during the second wave of infiltrating T cells thus propagating the 
autoimmune response (Duncan and Miller, 2011). Antigen-presentation on microglia is a multistep 
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activation process that involves stimulation through growth factors GM-CSF and IFN-γ and cognate 
signalling of B7/CD28 and CD40L/CD40 ligand interactions (Matyszak et al., 1999). These activated 
microglia release T cell activating growth factors such as IL-12, IL-23 and toxic mediators such as NO 
and oxygen radicles (Platten and Steinman, 2005), thus playing an important role in maintaining a 
pro-inflammatory environment, both through IFNγ secretion and T cell proliferation (via IL-23) and 
Th1 induction. Therefore any tissue damage inflicted by the immune response within the CNS may 
be as a result of the second wave of infiltrating lymphocytes directed against self-antigens.  
B cells on the other hand do not require entry across the BBB to exert a pathological response. They 
secrete destructive antibodies that can diffuse across the BBB and induce damage through terminal 
membrane attack complex formation, a product that (through complement activation) forms 
transmembrane channels that cause disruption of the cell membrane and cell lysis. As mentioned 
previously, the apperance of oligoclonal bands in the CSF of a patient is a diagnostic hallmark of MS 
and occurs in over 95% of patients. During late progression of MS, lymphoid-like structures (also 
referred to as ectopic lymphoid follicles) have been identified that contain B cells and plasma cells 
capable of expansion and maturation and possibly the source of the increased IgG and oligoclonal 
bands (Serafini et al., 2004).  
PATHOLOGY OF MS 
The pathology of MS involves both inflammation and demyelination with associated axonal loss, 
which results in plaque scarring or lesions. Archetypical lesions (active, chronic active and 
inactive/chronic inactive lesions) are sharply outlined grey and translucent areas scattered 
throughout the white and grey matter and are the most characteristic hallmarks of MS. They are 
defined by inflammatory cell infiltration, a level of demyelination and oligodendrocyte (OL) loss, 
microglial/macrophage activation and astrocyte scarring (Yuan et al., 2008). As discussed earlier, 
perivascular monocytes secrete growth factors and chemokines that alter adhesion molecule 
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function leading to the attraction and infiltration of non-specific and myelin-specific immune cells 
such as activated T cells. This process of inflammation initiates the demyelinating process in the 
newly developed inflammatory lesion (Arredondo, 2003).  
Within an initial active lesion, a solid mass of foamy Mø secreting toxic mediators such as reactive 
oxygen species (ROS), NO, glutamate, TNFα and MMPs (Anthony et al., 1998, Perry and Anthony, 
1999, Stuckey et al., 2005), is observed with infiltrating leukocytes, activated astrocytes and small 
numbers of OLs. This lesion progresses to a chronic active lesion that develops outwards as the 
myelin in the centre becomes progressively degraded and phagocytosed as demonstrated by the rim 
of Mø containing the lipid debris of the myelin sheath, such as myelin basic protein (MBP). Finally, 
the lesion dies out leaving a hypocellular scar-like lesion known as an inactive or chronic lesion in 
which no demyelination occurs but may contain some remnant Mø (Bruck et al., 1995).  
The spontaneous remyelination of axons within a lesion does occur in the RRMS but appears to fail 
within progressive stages of the disease. Remyelinating lesions are identified by their thin myelin 
sheaths and pronounced infiltration of Mø and lymphocytes. In late remyelinating lesions, only a 
small degree of inflammation is observed with marked astrocyte proliferation and gliosis (Bruck et 
al., 1995). The normal appearing white matter (NAWM) appears normal through light microscopy 
with no visible demyelination or phagocytosis. However, although there appears to be no 
demyelinating event occurring, axonal degradation and loss have been observed in early lesions 
(Trapp et al., 1998, Bitsch et al., 2000).  
Additionally, a preactive lesion has been defined (De Groot et al., 2001). Preactive lesions are round 
or oval regions that are demarcated by the clustering of activated microglia/macrophages (Maeda 
and Sobel, 1996). These activated microglia/Mø express increased levels of the human leukocyte 
antigen-DR (HLA-DR), CD68 and the benzodiazepine receptor. These lesions lack any detectable 
demyelination, leukocyte infiltration, gliosis or hypertrophic astrocytes, but occasionally display a 
small number of CD45+ cells within the perivascular space. Although they do not display any inciting 
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agents such as viral or bacterial, their vicinity to activated OLs suggests an unknown soluble factor 
that mediates the communication between these OLs and activated microglia. Activated 
microglia/Mø show increased expression of the small heat shock protein αβ-crystallin, a protein that 
is secreted into the CSF and its accumulation is linked to the activation of OLs in these preactive 
lesions (van Noort et al., 2010). Most notably the expression of αβ-crystallin is induced by 
antibodies, specifically myelin surface protein antibodies (Duvanel et al., 2004), thus linking the 
abundance of intrathecal antibodies observed in MS and these preactive lesions. Additionally, the 
number of preactive lesions observed is significantly more than the number of full blown active 
lesions that occur later in those same regions. This suggests that some intrinsic regulation allows the 
lesion to resolve without any subsequent damage (van der Valk and Amor, 2009).  
The inflammatory component of MS:  immune-mediated demyelination. 
The immunopathology of MS is not wholly understood but is generally regarded to be the initial 
penetration of the CNS by activated immune cells (such as CD4+ and CD8+ T cells, B cells and plasma 
cells, monocytes and Mø expressing MHC Class II (Bitsch et al., 2000)) that results in inflammatory 
destruction followed by demyelination. The exact order of events is as yet unclear, however recent 
studies have demonstrated axonal degradation early on in the disease in the absence of 
inflammation and demyelination, causing researchers to look more closely at the interactions 
between cellular and molecular processes (Trapp et al., 1998, Bitsch et al., 2000, Herz et al., 2010, 
Tallantyre et al., 2010).   
In EAE (experimental autoimmune encephalomyelitis, the animal model for MS) the spatial 
distribution of a lesion and its immune cell profile can differ depending on the antigen used to 
induce the disease. For example, the immunisation of rats with the myelin-specific antigen MOG 
(myelin oligodendrocyte glycoprotein) incurs lesion damage in the cerebellar white matter, whereas 
astroglial antigens (such as s100β and glial fibrillary acidic protein) elicit severe inflammation in the 
grey matter (Huizinga et al., 2008).  Immunisation of Biozzi ABH mice with the neurofilament light 
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(NF-L) protein induces symptoms of MS such as spastic paresis and paralysis, presumably due to 
axonal autoimmunity (Huizinga et al., 2008). Spinal cord lesions taken from these mice were 
compared with the spinal cord lesions taken from MOG-immunised Biozzi ABH mice. The lesions 
from NF-L-immunised mice had increased numbers of macrophages in the thoracic level compared 
to MOG-immunised mice. MOG-immunised mice had increased levels of T and B cells in the 
meninges compared to NF-L-immunised mice with similar levels in the parenchyma.  Activated 
endothelial cells, glial cells and occasionally astrocytes also play important roles in mediating this 
inflammatory event. The subsequent demyelination of neurons is driven by Mø that leads to the 
eventual destruction and loss of OLs.  
The oligodendrocyte-neuron unit 
The cytoarchitecture of the CNS is maintained by astrocytes and OLs that support the neural axon 
both structurally and functionally. OLs are important for several reasons: (1) they support neurons 
within the CNS through the induction of sodium channel clusters required for efficient saltatory 
conduction, a highly efficient method of signal transmission (Kaplan et al., 1997); (2) they increase 
axonal stability, and induce the accumulation and phosphorylation of neurofilaments within the 
axon (Sanchez et al., 1996); and (3) they myelinate axons by wrapping their cytoplasmic processes 
around the axon generating myelin sheaths.  
Oligodendrogenesis 
Oligodendrocyte precursor cells (OPCs) arise from multipotent neuronal stem and progenitor cells 
(MNSC) in the subventricular zones of the embryonic neural tube and from progenitor cells in the 
dorsal spinal cord and hindbrain (Miller, 1996, Vallstedt et al., 2005). OPCs migrate to various 
regions of the brain prior to proliferating and differentiating into neurons, astrocytes or OLs (McKay, 
1997, Temple, 2001). OPCs are morphologically bipolar with short processes and have the ability to 
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proliferate and migrate, whereas OLs are multipolar with long extended processes, they do not 
proliferate and have very little or no migratory abilities (Stangel and Hartung, 2002).  
OPCs proliferate mainly in response to mitogens including platelet-derived growth factor (PDGF) and 
bFGF (Bogler et al., 1990) expressed by astrocytes. Removal of PDGF results in early differentiation 
of OLs whereas overexpression results in a transient increase in OPCs. These precocious and 
excessive cells are later rectified by normal developmental processes such as programmed cell death 
and/or cell cycle control by p27 (Richardson et al., 1988, Calver et al., 1998) resulting in a ‘steady 
state’ of OPCs differentiating into OLs (Barres et al., 1992, Calver et al., 1998, Chen et al., 2009). 
However, the signals involved in OL differentiation and myelin formation are not wholly understood. 
OPC differentiation 
Only once all neuronal components of the developing CNS are in place, and when a critical threshold 
of OPCs have been recruited or reached, can the stages of OL differentiation begin. The different 
stages of development within the OPC lineage are governed by local trophic factors and feedback 
cues expressed by both OPCs and mature, myelinating OLs (Figure 1.3) (Zhang and Miller, 1996, 
Calver et al., 1998, Chen et al., 2009, Yang et al., 2011).  
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Figure 1.3. Transcriptional regulation of OPC development and differentiation into mature myelinating 
oligodendrocytes.  
Several transcription factors including Nkx6.1/6.2 and Olig2 in response to sonic hedgehog homolog (Shh) (reviewed in 
Richardson et al., 2006, Merchan et al., 2007) are involved in the commitment of MNSC to an OL lineage with Olig2 being 
essential. Once the lineage has been committed to develop into OLs, the expression of Sox5, Sox6 and the basic helix-loop-
helix inhibitory proteins Hes5, ID2 and ID4 (Wang et al., 2001), and the Olig1 regulated G protein-coupled receptor 17 
(GPR17) (Chen et al., 2009) maintain the level of OPCs and inhibit their differentiation into OLs (Emery, 2010). During early 
lineage stages the transcription factors Hes5, Sox5 and Sox6, as well as the DNA binding inhibitory proteins Id2 and Id4 are 
expressed, but when signaled to undergo differentiation, the transcription activator Tcf4 associtaes with the Wnt/β-
catenin pathway to target and inhibit Id2 and Id4. However, when Tcf4 associates with members of the Groucho/Tle 
family, it acts as a transcriptional repressor.Nkx2.2, Olig 1 and Sox10 function only as mediators in OPC differentiation and 
maturation but not on the expression of the myelin genes required for myelination. The maturation of OPCs and the 
expression of the myelin genes is driven by the transcriptional factor, MRF. During the initial differentiation stage, Nkx6.2 is 
upregulated, followed by down-regulation during the intermediatary stages, with further upregulation (for the 
development of the paranodes between the myelin sheaths) during the final ‘fine-tuning’ stage of OL maturation. 
Additionally, although myelination is inhibited by GPR17 and polysialylated-neural cell adhesion molecule (PSA-NCAM), it is 
also stimulated by the SRC family tyrosine kinase Fyn that is activated and regulated by the receptor type protein-tyrosine 
phosphatase alpha (PTPα). Furthermore, GPR17 is inhibited by the expression of Olig1 whose expression is required by the 
basic helix loop helix protein Ascl1/Mash1 for the generation of mature OL and for myelination. Adapted from Emery, 2010  
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The timing of development of myelinating OLs depends on the intrinsic and extrinsic environment, 
the cellular timers and on cell–cell interactions. Similar to myoblasts and erythroid precursor cells, 
OL lineage cells appear to utilise an intrinsic timing mechanism that requires both mitogens (such as 
PDGF) and lipid-soluble mediators (such as retinoic acid, dexamethasone or thyroid hormone (TH)) 
to operate and differentiate normally (Barres et al., 1994). This timing mechanism consists of two 
components: a counting component that is involved in OPC proliferation and operates 
independently of lipid-soluble mediators; and an effector component involved in OL differentiation 
that is dependent on the hydrophobic signals. It appears to count by measuring time and not cell 
cycle divisions (Gao et al., 1997), possibly through positive regulators of the cell cycle (such as the 
transcriptional activator AP-1) and by an accumulation of the cell-cycle inhibitor p27. The gradual 
inhibition of AP-1 by an increasing accumulation of thyroid hormone and p27 act concomitantly to 
slow the cell cycle enabling the cell to withdraw from it and to differentiate into myelinating OLs. 
The heterchronic genes (genes that regulate the timing of developmental events) responsible for the 
timing of OLs are as yet, unknown.  
The development of myelinating OLs also depends on cell-cell interactions. Notch1 receptors, part of 
a signalling family that regulates the interactions between adjacent cells, are expressed on OPCs and 
interact with the ligand Jagged1 expressed, in large amounts, by OLs. When a threshold of OLs is 
reached, Jagged1/Notch1 interactions signal to create feedback loops that restrict OPCs from 
differentiating (Wang et al., 1998). OPCs also express small amounts of this ligand, which may be 
autocrine, generating a small population of surplus OPCs that can be recruited at a later time if 
needed such as restoring damaged cells following injury in MS, or following demyelination and OL 
depletion. Interestingly, Notch1 activation has the ability to induce continual proliferation of OPCs 
when mitogens are withdrawn suggesting that OPC proliferation operates separately to the counting 
component of the intrinsic timing mechanism.  
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The specification and maintenance of OPCs is under transcriptional control. Several transcription 
factors including Nkx6.1/6.2 and Olig2 in response to sonic hedgehog homolog (Shh) (reviewed in 
Richardson et al., 2006, Merchan et al., 2007) are involved in the commitment of MNSC to an OL 
lineage with Olig2 being essential. Once the lineage has been committed to develop into OLs, the 
expression of Sox5, Sox6 and the basic helix-loop-helix inhibitory proteins Hes5, Id2 and Id4 (Wang 
et al., 2001), and the Olig1 regulated G protein-coupled receptor 17 (GPR17) (Chen et al., 2009) 
maintain the level of OPCs and inhibit their differentiation into OLs (Figure 1.3; Emery, 2010).  
The transcription factor Tcf4 (also known as Tcf7L2) acts as a transcriptional activator in OPC 
maintenance when associated with Wnt/β-catenin signalling that paradoxically targets the DNA-
binding inhibitors Id2 and Id4; and as a transcriptional repressor when associated with members of 
the Groucho/Tle family (Figure 1.3). It is an effector molecule involved in the intrinsic timing 
mechanism of the cell and is required for cell cycle exit and therefore, the onset of OL 
differentiation. It is found in MS lesions but not in normal white matter suggesting a role in 
remyelination (Fancy et al., 2009) . The transcription factors Nkx2.2, Sox10 and Olig1 are expressed 
early on in the development of the lineage but are only required for OL differentiation and 
maturation, and the expression of myelin genes. The myelin gene regulatory factor (MRF) 
presumably acts directly on Sox10 and Olig1 to drive OL maturation and up-regulate the majority of 
the myelin genes including myelin-basic protein (MBP) and proteolipid protein (PLP). During the late 
stages of OL differentiation, the basic helix-loop-helix proteins Ascl1/Mash1 are required by Olig1 for 
the generation of myelinating OLs and ZFP191 is essential for myelination although, the mechanism 
of ZFP191 in this process is not yet clear. Olig1 inhibits the actions of the differentiation-inhibitory 
molecule GPR17 by binding directly to its promoter thus promoting OL maturation and myelination 
(Chen et al., 2009). Myelination by OLs is inhibited by GPR17 and the polysialylated-neural cell 
adhesion molecule (PSA-NCAM) (Charles et al., 2000, Charles et al., 2002) but stimulated by Fyn, an 
SRC family tyrosine kinase, that is activated and regulated by the receptor type protein-tyrosine 
phosphatase alpha (PTPα) and is essential in OL differentiation, morphology and myelination 
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(Sperber and McMorris, 2001, Umemori et al., 1994, Wang et al., 2009). The correct assembly of 
myelin requires the myelin proteins MBP and PLP for the compaction of the sheaths, the protein 
MAG for axon-glia recognition (Stangel and Hartung, 2002) PTPα may also regulate survival cues, 
proliferation cues or even the cells withdrawal from the cell cycle (Wang et al., 2009). During the 
intermediate stages of OL differentiation the transcription factor Nkx6.2 is down-regulated but in 
the final stages it becomes up-regulated (Figure 1.3) and is required for the proper development of 
the myelin paranodes, but not for the expression of the myelin genes or for myelination suggesting 
that the fine-tuning of OL maturation is under separate transcriptional control. OL development is 
also under tight post-transcriptional control by microRNAs (miRNAs). Their main function is to act as 
negative feedback loops that define the transition between OPC maintenance and OL differentiation 
(Emery, 2010).  
In vitro studies have demonstrated the expression of myelin proteins and of myelin-like processes 
extending from OLs that have not yet encountered amyelinated axons (Lubetzki et al., 1993). Axons 
that express the appropriate recognition signals attract these myelin-like processes stimulating them 
to begin wrapping and compacting, forming mature myelin sheaths around the axon. The initial 
processes that ensheath an axon dictate what diameter of axon subsequent processes from the 
same OL can myelinate (Fanarraga et al., 1998). Although the degree of myelination does not vary in 
time and results in a constant G-ratio (the ratio of axon diameter to myelin fibre (Lubetzki et al., 
1993)), it does depend on size as axons less than 0.5 µm remain amyelinated (Charles et al., 2000). 
Furthermore, the act of ensheathing an axon with myelin results in rapid axonal expansion 
presumably through these trans-interactions and their recognition signals (Sanchez et al., 1996).  
Myelination 
Myelination is heavily invested in the neuronal/axonal network for structural support and is 
dependent on the neuronal axon for its expression of both recognition and survival signals. Several 
OLs are required to myelinate a single axon whilst a single OL can myelinate up to 50 axons (Kiernan 
CHAPTER 1: INTRODUCTION 
 
        48 
and Barr, 2004). This myelination enables saltatory conduction to occur as the electrical impulses 
utilise the Nodes of Ranvier, the gaps formed between the myelin sheaths along the nerve axon, to 
‘jump’ across the axonal junctions rather than travel the entire length of the axon. This significantly 
increases the conduction speed of an impulse. For example, myelinated skeletal muscle fibres can 
propagate a signal at a speed of 70–120 m/sec, whereas an unmyelinated nociceptive nerve fibre 
can propagate a signal at a speed around 0.5–2.5 m/sec (Kiernan and Barr, 2004).  
The mature neuron/axon cytoskeleton is built up from two neurofilament pools: a moving (or 
transport) pool that contains the newly synthesized unphosphorylated neurofilament molecules 
that, when induced by the myelin sheath to be phosphorylated, move into a stationary pool 
containing the phosphorylated units of neurofilament. This turnover of unphosphorylated 
neurofilament units into phosphorylated units increases the calibre of the axon and axonal 
conduction velocity (Trapp et al., 1998, Lovas et al., 2000). This increase in axon calibre may prove 
neuroprotective once a certain size is reached, as smaller calibre axons are preferentially 
degenerated in MS plaques and in NAWM (Lovas et al., 2000).  
The myelin sheath profits from this axonal wrapping by inducing axonal recognition signals such as 
type III neuregulin, an axonal recognition signal that does not initiate or induce myelination. It acts 
solely by regulating the degree of myelination and the expression of all CNS myelin components, and 
possibly the action of process extension and wrapping around an axon through signalling 
interactions with erbB receptors (Taveggia et al., 2008). The expression of axonal recognition signals 
contribute to the co-ordination of myelination by not only dictating the degree/thickness of compact 
myelin, but also by acting to enhance OL differentiation (Taveggia et al., 2008, Sanchez et al., 1996).  
Survival signals become apparent postnatally and encourage axon ensheathment as well as 
mediating MNSC homing to damaged regions of the CNS initiating the process of remyelination 
(Calver et al., 1998). 
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Demyelination and remyelination 
Demyelination is a major underlying factor to the symptoms experienced by MS patients. The loss of 
myelin can occur via a variety of pathways/routes, most notably through axonal degeneration 
and/or transection leading to axonal loss; or through the loss of the myelin-producing cell, the OL. 
Therefore, an obvious therapeutic strategy is one that enables the remyelination of demyelinated 
axons, and/or the protection of the axon from injury and subsequent loss.   
The death of oligodendrocytes and the subsequent loss of myelin 
Reactive oxygen species (ROS) are free radicals and related molecules that are produced by normal 
aerobic metabolism and neutralised by cellular antioxidants. Under pathological conditions, an 
increase in ROS may exceed the cells antioxidant mechanisms leading to oxidative stress (OS), the 
biological imbalance between the production and appearance of ROS, and the cells ability to 
detoxify or its ability to repair the damage produced. As well as containing the highest concentration 
of antioxidants, astrocytes also supply neurons with substrates for antioxidants such as glutathione, 
an antioxidant that can act directly on ROS. Within MS patients and lesions, elevated levels of ROS 
and decreased levels of glutathione have been observed (LeVine, 1992, Langemann et al., 1992).  
Glutamate, the precursor of glutathione, is a major excitatory neurotransmitter normally taken up 
by astrocytes to prevent excitotoxicity (Chen et al., 2001). During an excitatory crisis, as seen 
following CNS trauma, reactive astrocytes and microglia exposed to high levels of potassium release 
glutamate via reverse glutamate transport leading to the accumulation of pathological levels of 
glutamate within the extra-cellular space (Gilgun-Sherki et al., 2004, Pekny and Nilsson, 2005). This 
glutamate excitotoxicity may lead to OL loss through activation of the α-amino-3-hydroxy-5-methyl-
4-isoxasole propionic acid (AMPA)/kainate receptors (Tekkok and Goldberg, 2001, Pitt et al., 2000). 
Antagonists of these receptors result in an increase in OL survival and a decrease in 
dephosphorylation of neurofilament H, an indicator of axonal damage, leading to disease 
amelioration in a model of EAE (Pitt et al., 2000, Smith et al., 2000). 
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NO, a highly reactive molecule with a variety of pleiotropic physiological actions, may also contribute 
to axonal damage in chronic lesions. NO is synthesized from the amino acid L-arginine through the 
action of the enzyme nitric oxide synthase (NOS). NOS is normally expressed in very low nanomolar 
quantities in the CNS in the forms of endothelial and neuronal NOS (eNOS and nNOS respectively). A 
third form inducible NOS (iNOS) not normally found in the CNS has been found to be expressed 
within inflammatory lesions of EAE (De Groot et al., 1997, Kim et al., 2000) and by endothelial cells 
and cells of a microglial/Mø lineage. Reactive astrocytes and glial cells also produce NO, possibly via 
growth factor-mediated induction of NOS (Dawson and Dawson, 1998, Xiao et al., 1996).  
Within chronic lesions, activated microglia produce iNOS and (indirectly) NO which has been found 
to reversibly block axonal conduction in vitro (Redford et al., 1997, Jones et al., 2010, Shrager et al., 
1998). The exact mechanism of this blockage is still unclear but is thought to involve impairment of 
the Na+, K+ or Ca+ channels that are exposed following demyelination, or by depolarisation of the 
axon by cyclic guanosine monophosphate (cGMP) or the Na+ pump. Axonal demyelination may also 
involve a positive feedback loop that is initiated by NO-mediated lipid peroxidation (the oxidation of 
lipid by NO) resulting in the expression of the macrophage scavenger receptor. This receptor 
mediates the endocytosis of modified low density lipoprotein (LDL) and foreign negatively charged 
macromolecules. The expression of this receptor therefore stimulates Mø to phagocytose myelin, 
which in turn leads to Mø-activated NO production (Smith and Lassmann, 2002) (Figure 1.4). 
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Figure 1.4. Schematic representation of the pathological interactions that 
occur during inflammation in MS.  
Following the initial wave of leukocyte infiltration and activation, Mø express the co-
stimulatory ligand B7-H1 that down regulates the production of T cell growth factors and 
directs them towards immunological ignorance or anergy. However, during a second 
wave of infiltration, the Mø themselves become activated and act as APCs that express 
IL-12, IL-23 and NO. Once these activated Mø encounter the infiltrating activated T cells, 
they cause a phenotypic change in the T cell. The formation of the trimolecular complex 
(i.e. the interaction between the TCR, the MHC Class II molecules and the inciting antigen 
presented by the APC) in association with co-stimulatory molecules (such as B7-H1) 
triggers specific responses of the activated T cell. The growth factor IL-12 is a key growth 
factor that drives the differentiation of CD4+ T cells to a Th1 phenotype, releasing 
proinflammatory growth factors such as TNFα and IFNγ, growth factors that when 
exposed to endothelial cells, cause them to release NO and other oxygen radical species. 
The growth factor milieu also includes IL-4, which drives the development of Th2 cells 
that secrete anti-inflammatory growth factors (such as TGFβ and IL-10). These growth 
factors have the potential to down regulate the expression of the Th1 growth factors, of 
MHC class II antigens and co-stimulatory molecules found on activated Mø. These 
activated T cells also release the growth factor IL-17, which induces the differentiation of 
Th17 cells, thought to be involved in the pathogenesis of MS. NO released by activated 
Mø, astrocytes and endothelial cells induces the production of IL-2 in activated T cells, 
which in turn, induces expression of the T cell activation markers CD25 and OX-40. OX-40 
when engaged to its ligand OX-40L, leads to cell proliferation and cell survival. The 
presence of TNFα and IFNγ is toxic to both myelin and to their OLs and leads to the 
activation of phagocytic Mø, identified through the presence of lipid debris from the 
myelin sheath, mainly the remnants of MBP. During normal physiological conditions, 
astrocytes take up toxic levels of ROS, glutamate and NO. However, within a lesion, 
reactive astrocytes reverse this uptake and release the molecules into the cellular  
environment, causing death and destruction of the myelin sheath and of its OLs and 
surrounding microglia. B cells also play a role in the destruction of the myelin sheath. 
When activated, they release destructive antibodies that diffuse the BBB and induce 
damage through the terminal attack complex and complement activation. Abbreviations: 
Mø = macrophages; APCs = antigen-presenting cell; NO = nitric oxide; TCR = T-cell receptor;  ROS = reactive oxygen species. 
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The degenerative component of MS:  immune-mediated neurodegeneration 
Once an axon has undergone demyelination, it is subject to insult and injury that may result in 
transection of the axon itself. When a demyelinated axon is transected, the functionality (i.e. the 
axons ability to conduct impulses efficiently) is lost. Wallerian degeneration follows the transection 
of the axon and is a major component of axonal pathology in MS lesions (Dziedzic et al., 2010). 
Following Wallerian degeneration, the nerve cell body may survive forming a terminal axonal ovoid 
and may attempt to repair the axon, typically once the insult has dissipated. Within an acute MS 
lesion, an abundant number of these axonal ovoids have been observed (11 000/mm3 of lesion area; 
(Trapp et al., 1998)). This suggests that axons, in particular small calibre axons (Lovas et al., 2000), 
are vulnerable to inflammatory environments such as an active MS lesion, and that this axonal injury 
is mediated by microglia, Mø and CD8+ T cells (Bitsch et al., 2000) possibly through the expression of 
inflammatory factors such as proteolytic enzymes, growth factors, oxidative agents and free radicals 
(Anthony et al., 1998, Trapp et al., 1998, Perry and Anthony, 1999, Stuckey et al., 2005, Dutta and 
Trapp, 2011).  
Growing evidence suggests that axonal degeneration or loss, is the pathological substrate for the 
progressive disability of the disease (De Stefano et al., 1998, Ceccarelli et al., 2008, Tallantyre et al., 
2010), occurs independent to demyelination (Bitsch et al., 2000, Lovas et al., 2000, Huizinga et al., 
2008, Siffrin et al., 2010, Tallantyre et al., 2010) and is considered to be the most devastating aspect 
of the disease. MS patients experience a variety of neurological symptoms at various times during 
their disease course. They include spasticity, fatigue, bladder weakness, cognitive dysfunction, 
depression and pain. These symptoms may appear and disappear without an apparent pattern, 
making MS diagnosis difficult. Recent studies comparing MS patients with different clinical 
symptoms have shown a significant loss of grey matter volume and cortical thinning when compared 
to healthy controls (Ceccarelli et al., 2008). This cortical thinning may be attributed to axonal 
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degeneration following axonal injury (Sailer et al., 2003). Importantly, this study suggests that the 
areas of grey matter affected could explain the type of clinical symptoms experienced (Ceccarelli et 
al., 2008). For example, it was noted that in SPMS patients whose clinical phenotype includes a 
common occurrence of sensory deficits, grey matter loss was more ‘pronounced’ in the post central 
gyrus in the cortex. Damage to the post central gyrus can cause sensory deficits such as agnosia, the 
inability to interpret sensations and ultimately to recognise things (Soanes and Stevenson, 2006). 
These finding have been corroborated by other studies that have found a significant relationship 
between axon loss and disability in MS patients (Lovas et al., 2000, Siffrin et al., 2010, Tallantyre et 
al., 2010). 
TREATMENTS FOR MS 
Six therapeutic agents have been approved for the treatment of RRMS, with some overlap in the 
possible treatment of PPMS. Unfortunately, not all therapeutics that demonstrated promise in 
animal models have successfully been translated into human clinical trials (Wiendl et al., 2009, 
Ulzheimer et al., 2010). Nevertheless, the data generated from these trials is by no means wasted. 
Indeed, it has provided valuable insight into the complexity this disease. For example, several studies 
have demonstrated an inhibition of EAE by the anti-inflammatory growth factors TGFβ1 and TGFβ2 
(Johns et al., 1991, Kuruvilla et al., 1991, Fabry et al., 1995). However, when administering the active 
recombinant growth factor, no effects on the clinical score (i.e the expanded disability status scale 
(EDSS)) or on the MRI lesion load, were observed during a phase 1 trial of TGFβ2 (Calabresi et al., 
1998). However, it did identify safety concerns for its use in humans such as renal toxicity as the 
long-term treatment with constitutively active TGFβ1 has proven harmful by inducing liver fibrosis 
and glomerulosclerosis (Clouthier et al., 1997).  
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Disease-modifying therapies 
Significant developments in the treatment of RRMS were made following clinical trials during the 
1980s and 1990s using interferons, particularly IFNβ. The first approved treatment for RRMS was 
Betaseron® (IFN-β1b; Bayer Healthcare; subcutaneous injection [s.c]) in 1993, followed by Avonex® 
(IFN-β1a; Biogen Idec; intramuscular injection [i.m]) in 1996 and Rebif® (IFN-β1a; Serono (UK) Pfizer 
(US); s.c) in 1998 (Rudick, 2005). IFN- inhibits autoimmune inflammation in the CNS by suppressing 
pathogenic Th1 growth factor production, reducing the production of matrix metallo-proteinases 
(MMPs) and decreasing the expression of adhesion molecules by T cells and endothelial cells thus 
affecting their entrance into the CNS (Nagai et al., 2003, Yushchenko et al., 2003, reviewed by Billiau 
et al., 2004). Glatiramer acetate (GA, also known as Copaxone®, Teva Pharmaceutical Company, Ltd.) 
was approved by the FDA in 1996 for the reduction of relapses in MS patients with RRMS, and was 
the first non-interferon based treatment for MS (Johnson et al., 1998). GA activates antigen-specific 
T suppressor cells and shifts them towards a non-pathogenic Th2 response. These activated T cells 
then cross over the BBB where they are reactivated by myelin antigens prompting them to release 
anti-inflammatory growth factors (Table 1.1) (Dhib-Jalbut et al., 2006).  
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Table 1.1: Current treatments for MS in use or in clinical trials.  
Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
Oral Therapies 
FTY720 
(Fingolimod; 
Gilenya®) 
RRMS Once 
daily; 
1.25mg / 
0.5mg/da
y 
Targets the 
receptors for the 
potent signalling 
lipid sphingosine-
1-phospate (S1P) 
used for the 
migration of 
lymphocytes from 
secondary 
lymphoid organs 
to periphery. 
Sequesters 
naïve and 
central 
memory T cells 
in the lymph 
nodes; 
Increases 
endothelial 
barrier 
integrity; 
restricts the 
ability of 
lymphocytes to 
infiltrate the 
periphery. 
Improves 
myelination 
and reverses 
demyelinatio
n. 
Phase II - 12 month 
(1.25mg/0.5mg/day):  
ARR reduction  
53-55%;  
Gd+ lesion reduction 43-
62%  
 
Phase III  TRANSFORMS - 
24 month 
(1.25mg/0.5mg/day): 
ARR reduction  
39-52% 
 
Phase III FREEDOMS – 24 
month (0.5/1.25mg/day 
vs. placebo): 
ARR reduction  
54-60% 
Bradycardia, 
relapse, basal-
cell carcinoma. 
Phase III: FREEDOMS II for 
RRMS in over 1080 
patients 
 
Phase IIIb: INFORMS for 
PPMS in over 650 patients 
http://clinicaltrials.gov/ct2
/show/NCT00355134 
 
 
http://clinicaltrials.gov/ct2
/show/NCT000731692 
 
Laquinimod RRMS Once 
daily; 
0.6mg/da
y 
Through the 
suppression of the 
NFκB pathway 
Growth factor 
shift to Th2 
profile; through 
suppression of 
inflammatory 
pathways and 
enhanced 
apoptosis; 
suppression of 
antigen-
presenting 
mechanisms 
followed by 
decrease in 
chemotaxis and 
adhesion. 
Reduction in 
myelin 
destruction 
and axonal 
damage 
(indirect) 
Phase IIb 
(0.3mg/0.6mg/day): 
Gd+ reduction  
7(n/s)-40.4% 
 
Phase III ALLEGRO – 24 
month (0.6mg/day): 
ARR reduction  
23%;  
reduction in disease 
progression  
36%;  
reduced brain atrophy  
33.8% 
Back pain and 
abdominal pain, 
elevations in 
liver enzymes 
but no serious 
liver damage. 
Phase III BRAVO – 24 
month (0.6mg/day vs. 
IFNβ-1a [Avonex®, Biogen 
Idec] for RRMS in over 
1200 patients. 
http://clinicaltrials.gov/ct2
/show/NCT00605215 
 
Cladribine 
 
 
 
 
 
 
RRMS Once 
daily per 
5 day 
course 
for a 
total of 
10-20 
Causes 
accumulation of 
deoxynucleotides 
in lymphocytes. 
Immune cell 
depletion; 
reduces levels 
of 
proinflammato
ry growth 
factors and 
None Phase III CLARITY 
(5.25mg/3.5mg/kg): 
ARR reduction  
55-58%;  
reduction in disease 
progression  
31-33%;  
Headaches, 
upper 
respiratory tract 
infections, 
nasopharyngitis, 
nausea, 
lymphopenia; 
Phase II ONWARD – 104 
weeks (0.875mg/kg/cycle 
[1 cycle is the daily 
treatment of cladribine 
for 4 to 5 days 
consecutively] for up to 4 
cycles) vs. IFNβ-1a 
http://clinicaltrials.gov/ct2
/show/NCT00436826 
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Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
 
Cladribine cont. 
days per 
year 
treatmen
t 
chemokines; 
lymphocyte 
supression 
Gd+ reduction 
73-88% 
malignancies, 
choriocarcinoma
. 
[Rebif®, Serono Pfizer] for 
RRMS and SPMS with 
relapses in over 200 
patients. 
BG00012 RRMS 240mg/ti
d (three 
times a 
day) 
Not fully 
understood; 
Activates nuclear 
factor-E2-related 
factor 2 (Nrf2) 
transcriptional 
pathway whose 
downstream 
factors are 
involved in the 
expression of 
detoxification 
agents and may 
upregulate 
antioxidant 
players 
Upregulates 
Th2 response  
Reduction in 
myelin 
destruction 
and axonal 
damage 
(indirect) 
Phase II (240mg/tid vs. 
placebo): 
ARR reduction 
32% (n/s) 
Gd+ reduction 
69% 
None Phase III DEFINE – 24 
month (480mg/day vs. 
720mg/day vs. placebo) 
for RRMS in over 1230 
patients. 
 
Phase III CONFIRM – 24 
month (480mg/day vs. 
720mg/day vs. Glatiramer 
acetate [Copaxone®, Teva 
Pharmaceutical 
Industries, Ltd.] 
20mg/day s.c vs. placebo) 
for RRMS in over 1400 
patients. 
 
Phase III EXPLORE – 8 
month (240mg/tid + IFNβ 
vs. 240mg/tid + Copaxone 
20mg/day s.c) for RRMS 
in over 100 patients. 
 
http://clinicaltrials.gov/ct2
/show/NCT00420212 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00451451 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT01156311 
 
Teriflunomide 
(Aubagio®, 
Genzyme) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RRMS Once 
daily, 
oral 7mg 
or 14mg.  
Reversibly inhibits 
dihydroorotate 
dehydrogenase 
thus impairing 
DNA synthesis 
Supresses 
inflammatory 
factors, inhibits 
tyrosine kinase 
activity, 
impede T cell 
activation and 
APC interaction 
None Phase II TEMSO (7mg/day 
vs. 14mg/day vs. placebo): 
ARR reduction  
28-32% 
Gd+ reduction 
60-40% 
 
Increase in ALT, 
alopecia, 
diarrhea, 
influenza, 
nausea and 
paresthesia 
Phase III TOPIC – 40 
month (7mg/day vs. 
14mg/day vs. placebo) for 
RRMS in over 1110 
patients. 
 
Phase III TOWER – 24 
month (7mg/day vs. 
14mg/day vs. placebo) for 
CIS in over 780 patients. 
 
Phase III – 24 weeks 
(7mg/day + Copaxone® 
20mg/day s.c vs. 
14mg/day + Copaxone® 
20mg/day s.c vs. 
Copaxone® 20mg/day s.c) 
http://clinicaltrials.gov/ct2
/show/NCT00622700 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00751881 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00475865 
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Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
 
 
Teriflunomide 
cont. 
for RRMS, SPMS, PRMS in 
over 120 patients. 
 
Phase III – 48-172 weeks 
(7mg/day + IFNβ i.m. vs. 
14mg/day + IFNβ i.m. vs. 
IFNβ i.m.) for RRMS, in 
over 1455 patients. 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT01252355 
 
Injectable Therapies 
IFNβ-1a (i.m., 
Avonex®, 
Biogen Idec) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RRMS 30mcg 
once a 
week 
Unknown at 
present 
Slows down 
immune 
response, 
possibly by 
interfering with 
T cell activation 
and infiltration 
into CNS, 
apoptosis of 
autoreactive T 
cells, growth 
factor shift 
from Th1 to 
Th2, 
restoration of 
Treg activity 
Indirect 
effects 
possibly 
through the 
suppression 
of MMP9, T 
cell activation 
and 
infiltration 
and a shift in 
the growth 
factor profile 
to generate a 
pro-
myelinating 
environment 
and to 
prevent 
myelin and 
axonal 
damage. 
Decrease in exacerbation 
rate (0.67 per year in 
AVONEX-treated group vs. 
0.82 per year in the 
placebo-treated group 
(p=0.04). 
 
Significant decrease in 
frequency of 
exacerbations (p=0.03). 
 
Significant Gd+ reduction 
(p≤0.05) 
Flu-like 
symptoms 
including chills, 
fever, myalgia, 
and asthenia.  
Phase III BIIB017 
(PEGylated interferon 
beta-1a) – 24 month 
BIIB017 125 mcg s.c. vs. 
PBO s.c. (every 2-4 wks) 
for RRMS in over 1260  
patients.  
 
Combinational Trials 
Phase III Daclizumab High 
Yield Process (DAC HYP) 
vs. interferon beta-1a 
(Avonex®, 
Biogen Idec) – 96 to 144 
weeks (Avonex 30 
mcg/week i.m. + placebo 
s.c. vs. DAC HYP 150 
mg/every 4 weeks s.c. + 
placebo i.m. for RRMS in 
over 1500 patients. 
 
Phase III CombiRx study – 
36 month (Avonex 30 
mcg/week i.m. + 
Copaxone 20 mg/d s.c. vs. 
Avonex + placebo s.c. vs. 
Copaxone + placebo 
i.m.for RRMS in over 1000 
patients. 
 
Phase IV TOP MS – 24 
http://clinicaltrials.gov/ct2
/show/NCT00906399 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT01064401 
 
 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00211887 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
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Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
IFNβ-1a (i.m., 
Avonex®, 
Biogen Idec) 
cont. 
 
month (Avonex 30 
mcg/week i.m. vs. Rebif 
44 mcg tiw s.c. vs. 
Betaseron 250 mcg q.o.d 
s.c. 
vs. Copaxone 20 mg/d s.c. 
for active RRMS in over 
3000 patients. 
 
Phase III BRAVO – 24 
month (0.6mg/day vs. 
IFNβ-1a [Avonex®, Biogen 
Idec] for RRMS in over 
1200 patients. 
 
/show/NCT00819000 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00605215 
 
IFNβ-1a (s.c, 
Rebif®, Serono 
Pfizer) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RRMS 22mcg or 
44mcg 
tiw 
(three 
times a 
week) 
Unknown at 
present 
Slows down 
immune 
response, 
possibly by 
interfering with 
T cell activation 
and infiltration 
into CNS, 
apoptosis of 
autoreactive T 
cells, growth 
factor shift 
from Th1 to 
Th2, 
restoration of 
Treg activity 
Indirect 
effects 
possibly 
through the 
suppression 
of MMP9, T 
cell activation 
and 
infiltration 
and a shift in 
the growth 
factor profile 
to generate a 
pro-
myelinating 
environment 
and to 
prevent 
myelin and 
axonal 
damage. 
Decrease in exacerbations 
in Rebif-treated groups vs. 
placebo-treated group 
(29% and 32% in study 1 
[22mcg tiw and 44 mcg 
tiw]; p≤0.001). 
 
Proton-density/T2-
weighted MRI: Significant 
reduction  in lesion area 
after 2 years (p˂0.0001). 
 
Significant reduction in 
relapse rate after 24 
weeks (p˂0.001) and 48 
weeks (p=0.009).  
Flu-like 
symptoms 
including chills, 
fever, myalgia, 
and asthenia. 
Serious adverse 
reactions were 
psychiatric 
disorders 
including 
depression, 
suicidal ideation 
and attempt.  
Combinational Trials 
Phase III CARE-MS I, 
CAMMS 323 – 24 month 
(Alemtuzumab [Genzyme 
Corp.] 12 mg/day i.v. for 5 
days vs. Rebif 44 mcg tiw  
s.c. for RRMS  in over 580 
patients. 
 
Phase III CARE-MS II, 
CAMMS 324 – 24 month 
(Alemtuzumab [Genzyme 
Corp.] 12 mg/day i.v. for 5 
days at month 0 and 3 
days at month 12 vs. 
alemtuzumab 24 mg/day 
i.v. for 5 days at month 0 
and 3 days at month 12 
vs. Rebif 44 mcg tiw s.c. 
for RRMS in over 700 
patients. 
 
Phase II ONWARD – 104 
weeks (0.875mg/kg/cycle 
[1 cycle is the daily 
treatment of cladribine 
for 4 to 5 days 
consecutively] for up to 4 
cycles) vs. IFNβ-1a 
 
http://clinicaltrials.gov/ct2
/show/NCT00530348 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00548405 
 
 
 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00436826 
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Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
IFNβ-1a (s.c, 
Rebif®, Serono 
Pfizer) cont. 
[Rebif®, Serono Pfizer] for 
RRMS and SPMS with 
relapses in over 200 
patients. 
 
Phase II Interferon beta-
1a (Rebif®, EMD Serono 
and Pfizer Inc.) + 
estroprogestins – 24 
month (Rebif 44 mcg tiw 
s.c. vs. Rebif + desogestrel 
150 mcg p.o. + 
etinilestradiol 20 
mcg p.o. vs. Rebif + 
desogestrel 25 mcg + 
etinilestradiol 40 mcg for 
RRMS women in over 180 
patients. 
 
Phase IV TOP MS – 24 
month (Avonex 30 
mcg/week i.m. vs. Rebif 
44 mcg tiw s.c. vs. 
Betaseron 250 mcg q.o.d 
s.c. 
vs. Copaxone 20 mg/d s.c. 
for active RRMS in over 
3000 patients. 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00151801 
 
 
 
 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00819000 
 
IFNβ-1b (s.c, 
Betaseron®, 
Bayer 
Healthcare) 
 
 
 
 
 
 
 
 
 
 
 
 
RRMS 250mcg 
(μg) q.o.d 
(every 
other 
day) 
Unknown at 
present. 
Slows down 
immune 
response, 
possibly by 
interfering with 
T cell activation 
and infiltration 
into CNS, 
apoptosis of 
autoreactive T 
cells, growth 
factor shift 
from Th1 to 
Th2, 
restoration of 
Treg activity 
Indirect 
effects 
possibly 
through the 
suppression 
of MMP9, T 
cell activation 
and 
infiltration 
and a shift in 
the growth 
factor profile 
to generate a 
pro-
myelinating 
environment 
Significant change in MRI 
area (-1.1% for the 0.25mg 
Betaseron-treated group 
vs. +16.5% for the placebo-
treated group) 
Depression, risk 
to pregnancy, 
allergic 
reactions, 
injection site 
problems (i.e. 
skin reactions). 
Flu-like 
symptoms 
including chills, 
fever, myalgia, 
and asthenia. 
Serious adverse 
reactions were 
psychiatric 
disorders 
Long term study 
BEST study – 5 years (250 
mcg q.o.d s.c. for  RRMS 
in over 3560 patients) 
 
Combinational Trials 
Phase IV TOP MS – 24 
month (Avonex 30 
mcg/week i.m. vs. Rebif 
44 mcg tiw s.c. vs. 
Betaseron 250 mcg q.o.d 
s.c. 
vs. Copaxone 20 mg/d s.c. 
for active RRMS in over 
3000 patients. 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00819000 
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Agent Clinical 
Stage 
Regime Mechanism of 
Action 
Immunologic 
effects 
Neuroprotect
ive effects 
Data from completed 
phase II/III trials 
Side effects Future trials Clinical Trial Identifier 
IFNβ-1b (s.c, 
Betaseron®, 
Bayer 
Healthcare) 
cont. 
and to 
prevent 
myelin and 
axonal 
damage. 
including 
depression, 
suicidal ideation 
and attempt. 
Glatiramer 
acetate 
(Copaxone®, 
Teva 
Pharmaceutical 
Company, Ltd.) 
RRMS 20mg 
once a 
day 
Bystander 
suppression 
through activation 
of T cells as an 
altered peptide 
ligand that would 
shift towards 
antiinflammatory 
profile; increase 
expression of 
Foxp3 in CD4+ T 
cells. 
Generating 
suppressor 
cells, inducing 
tolerance, 
expanding Treg 
populations, 
and altering 
APC 
presentation 
mechanisms.  
None   Combinational Trials 
Phase III CombiRx study – 
36 month (Avonex 30 
mcg/week i.m. + 
Copaxone 20 mg/d s.c. vs. 
Avonex + placebo s.c. vs. 
Copaxone + placebo 
i.m.for RRMS in over 1000 
patients. 
 
Phase IV TOP MS – 24 
month (Avonex 30 
mcg/week i.m. vs. Rebif 
44 mcg tiw s.c. vs. 
Betaseron 250 mcg q.o.d 
s.c. 
vs. Copaxone 20 mg/d s.c. 
for active RRMS in over 
3000 patients. 
 
Phase III – 24 weeks 
(7mg/day + Copaxone® 
20mg/day s.c vs. 
14mg/day + Copaxone® 
20mg/day s.c vs. 
Copaxone® 20mg/day s.c) 
for RRMS, SPMS, PRMS in 
over 120 patients. 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00211887 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00819000 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2
/show/NCT00475865 
 
 
ARR= Annual Relapse Rate n/s= not-significant s.c.= subcutaneous i.v.=intravenous i.m.=intramuscular p.o= orally  q.o.d=every other day t.i.w=three times a week 
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Monoclonal antibody Therapies 
Monoclonal Ab Targeted 
molecule/Cell 
expression 
Type of 
antibody 
(Blocking/Si
gnalling) 
Mechanism of Action Data from completed phase II/III trials Future Trials Clinical Trial Identifier 
Alemtuzumab 
(Campath-1H, 
Genzyme 
Corporation) 
Targets CD52 
found on all T and 
B cells, NK cells, 
Mø, DCs, and 
tissue of the male 
reproductive 
system. 
Signalling 
Ab 
Complete depletion 
of CD52-bearing cells. 
Indirectly the 
stabilization of the 
BBB 
Phase II: 12mg/day vs. 24mg/day i.v. in 
annual cycles in conjunction with 44mcg 3 
t.i.w. IFNβ s.c. – reduction in accumulated 
disability – 9% vs 29.2% with improved 
clinical scores 0.39pts in alemtuzumab 
group vs. a worsening by 0.38pts in the IFNβ 
group. Due to serious adverse effects such 
as intracerebral haemorrhage, Grave’s 
disease, Goodpasture syndrome and 
melonoma’s, the safety of the drug in under 
investigation.  
Phase III CARE-MS I, CAMMS 323 – 24 month 
(Alemtuzumab [Genzyme Corp.] 12 mg/day i.v. for 
5 days vs. Rebif 44 mcg tiw  s.c. for RRMS  in over 
580 patients. 
 
Phase III CARE-MS II, CAMMS 324 – 24 month 
(Alemtuzumab [Genzyme Corp.] 12 mg/day i.v. for 
5 days at month 0 and 3 days at month 12 vs. 
alemtuzumab 24 mg/day i.v. for 5 days at month 0 
and 3 days at month 12 vs. Rebif 44 mcg tiw s.c. 
for RRMS in over 700 patients. 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT00530348 
 
 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT00548405 
 
Daclizumab 
(Zenapax) 
Targets CD25 (IL-
2Rα) found on 
activated T cells, 
FoxP3+ Treg cells, 
some NK cells, 
activated Mø, 
activated DCs and 
OLs. 
Blocking Ab Blocks CD25, the IL-2 
binding epitope for 
the IL-2R, exact MoA 
unknown suspected 
to limit T cell 
expansion. Widely 
used to prevent 
allogeneic tissue 
transplant rejection. 
Phase II: CHOICE – (2 mg/kg s.c. every 2 
weeks vs. 1 mg/kg s.c. every 4 weeks 
(alternates with placebo every 
2 weeks) + IFNβ vs. placebo s.c. + IFNβ). For 
active relapsing MS in 230 patients over 72 
weeks. Gd+ reduction – 72% in 2mg group 
and 25% in 1mg group with no change in T-, 
B-, NK cells but CD56
bright
 NK cells were 
found to be 7-8x higher in daclizumab 
group.  
Phase II ZAP MS study – 20.5 month (1 
mg/kg/month i.v. vs. placebo) for RRMS in 15 
patients. 
 
Phase III Daclizumab High Yield Process (DAC 
HYP) vs. interferon beta-1a (Avonex®, 
Biogen Idec) – 96 to 144 weeks (Avonex 30 
mcg/week i.m. + placebo s.c. vs. DAC HYP 150 
mg/every 4 weeks s.c. + 
placebo i.m. for RRMS in over 1500 patients. 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT00071838 
 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT01064401 
 
Natalizumab 
(Tysabri, 
Biogen Idec 
and Elan) 
 
 
 
 
 
 
 
 
 
 
Targets CD49d 
(VLA-4) for on all T 
and B cells, NK 
cells, most Mø 
and monocytes, 
and most 
granulocytes 
(except 
neutrophils) 
Blocking Ab Is a selective 
adhesion molecule 
inhibitor bwhose 
target is CD49d, the 
α4 subunit of VLA-4 
receptor, thus 
preventing cell 
adhesion and 
infiltration into CNS. 
Best for early inflammation, not later 
degenerative stages. 
 
SENTINEL Trial: Combination therapy with 
Avonex – 24% reduction in disease 
progression vs. IFNβ alone. 
 
AFFIRM Trial:  
Monotherapy – 42% reduction in disease 
progression and ARR reduction by 68%. 
Phase IV: To test effect of treatment on 
vaccination response in 46 RRMS patients over 8 
month.  
Dosage: Tysabri 300 mg i.v. every 4 weeks for at 
least 9 months, along with 3 immunisations of 
keyhole limpet hemocyanin s.c. at Day 168, 182, 
196 and immunisation of tetanus diphtheria 
vaccine i.m. at Day 168 vs. 3 immunisations of 
keyhole limpet hemocyanin s.c. at Day 0, 14, 28 
and immunisation with tetanus diphtheria vaccine 
i.m. at Day 0. 
 
Phase IV: ENER-G study – To reduce fatigue in 
over 200 patients with relapsing MS. 
http://clinicaltrials.gov/ct2/sh
ow/NCT00536120 
 
 
 
 
 
 
 
 
 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT00464074 
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Natalizumab 
(Tysabri, 
Biogen Idec 
and Elan) cont. 
Dosage: Tysabri 300 mg every 4 weeks i.v.  
 
Phase IV: TYGRIS – Tysabri Global ObseRvational 
Program In Safety in 5111 patients with relapsing 
forms of MS for 5 years (Long term safety trial). 
Dosage: 300 mg every 4 weeks i.v. 
 
 
http://clinicaltrials.gov/ct2/sh
ow/NCT00477113 
 
Rituximab 
(Rituxan,  
Targets CD20 
found on B cells 
(not plasma cells) 
and induces B-cell 
lysis. 
Signalling 
Ab 
Complete but 
transient depletion of 
B cells early on in the 
disease.  
Phase II: 26 patients with RRMS that is 
unresponsive to standard 
immunomodulatory drugs. Done over 12 
months at a dosage of 375 mg/m
2
 i.v. (4 
times). No change in EDSS observed but 
found depletion of T cells as well as B cells.  
 
Phase II/III: 435 patients with PPMS over  30 
months were treated with 1g/day i.v. vs. 
placebo. No difference in the time to 
disease progression observed. Interestingly, 
in sub-group analysis patients younger than 
51 years of age time to disease progression 
was significantly increased.  
None  
ARR= Annual Relapse Rate n/s= not-significant s.c.= subcutaneous i.v.=intravenous i.m.=intramuscular p.o.= orally q.o.d.=every other day t.i.w.=three times a week 
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Further treatments for MS have been developed including oral therapies (such as FTY720, 
Laquinimod, Cladribine, BG00012 and teriflunomide) and monoclonal antibodies (such as 
Alemtuzumab, Daclizumab, Natalizumab, and Rituximab) (Table 1.1), all of which have entered 
phase III/IV trials. Additionally, combination therapy has accumulated a great deal of interest. 
However, current treatments are aimed at reducing relapse rates, limit or reduce lesion loads, 
prevent the development of new lesions or target specific cell types based on the immune-mediated 
arm of the disease. They focus on reducing the occurrence of inflammatory demyelinating lesions by 
inhibiting the immune system, but they do not target tissue repair or remyelination of the CNS. As 
mentioned before, recent studies have demonstrated the importance of neurodegeneration in the 
pathology of MS i.e. it is the primary cause of irreversible neural damage and disease progression in 
MS (Chandran et al., 2008, Tallantyre et al., 2010) highlighting the importance of studies into 
neuroprotective factors and factors and molecules that initiate or increase remyelination (Ben-Hur, 
2010). 
Remyelination as a therapeutic target 
The current disease-modifying therapies predominantly target the inflammatory arm of the disease 
and are insufficient in targeting the degenerative aspects of the disease (Bitsch et al., 2000). 
Therefore remyelination, the reinvesting of new myelin around demyelinated axons, is important 
because it not only repairs saltatory conduction but is also neuroprotective (i.e it protects the 
neuronal axon by preventing degeneration (Chandran et al., 2008)), and for promoting axonal 
survival.  
Remyelination follows many of the developmental stages of myelination and begins with the 
recruitment of OPCs that differentiate into mature myelin producing OLs that remyelinate the naked 
axon. Following a demyelination event, resident astrocytes and microglia are activated and release 
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factors that recruit monocytes from the surrounding blood vessels. The microglia and the monocytes 
differentiate into Mø that remove the myelin remnants left over from the dissolution and 
degradation of the myelinated axon. These Mø also release growth factors that cause the OPCs 
recruited from the subventricular zones and surrounding areas around the lesion, to differentiate 
into mature myelin producing OLs that engage the demyelinated axons and establish new myelin 
that appears thinner, a characteristic feature of remyelination (Dangond, 2004). 
Why does remyelination fail in MS? 
During the progressive stages of MS, this spontaneous remyelination appears to fail. Although 
demyelinating plaques of MS contain a significant number of immature OLs as well as viable axons 
(Wilson et al., 2006) why remyelination fails is, at present, unclear. It has been suggested to be the 
result of impaired processes such as OPC proliferation, migration and differentiation, or due to poor 
axonal responsiveness (Olek, 2004). It may also be due to the loss of axonal recognition and survival 
signals through axonal degeneration (Lovas et al., 2000), or through the existence of inhibitory 
factors and/or mechanisms (Charles et al., 2002, Olek, 2004, Chandran et al., 2008) such as the 
polysialated form of the neural cell adhesion molecule (PSA-NCAM) (Charles et al., 2000) that 
negatively regulates myelination.  
Myelin repair 
The therapeutic avenues to remyelination can be simplified into two areas. Exogenous repair 
involves transplantation-mediated remyelination strategies, whereas endogenous repair involves 
the promotion of a multifaceted pro-myelinating environment (Stangel and Hartung, 2002, Dangond, 
2004, Billinghurst et al., 1998). 
Exogenous repair 
Exogenous remyelination strategies have been investigated for many years in various animals 
models such as the myelin-deficient shiverer mouse (Yandava et al., 1999, Mitome et al., 2001) and 
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in a toxic demyelination model (Allamargot et al., 2001). The cell types available for this type of 
transplantation-mediated strategy include neural stem cells (NSC), OPCs, Schwann cells and 
olfactory ensheathing cells.  
NSCs are highly proliferative, pluripotent cells that are easily manipulated in vitro allowing 
researchers to engineer specific cell types for use in cell-transplantation therapies. NSCs have 
demonstrated the ability to ameliorate disease in both mouse and marmoset EAE models for MS 
(Pluchino et al., 2003, Pluchino et al., 2009). However, a concern for NSC transplantation is the 
inability to direct their migration in vivo and therefore, into areas that require the replenishment of 
differentiated neural cells (such as OPCs) not knowing if they would target regions of inflammation 
and demyelination. Pluchino et al., (2003) were able to detect transduced NSCs (containing the 
E.coli-derived lacZ gene directed to the nuclear compartment) in areas of CNS damage such as 
demyelination and axonal loss for up to 30 days after transplantation intravenously or 
intracerebroventricularly. However, the in vivo transplantation of NSCs labelled with luciferase and 
green fluorescent protein in EAE mice failed to migrate to areas of CNS damage, and were destroyed 
soon after transplantation (Reekmans et al., 2011). These studies highlight the complexity of the use 
of cell transplantation as a therapeutic tool.  
An alternative to NSCs are Schwann cells. Schwann cells are myelinating cells of the peripheral 
nervous system that can be isolated from the sural nerve (found in the ankle and biopsied under 
local anaesthetic) and expanded in vitro. This cell type can remyelinate the CNS and has the benefit 
of being autologous to the patient, perhaps enabling them to escape the immune attack against CNS 
myelin (Dangond, 2004). Another autologous cell type capable of remyelination and that can be 
isolated from the patient are olfactory ensheathing cells. Olfactory ensheathing cells are cells that 
wrap around the axon of the first cranial nerve and have demonstrated myelination of axons in a rat 
model of spinal cord injury (Sasaki et al., 2004). 
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Within any transplant-mediated remyelination strategy, one must consider the normal cellular 
environment and whether the transplanted cells interact in a positive or negative manner with the 
endogenous glial cells: astrocytes and OLs. Indeed, the transplantation of Schwann cells lead to the 
induction of reactive astrocytes as indicated through an increase in glial fibrillary acidic protein 
expression within normal white matter of the spinal cord of adult Fisher rats (Lakatos et al., 2003). 
The reciprocal transplantation of olfactory ensheathing cells did not induce such increased reactivity 
in astrocytes (Lakatos et al., 2003). Interestingly, it was the transplantation of these Schwann cells 
that demonstrated a more beneficial effect regarding locomotor recovery than their olfactory 
ensheathing cell counterparts (Lakatos et al., 2003). Therefore, a therapeutic outcome must be 
carefully considered before the introduction of exogenous cells.  
Endogenous repair 
In EAE , the endogenous promotion of remyelination has been achieved through various approaches 
such as the administration of specific compounds associated with myelination such as thyroid 
hormone (Fernandez et al., 2004), platelet-derived growth factor (PDGF) (Allamargot et al., 2001), 
and IGF1 (Yao et al., 1995) ; the promotion of OPC proliferation and differentiation (Mi et al., 2009); 
the inhibition of inflammation (Piraino et al., 2005) and through intravenous immunoglobulins such 
as rHIgM22 (Pirko et al., 2004) and PEGylated anti-LINGO-1 Li33 antibody (Pepinsky et al., 2011).  
Neuroprotective Therapies 
Growth factors are soluble proteins that act as local mediators of communication between cells of 
the immune system (Nissim et al., 2004, Chitnis and Khoury, 2003). They include factors produced by 
mononuclear Mø (monokines), lymphocytes (lymphokines), colony-stimulating factors and 
interleukins (factors that are produced by monocytes and T cells and act on other lymphocytes). All 
growth factor receptors are ubiquitously expressed in most tissues and cells. Growth factors have 
been used therapeutically in many diseases. For example IL-2, IFN-α and IFN-γ in cancer; IFN-α in 
viral infection; IL-11 in post-chemotherapy induced thrombocytopenia; and IFN-β in MS. The growth 
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factors EPO, TGFβ and IGF1 have also been assessed for their therapeutic potential in the EAE mouse 
model of MS.  
Erythropoietin 
Until recently, EPO was known primarily as a renal protein involved in the generation and 
maintenance of erythroid cells, a process known as erythropoiesis. However, recent studies have 
demonstrated that EPO is a neuroprotective, anti-apoptotic, anti-inflammatory, anti-oxidative 
growth factor that is therapeutically promising for the treatment of several diseases including MS 
(Siren et al., 2001a, Agnello et al., 2002, Celik et al., 2002, Chong et al., 2003, Erbayraktar et al., 
2003, Villa et al., 2003, Brines et al., 2004, Avasarala and Konduru, 2005, Zhang et al., 2005, Genc et 
al., 2006, Savino et al., 2006, Mengozzi et al., 2008, Yoo et al., 2009).  
EPO Expression 
The EPO molecule is a 34 kDa glycoprotein produced in the foetal liver and in the adult kidney that 
promotes the formation of red blood cells. It also acts in response to ischemia or hypoxia, a 
condition where there is a decrease in the oxygen supply to tissue. It contains one O-linked and 
three N-linked glycosylated chains important for its production, secretion and biological activity 
(Gentry et al., 1988, Miyazono and Heldin, 1989, Wasley et al., 1991, Su et al., 2010). EPO mRNA and 
the protein for EPO and the EPOR are found in various regions of the brain including the cerebellum, 
hypothalamus, hippocampus, internal capsule, cortex and midbrain (Masuda et al., 1993, Yamaji et 
al., 1996, Bernaudin et al., 2000, Brines et al., 2000, Dame et al., 2000, Siren et al., 2001b, Sugawa et 
al., 2002, Mengozzi et al., 2008, Rabie and Marti, 2008, Kang et al., 2009). Under hypoxic conditions 
in vitro, EPO has been found to be expressed by neurons, OLs, microglia, CEC, inflammatory cells and 
reactive astrocytes. This expression stimulates erythropoiesis, the production of new red blood cells 
in the bone marrow, in order to maintain an adequate supply of oxygen to the tissue. Its expression 
is driven by the activation of the hypoxia inducible factor-1α (HIF-1α) or HIF-2 genes by stimuli such 
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as insulin, hypoxia, hypoglycaemia, ROS and IGF (Minet et al., 2000, Rabie and Marti, 2008, Lemus-
Varela et al., 2010).  
EPO Receptors 
Recent studies have shown that the molecular versatility of EPO is mediated through the interaction 
of portions of the helices A, C and D and the loop connecting helices A and B of EPO with the (EPOR)2 
(Brines et al., 2008). The classical erythropoietic homodimer receptor (EPOR)2, is involved in 
erythropoiesis, and the heteromer receptor (EPOR)2/βcR, is involved in mediating its tissue-
protective effects.  
The erythropoietic effects of EPO are mediated through (EPOR)2. (EPOR)2 is a member of the single-
chain growth factor type I receptor family and comprises two transmembrane EPOR molecules 
present on the cell surface of erythroid colony-forming units, that spontaneously associates to form 
a homodimer via a leucine zipper bridge within the cell membrane (Rabie and Marti, 2008). EPO, 
readily produced by the kidneys for use in erythropoiesis, is found circulating within the body in 
concentrations within the picomolar range (1–7 pmol/L) and interacts with (EPOR)2 with high affinity 
(100–200 pmol/L) (Brines and Cerami, 2008). 
On the contrary, the tissue-protective effects of EPO have been shown to be mediated through the 
EPOR and the beta common receptor (βcR), the signalling part of the receptor complex also used by 
IL-3, GM-CSF and IL-5 (Brines et al., 2004). This (EPO)2/βcR unit, normally expressed at low levels, is 
transiently upregulated in response to injury such as ischemia, or to hypoxia. Additionally, locally 
produced EPO is then expressed by the surrounding environment undergoing this stress or injury. 
The (EPO)2/βcR unit has a low affinity for EPO (1–20 nmol/L) and therefore requires higher 
concentrations of EPO (a minimum dose of 500IU/kg bw is required in a rat stroke model (Wang et 
al., 2007)) to initiate tissue-protection, yet it only requires a brief exposure to initiate sustained 
response (Brines and Cerami, 2008, Brines et al., 2008). Indeed, when a skin flap model for 
permanent ischemia is treated with a high (3μg/kg body weight [bw] equivalent to 300IU/kg bw) but 
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not a low (0.3μg/kg bw equivalent to 30 IU/kg bw EPO, a purely haematopoietic dose of EPO) dose 
of EPO, an increased rate of healing was observed (Erbayraktar et al., 2009). 
However, in the event that the βcR concentration is very low or absent, the redundant system for 
tissue-protection (such as anti-apoptosis) would not occur through the dimerization of EPOR (Um et 
al., 2007) and the newly engineered nonerythropoietic EPO analogues such as CEPO, asialoEPO and 
ARA290 (discussed below) would not be able to initiate the necessary signalling pathways.  
EPO Signalling Pathways  
The binding of EPO ligand leads a conformational change that activates the expression and 
phosphorylation of Janus tyrosine kinase 2 (JAK2) that is physically attached to the cytoplasmic 
portion of the receptors. This in turn leads to downstream activation of several transduction 
signalling pathways pertaining to the erythropoietic, neurotrophic and anti-apoptotic actions of EPO. 
For example, phosphorylation of JAK2 leads to the activation of the signal transducer and activator 
of transcription 5 (STAT5), which dimerizes and translocates to the nucleus inducing the 
transcription and translation of the anti-apoptotic protein Bcl-xL. This results in the survival of 
erythrocyte precursor cells (known as colony-forming units) that in turn give rise to mature 
erythrocytes (Brines and Cerami, 2008, Rabie and Marti, 2008).  
Additionally, the phosphorylation of JAK2 leads to the activation of phosphatidyl inositol 3 kinase 
(PI3K) which in turn activates Akt protein kinase B Akt/PKB. The activation of Akt/PKB leads to the 
inhibition of glycogen synthase kinase 3β (GSk-3β), Bcl2-associated agonist of cell death (BAD), and 
caspase activation resulting in a reduction in apoptosis. It also induces the activation of NFκB which 
inhibits apoptosis (Jelkmann and Hellwig-Burgel, 2001, Jelkmann, 2004, Brines and Cerami, 2008, 
Rabie and Marti, 2008). 
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EPO and EAE 
Following on from the discovery of EPOs tissue-protective abilities, researchers looked at the 
possibility of EPO being neuroprotective. Initially they believed that the large glycoprotein was 
unable to cross the BBB and therefore injected it intracranially, a procedure that would not be 
ethically feasible in human trials. It was therefore fortuitous that Ehrenreich et al., (2004) discovered 
the migration of EPO across the BBB when looking at EPO as an add-on therapeutic treatment for 
schizophrenia. This opened the way for EPO to be considered a therapeutic treatment for other 
neurological diseases, such as MS. Within the EAE model, EPO treatment has demonstrated a 
reduction in clinical score, neurological deficit duration, inflammatory cell infiltrate, demyelination 
and reactive gliosis in the EAE rodent models and in a model of focal cerebral ischemia (Brines et al 
2000; Agnello et al 2002; Savino et al 2006; Yuan et al 2008; Sirén 2001). 
A variety of studies have demonstrated that EPO is anti-inflammatory (Brines and Cerami 2008). 
Within the EAE model, EPO has demonstrated these anti-inflammatory effects by reducing the 
proliferation of autoreactive T cells and suppressing the production of the pro-inflammatory growth 
factors TNF-α and IFN-γ in negative feedback loops: inflammation induces TNFα and IFNγ which 
inhibit endogenous EPO induction, whilst the HIF-1α-induced expression of EPO by inflammatory 
stimuli inhibits the production of TNFα and IFNγ (Agnello et al., 2002, Mengozzi et al., 2008, Savino 
et al., 2006, Villa et al., 2003). EPO has also been shown to down-regulate TNF-α induced IL-6, IL1β, 
CXCR4 and IL-1α gene expression in CEC (Agnello et al., 2002, Avasarala and Konduru, 2005) thus 
limiting the ability of activated lymphocytes from crossing the BBB. These effects have been 
reported to persist for at least 20 days after EPO treatment cessation (Agnello et al., 2002, Savino et 
al., 2006). Additionally, EPO pre-treatment results in inhibition of VEGF, a multipotent growth factor 
up-regulated in acute and chronic MS lesions thought to promote the localised inflammatory 
response by inducing local BBB breakdown (Fan et al., 2009, Martinez-Estrada et al., 2003). 
Remarkably, these anti-inflammatory effects of EPO are not replicated in an adjuvant-induced model 
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of arthritis or in systemic lupus erythematosus (Agnello et al., 2002) and is therefore said to only 
occur in the setting of neuronal degeneration (Villa et al., 2003) and is CNS specific.  
The neuroprotective action of EPO has been demonstrated in vitro against kainite (KA)-induced 
excitotoxicity and cell death (Yoo et al., 2009), as well as in vivo in an ischemia spinal cord injury 
model (Brines et al., 2000, Celik et al., 2002) and in EAE (Brines et al., 2000, Zhang et al., 2005).  
Within the CNS, OLs and neurons are especially vulnerable to excitotoxicity, cytotoxicity and 
oxidative stress. EPO pre-treatment showed significant reductions in the expression of nitrite levels 
(a stable by-product generated by rapid NO oxidation) in vitro induced by IFN-γ and bacterial 
liposaccharide (LPS) in primary rat OL cultures. Pursuant to EPO pre-treatment, significant decreases 
in iNOS- and NO-induced oxidative stress by a downregulation in iNOS mRNA affords OLs and 
neurons its neuroprotection (Genc et al., 2006).  
EPO post-treatment also exhibits a neuroprotective effect by suppressing caspase-3 proteolytic 
activity and Bax expression, both key players in the process of programmed cell death, apoptosis 
(Siren et al., 2001a, Yoo et al., 2009). In parenchymal cells of the CNS, EPO treatment increased the 
expression of brain-derived neurotropic factor (BDNF). BDNF (a neurotrophin required for cell 
survival and regeneration) has been shown to suppress apoptosis of myelinating OLs as well as 
stimulating the proliferation of OPCs that may lead to an influx of new, mature OLs and 
remyelination of stripped axons (Zhang et al., 2005).  
Reactive gliosis observed in EAE is markedly reduced following EPO treatment (Agnello et al., 2002), 
resulting in a decrease in the production of ECM molecules including chondroitin and keratin 
sulphate proteoglycans released by reactive astrocytes (Silver and Miller, 2004, Canning et al., 1996, 
Zeinstra et al., 2003). These molecules are known to inhibit axonal regeneration (Canning et al., 
1996) and their reduction could improve the outcome of OL axon survival following demyelination 
and possibly transection. 
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Interestingly, astrogliosis (the proliferation of astrocytes in response to injury, also referred to as 
reactive gliosis) that was induced by KA injury is only partially reduced following EPO treatment and 
is not affected by EPOR blocking antibody. This is suggestive of an alternative pathway, not of the 
classical EPOR, for the reduction in reactive gliosis by EPO. Astrocyte proliferation in response to 
excitotoxicity may be mediated through activation of type 5 metabotropic glutamate receptors 
(mGluR5) which are found to be enhanced in astrocytes participating in reactive gliosis and which 
increase glutamate uptake (Yoo et al., 2009). Furthermore, the anti-inflammatory effects exerted by 
EPO are also thought not to be due to its direct intervention on the EPOR, but rather due to the 
prevention of the molecular signals released by injured neurons i.e. it is anti-inflammatory due to its 
neuroprotection (Villa et al., 2003). 
EPO presents a compelling case for use as a therapeutic agent in the treatment of MS. However, the 
issue of over-expression resulting in serious side-effects such as vascular perfusion defects, 
hypertension and thrombosis have caused researchers and doctors to be wary of its use. It was 
therefore crucial that the neuroprotection, anti-apoptotic, anti-oxidant, and anti-inflammatory 
actions of this molecule be separated from its haematopoietic properties or that it be modified such 
that the potential side-effects are negligible. 
EPO Derivatives that are nonerythropoietic but are tissue-protective 
In recent years, several derivatives of EPO have been produced that have the ability to be 
neuroprotective but not erythropoietic. The erythropoietic nature of EPO can be abolished through 
chemical modification i.e. carbamylation of the lysines (CEPO) or through amino acid substitution 
(asialoEPO). Erbayraktar et al., (2003) produced a variant of the EPO growth factor, 
asialoerythropoietin (asialoEPO) which was completely devoid of sialic acids. They found that even 
though it fails to increase erythrocyte mass, it is fully protective in animal models of stroke, spinal 
cord injury and peripheral neuropathy. It demonstrated a very short life in comparison to natural 
EPO (1.4 min vs. 5.6 hr), had a similar affinity to EPOR, was able to cross the BBB and has a 
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neuroprotective range between 5–50 µg/kg. The short half-life of the protein prevented any 
significant interactions occurring with the EPOR that may have initiated haematopoiesis as it was 
degraded so quickly, however once it crossed the BBB, it degraded much slower thus allowing 
EPOR/βcR binding and interaction that led to the initiation of neuroprotection (Rabie and Marti, 
2008).  
A carbamylated variant of EPO (CEPO) was produced by Leist et al. (2004) by changing all lysines to 
homocitruline. This carbamylation of the lysines of the EPO peptide profoundly altered the protein 
conformation resulting in a failure of CEPO to bind the EPOR dimer but retained its ability to cross 
the BBB. CEPO also had no effect on haematocrit even at high concentrations in the plasma and 
demonstrated reduced inflammatory response. The protective effect, also observed between the 
ranges of 5–50µg/kg, was retained as demonstrated by rescuing P19 mouse teratocarcinoma cells 
and hippocampal cells from apoptosis.  
Interestingly these alterations did not affect the tissue-protective aspects of EPO. Through analysis 
of the tertiary structure of EPO in aqueous media, it was determined that the helix B of EPO was the 
region of neuroprotective capabilities. A 25-mer peptide synthesized from helix B (HBP) was shown 
to be a potent tissue-protective molecule that was not erythropoietic both in vitro (in the UT-7 cell 
line) and in vivo (in a rat motoneuron model) (Brines et al., 2008). Notably, additional doses of HBP 
did not increase the level or degree of tissue-protection, corroborating the findings that a single 
signalling event is required to initiate sustained tissue-protection. Additionally, the aqueous face of 
the EPO molecule was obtained from crystallographic studies and an 11-mer peptide was 
synthesized from those amino acids of the aqueous face of EPO along with the three amino acids 
found within the proximal portion of the BC loop. This peptide (HBSP also known as ARA290: 
QEQLERALNSS) was completely unrelated to the EPO sequence but mimicked a particular section of 
its tertiary structure, was shown to have a very short half-life (~ 2min), was nonerythropoietic (as 
determined in vitro using the UT7-EPO cell line and in vivo in the rat) and was highly protective (as 
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demonstrated by a reduced degree of injury in a sciatic nerve crush model and an increase in the 
rate of healing in a model of non-ischemic wounding) (Brines et al., 2008, Erbayraktar et al., 2009).  
Transforming Growth Factor β  
Mature TGFβ is a 25 kDa multifunctional growth factor that is ubiquitously expressed in normal 
tissue and cell lines including mitogen-activated T cells, B cells, monocytes and fibroblasts (Rollnik et 
al., 1997). It is a member of a family of growth, differentiation, and morphogenesis autocrine and 
paracrine factors (Schultz-Cherry and Murphy-Ullrich, 1993).  
TGFβ Expression 
TGFβ is initially synthesized as a precursor peptide consisting of a signal peptide, a latency-
associated peptide (LAP) and the mature TGFβ molecule that are bound in conformation by covalent 
and noncovalent interactions. The signalling peptide of TGFβ is cleaved from the precursor peptide 
at amino acid residues Gly29 and Leu30 during transit through the rough endoplasmic reticulum. Once 
cleaved it is glycosylated at Asn82, Asn136 and Asn176 within the Golgi complex with sialated 
oligosaccharides (Gentry et al., 1988). Two 12.5 kDa polypeptide chains of mature TGFβ form a 
homodimeric TGFβ complex bound by a single disulphide bond (Shi et al., 2011). The C-terminal of 
the homodimeric TGFβ complex associates by non-covalent interactions to the N-terminal pro-
domain of its LAP (this structure is referred to as pro-TGFβ). LAP plays a variety of roles in the 
production and secretion of TGFβ by binding to various proteins during its transportation and 
processing. Importantly, LAP dimizes to create a ‘shell’ around TGFβ (forming the prodomain) thus 
conferring latency onto TGFβ. This latency regulates the bioavailability of TGFβ by controlling is 
activity and rendering it biologically inactive, and making it unable to engage the TGFβ receptor at its 
binding site. Interestingly, although the various isoforms of TGFβ (i.e. TGFβ1, TGFβ2 and TGFβ3) are 
structurally conserved, their LAPs differ in their amino acid sequences, perhaps contributing to their 
isoform-specific actions. Two polypeptide chains of pro-TGFβ, forming a dimer through a single 
disulphide bond, are attached to LAP by hydrophobic contacts to form a dimer called the Small 
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Latent TGFβ complex (SLTC) (also referred to as latent TGFβ) (Miyazono et al., 1988, Shi et al., 2011). 
It is in this form that TGFβ is secreted from the cell following processing with the Golgi network.  
Latent TGFβ also associates with latent binding proteins (LTBP’s), members of the LTBP/fibrillin-
family of ECM proteins prior to secretion via the forth cysteine residue, to form the Large Latent 
Complex (LLTC) before trafficking to the ECM (Shi et al., 2011). LTBP’s are important in the folding, 
activation and localisation of these protein complexes to the ECM. The release of the LLTC from the 
ECM is thought to occur at the hinge region i.e. a protease-sensitive region within the N-terminal 
domain of the LTBP found between the domains responsible for the binding of the molecule to the 
ECM and the SLTC (Koli et al., 2001). Intracellularly, mature TGFβ can be cleaved from the SLTC 
during transit within the Golgi network through proteolytic cleavage by Furin, a Ca2+ dependent 
serine endopeptidase that cleaves the protein at the RX(K/R)R motif found immediately upstream of 
the NH2-terminal of mature TGFβ (Dubois et al., 1995). This cleavage however, does not result in the 
release of the mature protein. TGFβ is maintained within the LAP prodomain dimers via electrostatic 
and ionic interactions. In vitro the electrostatic interactions can be broken through a number of 
actions such as extremes in pH, high temperatures, sodium dodecyl sulphate (SDS), urea, or by some 
endopeptidases. Liberation of the mature TGFβ peptide can also be achieved by altering the protein 
conformation, by direct interaction with integrins or thrombospondin-1 (TSP1) (Schultz-Cherry and 
Murphy-Ullrich, 1993), through exposure of the TGFβ receptor type II binding site of the cell surface, 
or through receptor binding of LAP (Miyazono and Heldin, 1989). LAP contains 3 N-linked 
glycosylation sites, two of which have mannose-6-phosphate residues that are thought to act in the 
activation of the latent protein by binding to mannose-6-phosphate receptors.  
TGFβ Receptor and Signalling Pathways 
Many cells have TGFβ receptors and the protein is expressed by most cells. Within the CNS, TGFβ is 
produced by T cells, LPS-activated mononuclear phagocytes, astrocytes, microglia and neurons. The 
receptor consists of two proteins, TGFβ receptor type I (TGFβRI) and TGFβ receptor type II (TGFβRII). 
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Once active TGFβ binds to its receptor, TGFβRII signals through a serine/threonine kinase domain. 
This signals the phosphorylation of the Caenorhabditis elegans Sma and Drosophila Mad (SMAD) 
proteins, whilst forming a receptor-ligand heterodimeric complex. This results in the auto-
phosphorylation of the receptor followed by the phosphorylation of the receptor-regulated SMAD 
(R-SMAD). This leads to the activation of homo-oligomeric and hetero-oligomeric complexes that 
translocate to the nucleus to associate with various molecules such as DNA-binding molecules and 
transcriptional co-activators/co-repressors to regulate the activity of the target genes (Mirshafiey 
and Mohsenzadegan, 2009).  
TGFβ has demonstrated a pivotal role in the functioning of the immune system. It has been found to 
inhibit pro-inflammatory growth factor expression such as TNF-α, IFN-γ, IL-1, IL-2 and lymphotoxin, 
block growth factor induction of adhesion molecules, and to prevent entrance of sensitised T cells 
into the CNS by inhibiting the adhesive ability of endothelial cells (Gamble and Vadas, 1991, 
Santambrogio et al., 1993, Rollnik et al., 1997, Mirshafiey and Mohsenzadegan, 2009). It also plays a 
significant role in immune tolerance through the differentiation of CD4+ T cell into TReg cells (CD4
+, 
CD25+, FoxP3+) (Fantini et al., 2004), inhibition of T cell proliferation by blocking the expression of 
pro-inflammatory growth factors such as IL-2 (Li and Flavell, 2006), by blocking growth factor 
induction on adhesion molecules and by maintaining APCs in an immature state (Mirshafiey and 
Mohsenzadegan, 2009). TGFβ has also recently been demonstrated having a role in differentiation of 
the autoreactive and disease promoting CD4+ T cell, Th17, which secretes the pro-inflammatory 
growth factor IL-17 (Veldhoen and Stockinger, 2006). These properties highlighted TGFβ as a 
potential regulatory molecule for the treatment of the EAE.  
TGFβ and EAE/MS 
Initial studies utilizing TGFβ as a therapeutic molecule in EAE demonstrated inhibition of the disease 
in T cell adoptive transfer induced EAE mouse models. TGFβ also reduced the degree of perivascular 
inflammatory cell infiltrates and prevented demyelination in the CNS (Racke et al., 1991). Further 
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studies demonstrated that treatment with TGFβ activated T cells inhibit the secretion of the pro-
inflammatory growth factors TNF-α and IFN-γ, and suppress its capacity to induce EAE. TGFβ1 has 
also demonstrated disease amelioration through the proliferation of the protective Th3 cell type.  
TGFβ has also demonstrated significant neuroprotective effects both in vitro and in vivo (Flanders et 
al., 1998). It has demonstrated anti-apoptotic effects via the suppression of Bad expression and an 
increase in Bad phosphorylation (Zhu et al., 2002); and in murine cortical cells and rat hippocampal 
neurons, TGFβ prevents excitotoxity-induced neuronal death (Prehn et al., 1994, Ruocco et al., 
1999). Additionally TGFβ, when injected into the CNS of Biozzi ABH mice as a DNA-cationic liposome 
complex, inhibited the development of clinical EAE (Croxford et al., 1998).  
In a phase I clinical trial involving 11 patients with SPMS, five patients treated with active TGFβ2 had 
a reversible decline in the glomerular filtration rate (the flow rate of filtered fluid through the kidney 
giving an indication of the kidney’s state). In addition, 8 patients displayed a decrease in 
haemoglobin; however, to what extent this was attributable to the drug is unclear. Furthermore, no 
notable change was observed in EDSS scores but, as the trial was designed to access the safety of the 
drug and not its efficacy, no definite conclusions could be made (Calabresi et al., 1998). 
On the other hand, studies on EAE mice models using TGFβ have demonstrated disease 
amelioration, as well as a reduction in demyelination and proinflammatory growth factors (Johns et 
al., 1991). Furthermore as increased levels of total TGFβ are seen in the cerebrospinal fluid but are 
reduced as biologically active TGFβ in the serum, it can be said that TGFβ may act as an indicator of 
disease limitation (Rollnik et al., 1997). With these points in mind, TGFβ still remains a promising 
therapeutic agent for MS.   
CHAPTER 1: INTRODUCTION 
 
        78 
Insulin-like Growth Factor 1 (IGF1) 
IGF1 Expression and Regulation 
IGF1 is a single chain polypeptide of approximately 17 kDa. It is produced by many tissues including 
the CNS and the liver (Cohick and Clemmons, 1993, van Buul-Offers and Kooijman, 1998). There are 
four splice variants of the IGF1 gene: Types 1 and 2 and classes A and B are all derived from 
alternative splicing and from the two transcriptional start sites found on either exon 1 or 2 (Figure 
1.5). At the time of writing, no studies that compare the two isoforms IGF1A and IGF1B and their 
functions within the CNS have been reported.  
IGFs bind to the IGF type I receptor (IGF1R) and can also activate the insulin receptor (INSR). These 
receptors are α2β2 (tetrameric) transmembrane glycoproteins that auto-phosphorylate following 
ligand interaction (Cohick and Clemmons, 1993). The IGF1R is expressed on lymphocytes, 
myelinating OLs, and brain capillary endothelium (van Buul-Offers and Kooijman, 1998, Liu et al., 
1994, Komoly et al., 1992, Wilczak et al., 2008).  
The IGF system includes the IGF binding proteins (IGFBPs) of which 6 have been identified (IGFBP1-
6). The IGFBPs are carrier proteins and are responsible for the transport of IGFs to their target cells, 
for prolonging their half-life and for diminishing their hypoglycaemic effect (Wilczak et al., 2008, van 
Buul-Offers and Kooijman, 1998). They also have the ability to sequester IGFs away from their 
receptors. These 25–45 kDa binding proteins have phosphorylation and glycosylation sites that 
facilitate their binding to IGF’s with varying affinities (van Buul-Offers and Kooijman, 1998). IGF1 and 
IGF2 circulate predominantly in growth hormone-dependent ternary complexes of high molecular 
weight that consist of IGFBP, IGF and an acid-labile glycoprotein subunit that does not bind IGF. 
IGFBP3 is the most abundant IGF-binding subunit of the growth hormone-dependent binding 
complex found in the serum. It has a very high-affinity for both IGF1 and IGF2, and over 95% of free 
IGF1 is found bound to IGFBP3 (Cohick and Clemmons, 1993). 
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Figure 1.5: Schematic diagram indicating IGF1 alternative splicing.  
(A) Alternative splicing of IGF1 mRNA. The IGF1 gene contains six exons that, through alternative splicing, generate four 
isoforms of IGF1: two classes and two types. (B and C) Alternative splicing of exons 1, 2, 5 and 6 leads to four isoforms of 
IGF1. Exon 1 and 2 encode distinct leader peptide sequences defining the class (i.e. 1 or 2), as well as part of the signal 
peptide and are known as the leader sequences. Exons 3 and 4 are identical in all isoforms. Exon 3 encodes the remainder 
of the signal peptide along with part of the mature peptide. Exon 4 encodes the remainder of the mature peptide and part 
of the amino-terminal end of the E-peptide. Exons 5 and 6 encodes distinct carboxy-terminal ends and the 3’ UTR that 
define the type (i.e. a or b) of the IGF1 isoform. The initiation of transcription at exon 1 and excition of exon 2 results in the 
class 1 isoforms; whereas class 2 isoforms are transcribed from exon 2 leading to the exclusion of exon 1 during 
transcription. Stop codons and polyadenylation sites within exon 5 result in type ‘b’ isoforms, whereas the excision of exon 
5 coupled with stop codons and polyadenylation sites within exon 6 result in type ‘a’ isoforms.    
 
IGF1 and EAE/MS 
In vitro IGF1 has been shown to be neuroprotective by promoting oligodendrocyte development, 
maturation and growth; and has demonstrated myelination and regeneration (Mozell and McMorris, 
1991). In vivo, IGF1 is expressed in remyelinating lesions by reactive astrocytes, OLs and Mø, 
presumably induced by the proinflammatory growth factor IL-1β, and by OLs (Komoly et al., 1991, 
Lee et al., 1992, Liu et al., 1994, Yao et al., 1995, Mason et al., 2000, Mason et al., 2001, Wilkins et 
al., 2001, O'Leary et al., 2002, Wilczak et al., 2008). Expression of IGFBP1 and IGFBP6 by OLs at the 
edge of demyelinated lesions and of IGFBP2 by astrocytes in the CNS of EAE mice is reported to 
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coincide with IGF1 expression (Liu et al., 1994, Yao et al., 1995, Wilczak et al., 2008). Additionally, its 
effects are enhanced when coupled to a growth factor complex (Finkelman et al., 1993). Indeed, 
when IGF1 was coupled to IGFBP3 in vitro and injected i.p. into EAE mice, the onset of disease was 
delayed. This initial delay in onset of disease may be attributable to IGF1 preventing disease-causing 
cells from entering the CNS. However, those mice injected with the IGF1/IGFBP3 complex eventually 
went on to develop more severe disease symptoms. It was discovered that not only did the 
IGF1/IGFBP3 complex fail to inhibit the transfer of disease by adoptive transfer, it also enhanced the 
proliferation of those encephalitogenic T cells (Lovett-Racke et al., 1998).  This is corroborated by the 
study by Ye et al., (1995) demonstrating that IGF1-induced cell survival and myelination is inhibited 
by IGFBP1 which may account, at least in part, for the failure of IGF1 to enhance CNS myelin repair 
during autoimmune demyelination or the lack of remyelination in chronic demyelinated lesions 
(Cannella et al., 2000). 
IGF1 is a potent inducer of OL development and of myelination in vitro, and a promoter of neural cell 
proliferation and differentiation during development (McMorris et al., 1986, McMorris and Dubois-
Dalcq, 1988, Mozell and McMorris, 1991, Shinar and McMorris, 1995, Annenkov, 2009). IGF1 has 
demonstrated enhanced synthesis of myelin proteins MBP and PLP in a monophasic model of EAE, 
as well as a reduction in lesion size and number and an improvement in clinical signs (Yao et al., 
1995). This improvement in clinical signs in EAE has been confirmed by other studies in the acute 
phase (Cannella et al., 2000, Li et al., 1998, Lovett-Racke et al., 1998) including the lack of 
demyelination observed during the chronic phase following IGF1 treatment (Cannella et al., 2000, 
Frank et al., 2002, O'Leary et al., 2002). The initial appearance of myelin proteins during early 
disease may be due to a distinct mechanism involving multiple factors not directly influential on OLs 
that IGF1 alone cannot replicate within the chronic demyelinated lesion (Komoly et al., 1992, O'Leary 
et al., 2002).  
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However, when patients with secondary progressive MS were treated with recombinant IGF1 for a 
period of 24 weeks in an open-label early phase II crossover trial design, no evidence of 
remyelination or even demyelination were detectable by MRI studies (Frank et al., 2002).  
Although the delivery of IGF1 within the EAE model and within the pilot study has been s.c, 
intraperitoneal (i.p), or systemic, the efficacy (or lack of it) may be in part due to the limited delivery 
of the protein to the CNS or the OLs. Additionally, due to the pleotropic nature of the protein, 
systemic release may directly influence the immune response (Liu et al., 1997) resulting in the 
exacerbation of the disease and unwanted side effects. The delivery of IGF1 through retrograde 
transport by an adeno-associated viral vector in a mouse amyotrophic lateral sclerosis (ALS) model, 
demonstrated local sustained delivery of the protein to the CNS without eliciting an immune 
response (Kaspar et al., 2003, Genoud et al., 2005). However, no clinical recovery was observed and 
moreover, symptoms were exacerbated when IGF1 was delivered after disease onset (Lovett-Racke 
et al., 1998, Genoud et al., 2005). These studies used dose levels that were acceptable in treating 
endocrine disorders which, when delivered locally, may be overwhelming and negative.  
Gene Therapy 
The introduction of genetic material into the cells of a patient with the intention of alleviating or 
treating a disease is known as somatic gene therapy. It is the lack of effective conventional 
treatments for disease that is the driving force for the development of novel gene therapies. 
Conventional treatments such as protein therapies are expensive to produce, involve proteins with 
short half-lives, and require systemic administration in high concentrations in order to elicit a local 
response in biologically relevant concentrations. This systemic administration may also result in 
unwanted side-effects. Gene therapy on the other hand, has the potential for long-term expression 
that is not only safe (proteins can be engineered to have short half-lives or indeed to be latent until 
reaching sites of disease (Adams et al., 2003, Chernajovsky et al., 2004)) but also have the ability to 
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be locally regulated by transcriptionally regulated plasmids that are modulated in response to 
pharmalogical agents (e.g. tetracycline), or to pathological conditions (e.g. in inflammation).  
The use of viral vectors is the adaptation of a virus’ natural ability to infect a host cell. They have 
been modified in vitro to be replication-deficient and are therefore unable to proliferate. This 
increases the safety of using viral vectors as therapeutic tools. Further strategies used for improving 
the safety of viral vectors includes the use of gutless adenoviral vectors (adenoviral vectors in which 
most of the viral genes have been removed in order to avoid immunogenicity), and the deletion of 3’ 
long-terminal repeats (LTR). Infection of cells with therapeutic genes boosts the ability of utilizing 
ones own cells to produce the therapeutic molecules i.e. to become in vivo factories of recombinant 
proteins.  
The approach taken for gene therapy of a particular disease is dependent on the molecular target, 
for example with the reconstitution of insulin expression in type-1 diabetes. Another approach may 
be the compensation of reactive immune cells expressing pro-inflammatory growth factors with the 
expression of anti-inflammatory growth factors such as TGFβ.  The choice of vector to use in gene 
therapy is dependant on the size of the therapeutic gene needing to be introduced, the 
immunogenicity of the vector (less important if the expression is only required for a short duration), 
the longevity of expression, as well as the type and location of the cells targeted for infection. 
Transcriptionally regulated plasmids (such as the Tet-On system) are beneficial for diseases that 
require the cessation of a therapeutic treatment during periods of remission, such as in MS. Tet-On 
is a method of inducible expression in which transcription of the therapeutic gene is reversibly 
turned on or off in the presence of the tetracycline analogue doxycycline. The vector contains the 
gene encoding the transactivator protein rtTA (reverse-tetracycline-regulated transactivator) which, 
in the presence of doxycycline, envokes a conformational change allowing it to bind to the promoter 
leading to transcription of the therapeutic gene. In the absence of doxycycline, TetR (a eukaryotic 
repressor, Tetracycline repressor) binds strongly to the gene preventing transcription, but when 
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exposed to doxycycline, is removed. Immunogenecity of the vector can also be modified, for 
example through the addition of poly-glycine-alanine repeats of the Epstein-Barr virus nuclear 
antigen 1 (EBNA1) which prevents the degradation of the protein by the proteasome (Chernajovsky 
et al., 2004). The type of viral vector used will also affect the type of cell that can be infected such as 
the use of a lentiviral vector in order to infect cells that are non-dividing. Additionally, the location is 
an important consideration for determining the route of gene therapy administration. For example, 
gene therapy for MS involves targeting the CNS, an environment that is preferential in its entry to 
therapeutic molecules. The modification of a therapeutic gene to secrete latent growth factors has 
the potential to gain entry into this privileged area (Adams et al., 2003).     
A successful therapeutic approach for MS should be able to deliver the therapeutic molecules 
directly into the CNS, not be immunogenic, be able to rescue surviving OLs and induce OL migration 
and differentiation into demyelinating areas (Martino, 2003) resulting in tissue regeneration and 
repair. Such approaches have been taken in the EAE model of MS, for example through the systemic 
delivery of genetically modified encephalitogenic T cells expressing either the α-subunit of PDGF 
(platelet-derived growth factor) or of NGF (nerve growth factor) into the CNS ; and by direct 
introduction into the CNS via intraparenchymal and intrathecal implantation of TGFβ and dTNFR 
respectively (Chen et al., 1998, Croxford et al., 2000, Martino, 2003, Chernajovsky et al., 2004). 
The Role of MMPs in the pathology of MS 
MMPs are zinc-containing, calcium-dependent endopeptidases (Meraz-Cruz et al., 2006) involved in 
the degradation and remodelling of the extracellular matrix (ECM). They perform a pivotal role in 
physiological conditions such as wound healing, angiogenesis, bone remodelling, and in pathological 
conditions such as tumour invasion, inflammation, BBB disruption, and MS. The family of MMPs 
consists of at least 23 members comprising collagenases, gelatinases A and B (MMP2 and MMP9 
respectively), stromelysins (such as MMP3), matrilysin (MMP7), metalloelastase and membrane-
type metallo-proteinases. T cells, Mø, neurons, astrocytes and OLs all express MMPs (Anthony et al., 
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1998, Cossins et al., 1997, Maeda and Sobel, 1996). MMP activity is tightly regulated at three distinct 
levels: gene-transcription, pro-enzyme activation and by the activity of tissue-inhibitors of metallo-
proteinases (TIMPs). Gene transcription of MMPs can be supressed or induced by growth factors 
such as TNFα, IL-1 and TGFβ respectively. MMPs are initially secreted as inactive enzymes containing 
a zinc-molecule bound to a cysteine residue in its catalytic domain. Activation occurs via proteolytic 
cleavage by other MMPs or other proteinases such as plasmin. This cleavage disrupts the cysteine-
zinc interaction, modifies the enzyme conformation and exposes the active catalytic site. After 
activation, MMPs are regulated through inhibition by TIMPs. TIMPs are ubiquitously expressed in the 
extracellular environment and form a complex of 1:1 ratio with the MMP. This regulation may be 
overcome by a decrease in inhibitors such as α1-antitrypsin, a serine proteinase inhibitor that has 
the ability to inhibit TNFα and MMP in alveolar Mø in response to thrombin and cigarette smoke 
extract  (Kieseier et al., 1999, Churg et al., 2003), or an excess in MMP production and activation 
leading to tissue damage and cell invasion.  
MMPs play a role in the pathogenesis of inflammatory demyelinating diseases such as MS. Increased 
MMP expression has been demonstrated in animal models of EAE (Anthony et al., 1998, Proost et 
al., 1993) and in the CSF of MS patients, as well as in preactive and demyelinating lesions (van 
Horssen et al., 2006, Gold et al., 2000, Maeda and Sobel, 1996, Cossins et al., 1997) with MMP7 and 
MMP9, expressed by Mø within the lesion (Anthony et al., 1998), coinciding with peak disease 
severity (Clements et al., 1997). MMPs are expressed within CECs and open the BBB through 
hydrolysis of ECM components such as type IV collagen, fibronectin and laminin in the basal 
membrane, facilitating the trafficking of leukocytes into the CNS (Rosenberg et al., 1992, Vince et al., 
1999, Costello et al., 1994). This degradation of the BBB and the subsequent transmigration of T cells 
across the endothelium are normally blocked by TIMPs activity, as is the activation of pro–
inflammatory growth factors such as TNFα by MMPs. However, MMPs can be stimulated by pro–
inflammatory growth factors (Han et al., 2001, Gearing et al., 1995).  
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MMPs can also degrade components of the myelin sheath such as MBP with the resulting peptide 
fragments viewed as a foreign antigen (Chandler et al., 1995). This may elicit an immune response 
that could contribute to the preservation of the inflammatory response within a lesion and to its 
demyelination. The ability of MMPs to activate latent enzymes through proteolytic cleavage, and 
their increased expression during inflammation is an attractive combination for the development of 
a therapeutic molecule that if initially latent can be rendered active at sites of increased MMP 
expression such as in MS lesions.  
LAP TECHNOLOGY 
Even after 150 years since the first formal classification of the disease, MS does not have any 
answers that shed light on its epidemiology, risks or aetiology. Many therapeutics have been 
investigated and proposed for the treatment of MS. Unfortunately none have yet been identified 
that arrest the destruction and degeneration of the CNS or restore functionality to those areas of the 
CNS that have been affected.  
The growth factors EPO, TGFβ and IGF1 have demonstrated therapeutic potential in the EAE model 
for the treatment of MS. However, they exhibit several undesirable characteristics such as a short 
half-life, unwanted and potentially harmful side-effects in the high concentrations needed for 
treatment, and have ubiquitous and widespread biological activity. In order to develop a therapeutic 
molecule whose biological activity is inhibited but that can be unblocked at the site of disease, 
Adams et al. (2003) produced a latent growth factor. They encapsulated IFN- within a shell 
provided by LAP of TGF. LAP was fused to the growth factor via a MMP cleavage site. The LAP shell 
is disulphide bonded closing the shell and rendering the growth factor latent (Figure 1.6). Activation 
of the growth factor was achieved by cleavage of the LAP, from the growth factor, by the action of 
the endogenous MMPs that are found at sites of inflammation and tissue remodelling. By adopting 
the LAP from a native protein, they were able to bypass the side effects normally seen from systemic 
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administration of a novel protein that is not latent. This LAP technology increases the half-life of 
peptides and growth factors and enables their specific delivery to sites of disease through the 
targeted release of local MMPs.
 
Figure 1.6 Latent growth factor fusion-protein structure.  
The protective shell surrounding the growth factor is derived from the latency-associated peptide (LAP) of TGF 
(transforming growth factor)-β and serves to prevent growth factor interaction with its receptors, increasing the half-life of 
the growth factor in vivo. The cleavable matrix metalloproteinase (MMP) site can be tailored to be sensitive to the MMPs 
that are abundant in certain pathological conditions. Cleavage by MMP releases the growth factor or other therapeutic 
agent so that it acts locally, at the site of disease.  
AIM 
The aim of this study was to utilise the latency associated peptide technology to render each of the 
growth factors EPO, TGFβ and IGF1 latent in order to localise effective concentrations to sites of 
inflammation and damage found within the CNS of the EAE mouse model of MS. I hypothesise that 
the latent rendering of these growth factors will inhibit any interaction with the respective receptors 
until they have been released within regions of up-regulated MMP activity such as within 
demyelinating lesions. Once released, the biologically active growth factor can exert its 
neuroprotective and/or anti-inflammatory influence on its targets in the immediate 
microenvironment. As the concentrations of the growth factor are therapeutically effective but 
localised, they should not lead to systemic side effects.  
This thesis details the structural design, production and in vivo testing of this novel therapeutic tool. 
In chapter 3, the construction and in vitro characterisation of these latent growth factors is 
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addressed. Chapter 4 details the delivery of these growth factors by cells genetically modified in 
vitro using lentiviral vector. The final chapter, chapter 5, assesses the therapeutic potential of the 
latent growth factors EPO and TGFβ in the EAE mouse model of MS. 
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MOLECULAR CLONING 
All chemical reagents came from Sigma-Aldrich®, Dorset, UK, unless otherwise stated. All DNA 
restriction enzymes and DNA modifying enzymes came from New England Biolabs (NEB), Hitchin, UK, 
unless otherwise stated. All cell culture reagents came from Cambrex, Workingham, UK unless 
otherwise stated. 
PCR amplification 
In order to generate the DNA sequences required for subcloning into an expression vector, the 
growth factor specific DNA was amplified using growth factor specific primers (Table 2.1) that 
incorporated specific restriction enzyme recognition sequences to both the 5’ and the 3’ end of the 
required DNA sequence. The DNA was amplified by 30 cycles of amplification using the Bio-Rad Gene 
Cycler Thermal Cycler® PCR machine. Optimal conditions were determined by performing PCR at 
different concentrations of MgCl2 (1–2.5mM) and different annealing temperatures (45°C–65°C).  
huTGFβ PCR amplification 
The human TGFβ gene (huTGFβ) was amplified by Platinum® Pfx DNA polymerase (Invitrogen, 
Paisley, UK)–a DNA polymerase possessing proofreading capabilities–using plasmid huTGFβ-Babe 
neo (-5’UTR) (Chernajovsky et al., 1997) as a template. Based on the gene sequence of huTGFβ, 
oligonucleotide primers were synthesized to amplify the intact DNA sequence region of mature 
TGFβ. The forward primer (A) 5’-CGCGGCCGCAGCCCTGGACACCAACTATTGC-3’ introduced a NotI 
restriction site (underlined) just prior to initiation of the mature protein antisense. The reverse 
primer (B) 5’-CGCTCCTGCAAGTGCAGCTGACTCTAGACC-3’ is complementary to the nucleotides 
positioned prior to the stop codon and introduced an XbaI (underline) restriction site just 
downstream to the stop codon. The PCR mixture consisted of 10μl Pfx amplification buffer (1x final), 
2μl dNTP mix (200μM of each final), 1.5μL each of forward and reverse primers (0.3μM each primer 
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final), 0.5μl of Platinum Pfx DNA polymerase (1 unit), and 200ng of template in a total volume of 
50μl. The PCR was performed with the following cycling profile: initial denaturation at 95°C for 2 
min, followed by 30 cycles of 1 min denaturation at 95°C, annealing at 50°C for 1 min, and extension 
at 72°C for 2 min. The time for the final extension step was 5 min at 72°C. After PCR the product was 
pooled and purified using either the Qiagen Qiaquick PCR purification kit (Qiagen, Cawley, UK) 
following the manufacturer’s protocol; or by phenol: chloroform extraction and then by DNA 
precipitation either using 0.3M sodium acetate pH 5.2, or 2M ammonium acetate pH 4.8, and 2.5-3 
volumes ethanol, prior to separation using agarose gel electrophoresis, to a final volume of 50µl. 
mIGF1 PCR amplification 
The mature IGF1A or IGF1B genes were initially amplified by Taq polymerase using the cDNA from 
mouse brain as a template. The difference in the isotypes IGF1A and IGF1B is the inclusion or 
exclusion of exon 5. Based on this, the oligonucleotide primers were synthesized to amplify the 
intact IGF1B and a truncated IGF1A product. The forward primer (W) 5’- 
CGCGGCCGCAGGACCAGAGACCCTTTGC-3’, introduced a NotI restriction site (underlined) just prior to 
initiation of the mature protein. The reverse primer 5’-CTACTTGTGTTCTTC-3’ is complimentary to 
the nucleotides positioned before a stop codon within exon 6, exon 6 has the same nucleotide 
sequence for both isoforms mIGF1A and mIGF1B. These primers correspond to the boundaries of the 
coding sequence for both isoforms mIGF1A and mIGF1B from translation initiation to a termination 
codon found near the beginning of exon 6. The PCR mixture consisted of 5μl reaction Taq buffer (1x 
final), 1.5μl dNTP mix (0.3μM of each final), 1.5μL each of forward and reverse primers (0.3μM each 
primer), 0.5μl of Taq DNA polymerase (5U/μl), and 100ng of template in a total volume of 50μl. The 
PCR was performed with the following cycling profile: initial denaturation at 94°C for 5 min, followed 
by 30 cycles of 1 min denaturation at 94°C, annealing at 55°C for 2 min, and extension at 72°C for 3 
min. The time for the final extension step was 5 min at 72°C. After PCR the product was pooled and 
purified using either the Qiagen Qiaquick PCR purification kit (Qiagen, Cawley, UK) following the 
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manufacturer’s protocol; or by phenol: chloroform extraction and then by DNA precipitation either 
using sodium acetate or ammonium acetate and 2.5-3 volumes ethanol, prior to separation using 
agarose gel electrophoresis. Once separated the PCR fragments were excised using a sharp scalpel 
and purified (see below). 
 
However, once the products were sequenced, it was found that the mIGF1A PCR product was 
truncated at the 3’ end. The difference between the two isoforms mIGF1A and mIGF1B is due to 
alternative splicing of exon 5. Inclusion of this exon in mIGF1B generates a frame shift in the reading 
frame resulting in the stop codon used in the design of the original reverse primer. However mIGF1A 
does not contain exon 5 and therefore this stop codon does not exist within its reading frame, its 
(mIGF1A) stop codon occurs further downstream towards the end of exon 6. By using the reverse 
oligonucleotide primer (AJ) 5’-TATGCATCTAGACTACATTCTGTAGGTCTTGTTTCCTGCACTTCCTCTACTT 
GTGTTCTTCAAATGTAC-3’ that is complimentary (bold nucleotides) to the nucleotides positioned 
towards the 3’ end of the truncated IGF1A product, and which additionally contains the remaining 
nucleotides required to complete the mature IGF1A DNA sequence and introduces an XbaI 
restriction site (underlined) just downstream to the stop codon, the sequence was elongated and 
completed. The elongation of the truncated IGF1A product was performed using the Platinum® Pfx 
DNA (Invitrogen) polymerase to ensure correct amplification. The PCR product was purified using 
either the Qiagen Qiaquick PCR purification kit (Qiagen, Cawley, UK) following the manufacturer’s 
protocol; or by phenol: chloroform extraction and then by DNA precipitation either 0.3M sodium 
acetate pH 5.2, or 2M ammonium acetate pH 4.8, and 2.5-3 volumes ethanol, prior to separation 
using agarose gel electrophoresis. Once separated the PCR fragments were excised using a sharp 
scalpel and purified.  
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Table 2.1 Sequences of PCR primers and annealing oligonucleotides.  
Restriction sites used for cloning are underlined. The base pairs added for better efficiency of restriction enzyme cutting 
are in small, plain letters. Those nucleotides in bold, of the antisense IGF1 (AJ) primer, represent the nucleotides that 
anneal to the beginning of exon 6 on the IGF1 DNA sequences, with the remaining nucleotides until the XbaI restriction site 
filling in the missing remainder of the exon. The nucleotides in italics indicate the in-frame stop codon introduced within 
the stuffer sequence. 
 
Separation of DNA fragments using agarose gel electrophoresis 
The quantity and quality of the PCR product was assessed by agarose gel electrophoresis. DNA was 
diluted in either 1x Orange G (Sigma-Aldrich, Dorset, UK) or 1x bromophenol blue loading dye (6x 
stock: 0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol made up in distilled water) 
and loaded into a 1% (w/v) agarose gel (containing 0.5μg/ml ethidium bromide final) placed in 0.5x 
TAE (50x: 2M Tris-acetate, 100mM Na2EDTA in dionized water, pH 8.3, National Diagnostics, 
Yorkshire, UK). Electrophoresis was done for ~45 min at 120V alongside 10µl of either 1 kb or 1 kb 
Primer Sequence Restriction site 
mIGF1 Sense (W) 
5’-CGCGGCCGCAGGACCAGAGACCCTTTGC 
Antisense (M) 
5’- AGATCTCTACTTGTGTTCTTCA 
 
NotI 
 
XbaI 
mIGF1  Antisense (AJ) 
5’-TATGCATCTAGACTACATTCTGTAGGTCTTGTTTCCTGCACTTCCTCTACTTG 
TGTTCTTCAAATGTAC 
 
XbaI 
huTGF  Sense (1) 
5’-CGCGGCCGCAGCCCTGGACACCAACTATTGC 
Sense (2) 
5’-TAGACTAGATCTATGCCGCCCTCCGGGCTGC 
Antisense (1) 
5’- GGTCTAGAGTCAGCTGCACTTGCAGGAGCG  
Antisense (2) 
5’-TAGACTTACGTATTCGAACTAGTCAGCTGCACTTGCAGGAGCGCACG 
 
NotI  
 
XbaI  
 
BglII 
 
SpeI/ 
BstBI/ 
SnaBI 
GlySer linker Sense 
5’-AATTCGGGTGGGGGCGGTTCGGGTGGCGGGGGCTCGGGCGGGGGTGGCTC 
AGGC 
Antisense 
5’-TCGAGCCTGAGCCACCCCCGCCCGAGCCCCCGCCACCCGAACCGCCCCCACC 
CG 
 
EcoRI 
 
 
XhoI 
Stuffer 
nucleotides 
Sense 
5’-GGCCGCATGAATTCA 
Antisense 
5’-CTAGTGAATTCATGC 
NotI overhang/ 
EcoRI 
 
SpeI overhang 
CHAPTER 2: MATERIALS AND METHODS 
 
        93 
Plus DNA ladder (Invitrogen), in 0.5x TAE running buffer. The DNA fragments were then visualised 
under UV light and the image captured using a gel documentation system (UviTec, Cambridge, UK).  
Purification of DNA from agarose gel 
Following separation of the DNA fragments by electrophoresis, gel slices containing bands of interest 
were purified using the Roche Agarose Gel DNA Extraction kit (Roche Applied Science, Mannheim, 
Germany) according to the manufacturer’s’ protocol. Briefly, the gel slice was solubilised at 65°C in 
solubilisation buffer containing a silica suspension. Following centrifugation, the pellet was 
resuspended in DNA binding buffer before washing and resuspending in deionised H2O (dH2O, Elix™ 
Purification system; Millipore, Watford, UK). 
Purification of DNA from solutions 
All centrifugation steps were done at room temperature in a bench top microfuge centrifuge unless 
otherwise stated. 
For DNA extraction, an equal volume of water-saturated phenol: chloroform 
(Phenol:Chloroform:Isoamyl alcohol (25:24:1), Biogene, Cambs, UK) was added to the sample, 
vortexed for 1 min and then centrifuged (12 000 rpm, 2 min). The top aqueous phase containing the 
DNA was carefully removed and transferred into a sterile microfuge tube. Either 1μl of 3M Sodium 
Acetate pH5 was added to every 10 μl of sample, followed by the addition of 2.5 volumes absolute 
ethanol; or ammonium acetate was added to a final concentration of 2M, followed by the addition 
of 3 volumes absolute ethanol. The tube was gently inverted to mix and then placed at -20°C for 20 
minutes to allow the DNA to precipitate. The sample was then centrifuged (12 000rpm, 10 minutes), 
the supernatant aspirated using a gentle vacuum, and the DNA resuspended in an appropriate 
amount of buffer (10mM Tris-Cl, 1mM EDTA, pH 8.5) and stored at 4°C until needed. DNA 
concentration was determined using either a GenQuant spectrophotometer (Pharmacia, Surrey, UK) 
or the NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, U.S.A.) at the 
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260 nm wavelengths. Alternatively, the Qiagen Qiaquick PCR purification kit (Qiagen, Cawley, UK) 
following the manufacturer’s protocol was used. 
TA® Cloning 
The purified PCR products (huTGFβ, mIGF1A and mIGF1B) were then cloned into the pCR2.1 plasmid 
vector. PCR products generated using Taq polymerase have a non-template derived deoxyadenosine 
(A) addition to its 3’ end, which the TA Cloning® kit exploits by enabling ligation of the PCR product 
to the pCR 2.1 plasmid vector–a linearised plasmid vector that contains a single 3’ deoxythymidine 
(T) residue. Products amplified by Pfx DNA polymerase do not contain this additional 
deoxyadenosine as the enzyme removes the 3’ A-overhangs in its proofreading activity. Addition of 
these 3’ A-overhangs was achieved through incubation with Taq at the end of the reaction. The PCR 
reaction sample was incubated on ice and 1U of Taq polymerase was added and the sample mixed 
well. The sample was then incubated at 72°C for 10 minutes before immediate extraction via phenol: 
chloroform precipitation and was resuspended in an appropriate amount of deionized H2O. For 
cloning of the PCR products into the pCR2.1 plasmid vector, the amount of PCR product required is 
calculated using the following equation: 
X ng PCR product = (y bp PCR product) (50ng pCR®2.1 vector) 
                Size in bp of pCR®2.1 vector ~ 3 900bp 
 
, where x ng is the amount of PCR product of y base pairs to be ligated for a 1:1 (vector: insert) molar 
ratio.  
Digestion and Ligation 
The latent growth factor constructs were produced by sequential cloning of the different growth 
factor fragments into, firstly, the pCR2.1 cloning vector followed by subcloning into the pcDNA3 
expression vector.  
CHAPTER 2: MATERIALS AND METHODS 
 
        95 
All PCR products, as well as the plasmid vectors and viral vectors, were incubated overnight at 37°C 
with specific restriction enzymes (Table 2.1). The digested fragments were separated on 2% and 1% 
agarose gels according to fragment size with 0.5% TAE as described earlier. DNA fragments of 
interest were excised using a sharp scalpel, before purifying as described earlier.  
The ligation stage was achieved using T4 DNA ligase (NEB) and was performed using the 
manufacturer’s recommended protocol. The amount of DNA needed for a 3:1 (insert: vector) molar 
ratio is determined by the equation: 
X ng product = (y bp product) (z ng vector) 
          Size in bp of vector 
 
followed by the addition of 1x T4 DNA ligation buffer (500mM Tris-HCl, 100mM MgCl2, 10mM ATP, 
100mM dithithreitol (DTT; pH 7.5) and 1U T4 DNA ligase enzyme to a final volume of 10µl, and 
incubated overnight at 4°C. This was followed by competent Escherichia coli (E.coli) DH5α bacterial 
transformation.  
Klenow Blunt Ending 
Blunt ending of DNA sequences containing a 3’ overhang is carried out using the Klenow enzyme 
(Roche Applied Science, Mannheim, Germany)–the large fragment (Mr 75 000) of DNA Polymerase 
1, that retains the 3’–5’ exonuclease activity but which lacks the 5’–3’ exonuclease activity.  
A typical 20µl reaction comprised of 1µg DNA, 1mM of each oligonucleotide (final concentration), 
filling buffer (50mM Tris pH 7.5, 10mM MgCl2, 1mM DTT, and 50µg/ml bovine serum albumin (BSA)) 
and 1U Klenow enzyme (2U/µl), followed by incubation for 15 min at 37°C. The reaction was stopped 
by the addition of 2µl 0.2M EDTA (pH 8.0) followed by incubation for 10 min at 65°C.  
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Oligonucleotide Annealing 
Complementary strands of oligonucleotides (10μg of each oligo), used for the production of the 
control plasmid vector pcDNA3 (LAP-(Gly4Ser)3-mEPO) and the control lentiviral vector pHRSIN-
CSGW (LAP-MMP), were annealed by boiling for 5 min with 10μl T4 DNA ligation buffer (10x stock) in 
a final volume of 100µl before allowing the bath to cool to room temperature overnight to facilitate 
annealing, followed by storage at 4°C until required.  
Dephosphorylation of vectors 
Calf intestinal alkaline phosphatase (CIP; NEB) catalyses the removal of 5’ phosphate groups from 
DNA resulting in the failure of vector backbones to re-ligate during cloning DNA inserts.  
1U CIP (10 000U/ml) was added per 2µg DNA diluted in 40µl 1x buffer (50mM Tris-HCl, 100mM NaCl, 
10mM MgCl2, 1mM DTT pH 7.9) and incubated for 60 min at 37°C. The DNA was purified using 
phenol extraction, its presence and size confirmed by agarose gel electrophoresis and quantified 
using spectrophotometry. 
Preparation of Competent DH5α E.coli bacteria 
DH5α E.coli cells are rendered competent for the uptake of DNA by a calcium chloride protocol 
(Sambrook et al., 1989). 5ml of LB broth (Merck, Nottingham, UK) was inoculated with E.coli DH5α 
bacterial cells and incubated overnight at 37°C. The culture was added to 500ml fresh LB broth and 
incubated at 37°C until the optical density (OD) measured at 600nm was within 0.4 and 0.6, 
corresponding to exponential growth. The culture was centrifuged (5000 rpm, 10 min, 4°C) and the 
supernatant discarded. The pellet was resuspended in 50ml of ice cold 0.1M MgCl2 and centrifuged 
(2000 rpm, 10 min, 4°C). The supernatant was discarded, the pellet resuspended in ice cold 0.1M 
CaCl2, incubated on ice for 20 minutes and then centrifuged at 2000rpm for 10 min at 4°C. The pellet 
was resuspended in 12.5ml ice cold 0.1M CaCl2 containing 14% glycerol, aliquoted, snap frozen on 
dry ice and stored at -80°C. 
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Transformation of Bacteria 
Following the successful ligation of vector and insert, the recombinant plasmid vectors were 
transformed into competent DH5α E.coli bacteria. A 50µl aliquot of competent DH5α bacteria E.coli 
suspension was thawed on ice before the addition of 2µl ligation mix. The mixture was incubated on 
ice for 30 min, followed by heat shocking at 42°C for 2 min before being returned to ice. 250µl LB 
broth was added to the cell mixture and incubated for 1 hour at 37°C with shaking at 220 rpm. 100µl 
of bacterial culture was spread on pre-warmed agar plates (Biogene) containing ampicillin 
(100ug/ml) with or without 1.6mg X-gal and incubated overnight at 37°C. When cloning DNA 
fragments into pCR2.1, which has the galactosidase gene, individual white colonies were picked and 
placed in a 7ml bijou containing 5ml LB broth and ampicillin, and incubated at 37°C for 8–18 hours 
with shaking at 220 rpm.  
Extraction of Plasmid DNA  
Following transformation, a small volume (1.5ml in a clean microfuge tube) of the bacterial culture 
was centrifuged (11 000g; 20 sec) and the plasmid DNA recovered using the QIAspin Miniprep kit 
(Qiagen, Hilden, Germany) following the manufacturer’s protocol. The presence of the insert and its 
correct orientation within the plasmid vector was confirmed by restriction enzyme digestion, 
followed by agarose gel electrophoresis as described previously.  Once a clone containing the correct 
insert size was identified, a sample was sent for complete DNA sequencing, and a large-scale culture 
prepared–1ml of the 5ml starter culture was incubated overnight at 37°C in 500ml LB with ampicillin 
(100μg/ml). The recovery of plasmid DNA was obtained using either the QIAprep MegaPrep Kit 
(Qiagen) or the PureLink™ HiPure Plasmid DNA Megaprep Kit (Invitrogen, Paisley, UK) following the 
manufacturer’s protocols. Briefly, the bacterial culture is centrifuged and the pellet lysed under 
alkaline conditions. The DNA is absorbed onto a silica membrane column under high salt conditions 
before being washed and eluted under low salt conditions and stored at 4°C until required. 
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DNA Sequencing 
All DNA sequencing was performed by the Genome Centre (WHRI, Queen Mary University, UK) using 
400–800ng of either plasmid DNA or 200–600ng PCR product and 10pmoles/µl DNA primers. 
Construction of the latent growth factor gene plasmid vectors 
pcDNA3 (LAP-MMP) 
This construct has been described and used before by our group (Adams et al., 2003). The LAP 
sequence of huTGFβ spanning Met1–Ser273 is followed by a linker sequence (GGGGS), a MMP 
cleavage site (PLGLWA) and a final flexible linker sequence (GGGGSAAA) and is cloned into the 
pcDNA3 plasmid. 
Cloning of the MMP cleavage site: 
A double-stranded deoxyoligonucleotide coding for the MMP cleavage site 
(GGGGSPLGLWAGGGGSAAA) was designed using the following deoxyoligonucleotides: sense 5′-
AATTCGGGGGAGGCGGATCCCCGCTCGGGCTTTGGGCGGGAGGGGGCTCAGC-3′; antisense: 5′-
GGCCGCTGAGCCCCCTCCCGCCCAAAGCCCGAGCGGGGATCCGCCTCCCCCG-3′. The annealed 
deoxyoligonucleotides were cloned into the pcDNA3 plasmid cut with EcoRI and NotI. This construct 
was named GS-MMP-GS. 
Cloning of the pcDNA3(LAP-MMP) construct. 
The signal peptide of huTGFβ LAP and with the restriction sites HindIII and EcoRI were cloned from 
the plasmid huTGFβ-Babe neo (-5’UTR) (Chernajovsky et al., 1997), using the following primers : 
sense 5′-CCAAGCTTATGCCGCCCTCCGGGCTGCGG-3′; antisense 5′-
CCGAATTCGCTTTGCAGATGCTGGGCCCT-3′. This sequence (820bp) was cloned into the GS-MMP-GS 
construct cut with HindIII and EcoRI. This construct was named pcDNA3(LAP-MMP).  
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pcDNA3 (LAP-MMP-huTGFβ) 
Human TGFβ with NotI and XbaI ends was cloned by PCR from the plasmid huTGFβ-Babe neo (-
5’UTR) (Chernajovsky et al., 1997, Adams et al., 2003). The 358-base pair (bp) product was cloned 
into the pcDNA3 (LAP-MMP) plasmid vector cut with NotI and XbaI. The clone was named pcDNA3 
(LAP-MMP-huTGFβ).  
pcDNA3 (LAP-MMP-mIGF1)  
Both isoforms of mIGF1 were cloned by PCR from mouse brain cDNA using the forward and reverse 
primers W and M. The original 294bp PCR product of mIGF1A was truncated at the 3’ end. This was 
rectified by elongation of the product by PCR using a second reverse primer incorporating the 
missing nucleotides and an XbaI restriction site resulting in a 340bp fragment. The correctly cloned 
and sequenced product of mIGF1A was cloned into the pcDNA3 (LAP-MMP) plasmid cut with NotI 
and XbaI. The clone named pcDNA3 (LAP-MMP-mIGF1A).  
However the 346bp product of mIGF1B did not contain a restriction site. This was overcome by 
exploiting the XbaI site found downstream of the PCR product insertion site of pCR2.1.  Additionally, 
the pCR2.1 plasmid vector contained a NotI site downstream from mIGF1B (already containing a NotI 
site) and upstream from the XbaI site as illustrated in Figure 2.1 which needed to be removed. The 
pCR2.1 plasmid was cut with EcoRV and XbaI resulting in the linearised vector and a fragment 
containing the second NotI site. The XbaI overhang within the linearised vector was then blunt-
ended with Klenow enzyme before religating back. The DNA product mIGF1B, cut with NotI and XbaI 
from the religated pCR2.1 plasmid vector, was cloned into the pcDNA3 (LAP-MMP) plasmid cut with 
NotI and XbaI. The clone was named pcDNA3 (LAP-MMP-mIGF1B). 
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Figure 2.1: Construction of plasmids containing the IGF1A and IGF1B isoforms.  
(A) Primers W and M bind to both isoforms of mouse IGF1 prior to initiation of the mature protein and at a termination 
codon within exon 6 for IGF1B and include a NotI restriction site at the 5’ end. Elongation of the truncated IGF1A gene 
sequence performed using reverse primer AJ binding to complementary sequence at 3’ end and extended to include a 
termination codon and an XbaI restriction site. (B) The plasmid pCR2.1 contains a NotI site (red square) downstream of the 
inserted PCR products but upstream from the XbaI site. This is only significant in the generation of the IGF1B plasmid, as 
the 3’ primer (M) did not attach an XbaI site at the 3’ end. 
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pcDNA3 (LAP-(Gly4Ser)3-mEPO) 
The control vector, with the MMP site removed and replaced with a glycine-serine linker bridge, was 
produced by subcloning the annealed oligonucleotides sense: 5’- 
AATTCGGGGGAGGCGGATCCGGAGGTGGCGGTTCGGGTGGAGGGGGCTCAGC-3’; antisense: 5’- 
GGCCGCTGAGCCCCCTCCACCCGAACCGCCACCTCCGGATCCGCCTCCCCCG-3’ containing EcoRI and NotI 
overhangs, into the pcDNA3 (LAP-MMP-mEPO) plasmid cut with EcoRI and NotI. The clone was 
named pcDNA3 (LAP-(Gly4Ser)3-mEPO).  
Construction of lentiviral vectors with latent growth factor genes. 
All lentiviral techniques were performed in Class II biological hoods using aseptic techniques. All 
biological waste was neutralised in Microsol 3 (Anachem, Bedfordshire, UK) and all surfaces 
decontaminated with Microsol 3 and 70% ethanol prior to and during use. All cell lines were 
incubated at 37°C with 10% CO2 humidified atmosphere unless otherwise stated. 
The self-inactivating lentiviral vector pHRSIN-CSGW was kindly provided by Dr Adrian Thrasher 
(Institute of Child Health, UCL, London, UK) and has been described previously (Demaison et al., 
2002). The engineered constructs LAP-MMP-mEPO, LAP-(Gly4Ser)3-mEPO, LAP-MMP-huTGFβ, LAP-
MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-MMP and mEPO alone were subcloned into the pHRSIN-
CSGW lentiviral vector between the BamHI and NotI restriction sites.  
LAP-MMP-huTGFβ generic lentiviral vector 
A generic lentiviral vector was produced for the insertion of other growth factors or trophic factors 
downstream of the LAP fragment. Following sequence confirmation of pcDNA3(LAP-MMP-huTGFβ), 
PCR amplification of the LAP-MMP-huTGFβ fragment was done using pcDNA3(LAP-MMP-huTGFβ) as 
a template. The oligonucleotide primers were synthesized to incorporate a 5’ BglII restriction site 
and 3’ SnaBI/SpeI restriction sites (Table 2.1). This sequence, when cut with BglII and SnaBI, has a 
complementary 5’ GATC overhang to the BamHI sequence and a 3’ blunt end. The LAP-MMP-huTGFβ 
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fragment with BglII and SnaBI ends was cloned into the pHRSIN-CSGW lentiviral vector cut with NotI, 
and blunt ended with Klenow. The lentiviral vectors were sequenced and the correct clone was 
named pHRSIN-CSGW-(LAP-MMP-huTGFβ).  
LAP-MMP-mEPO, LAP-MMP-mIGF1A and LAP-MMP-mIGF1B lentiviral vectors 
The pcDN3 plasmid vectors for LAP-MMP-mEPO, LAP-MMP-mIGF1A and LAP-MMP-mIGF1B were 
digested with NotI and XbaI and the fragments isolated through agarose gel electrophoresis and 
purification. The fragments mEPO, mIGF1A and mIGF1B with NotI and XbaI ends were cloned into 
the generic lentiviral vector pHRSIN-CSGW-(LAP-MMP-huTGFβ) pre-digested with NotI and SpeI–
releasing the huTGFβ fragment and leaving 3’ overhang compatible with XbaI digested ends. The 
resulting clones were sequenced and the correct clones named pHRSIN-CSGW-(LAP-MMP-mEPO) 
pHRSIN-CSGW-(LAP-MMP-mIGF1A), pHRSIN-CSGW-(LAP-MMP-mIGF1B)  
Control lentiviral vectors 
The mEPO and LAP-MMP control lentiviral vectors were produced in our lab by Dr Anne Rigby during 
my maternity leave.   
LAP-MMP lentiviral vector 
The pHRSIN-CSGW-(LAP-MMP) control lentiviral vector was produced by removal of the huTGFβ 
fragment from the generic pHRSIN-CSGW-(LAP-MMP-huTGFβ) lentiviral vector and replacing it with 
a stop codon. Synthetic oligonucleotides were designed to contain a stop codon between NotI and 
SpeI overhangs (Table 2.1). An additional EcoRI restriction site was included to perform diagnostic 
restriction digestion following ligation. The annealed oligonucleotides with NotI and SpeI ends were 
cloned into the pHRSIN-CSGW-(LAP-MMP-huTGFβ) lentiviral vector cut with NotI and XbaI. Correct 
clones were screened through EcoRI restriction enzyme digestion. The correct clone was named 
pHRSIN-CSGW-(LAP-MMP).  
CHAPTER 2: MATERIALS AND METHODS 
 
        103 
mEPO lentiviral vector 
The control lentiviral vector mEPO has been described previously (Rigby, 2009). Briefly, the mouse 
EPO protein (complete with its signal peptide) was digested with BamHI and SbfI to release a 
fragment consisting of the signal peptide and the upstream portion of mEPO. The downstream 
portion of EPO was obtained through digestion with SbfI and NotI of the plasmid pHRSIN-CSGW 
containing scFV-EPO with a V5-His B tag for immunoblotting with the anti-V4 probe. The two 
fragments containing the upstream (with BamHI and SbfI ends) and downstream portions (with SbfI 
and NotI ends) of mEPO were then subcloned into the pHRSIN-CSGW lentiviral vector cut with 
BamHI and NotI. The lentiviral vector was named pHRSIN-CSGW-mEPO.  
RECOMBINANT PROTEIN EXPRESSION 
Once the sequences of the plasmid DNA were confirmed, various cell lines were transfected to 
produce the recombinant proteins, beginning with the dominant mammalian host for recombinant 
protein manufacturing, the DG44 CHO cell line. 
Production of protein therapeutic agents in mammalian cells 
Chinese hamster ovary (CHO) cell line expression system 
The DG44 CHO cell line was deficient in DHFR (-/-) and required thymidine to enable growth. DHFR is 
responsible for the formation of tetrahydrofolic acid, a cofactor necessary for de novo DNA synthesis 
(Urlaub and Chasin, 1980). The enzyme is very sensitive to the tetrahydrofolate analog methotrexate 
and is useful for gene amplification through metabolic manipulation (Gasser et al., 1982). 
Transfection of CHO DHFR deficient cells, with a DHFR-expressing plasmid pSV2DHF (Chernajovsky et 
al., 1984), resulted in clones that were resistant to methotrexate in a dose-dependent manner 
because these clones express different copy numbers of the plasmid. Clones with the highest copy 
number were selected for by applying high doses of methotrexate. Once co-transfected with the 
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gene of interest and the DHFR gene, these cells have the highest copy number of the gene of 
interest. 
DG44 cells were routinely cultured and maintained in DG44 growth medium (Ham’s F12 medium 
supplemented with Penicillin/Streptomycin (final concentration:100U/ml and 100µg/ml respectively; 
Pen/Strep; L-Glutamine (final concentration:  2mM; Glut); thymidine (final concentration: 30µg/ml; 
Sigma-Aldrich) and 10% (v/v) heat-inactivated foetal bovine serum (FBS; Invitrogen)) at 37°C with a 
humidified atmosphere of 10% CO2 in air. Cells have a doubling time of 22–26 hours and were split 
when they reached confluency (80-100%) using trypsin-EDTA (2.5% final) incubated for 10 min and 
washed with FCS containing medium (800g, 5 min) before plating. 
DG44 cells were permanently co-transfected with plasmids (20μg) expressing LAP-MMP-mEPO, LAP-
MMP-huTGFβ, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B or LAP-MMP, and the pSV2DHFR gene vector 
(Chernajovsky et al., 1984) using a calcium phosphate DNA co-precipitation protocol (Sambrook et 
al., 1989). The cells were seeded at a density of 0.5x106 per 10cm plate (BD Falcon®; BD Bioscience, 
Oxford, UK) in DG44 growth medium and incubated overnight. The medium was replaced with fresh 
medium for 3 hours the following day to induce cell proliferation. 20µg of plasmid DNA and 1μg 
pSV2DHFR gene vector was made up to 450µl with dH2O to which 500µl of 2x HBS (280mM NaCl, 
50mM HEPES, 1.5mM NaHPO4; pH 7.05) was added followed by the drop wise addition of 50µl of 
2.5M CaCl2. The solution was allowed to develop a precipitate for 30 min at room temperature. 
The medium was removed by gentle vacuum aspiration, and the precipitate added to the side of the 
plates and tilted until the cells on the plates were completely covered, followed by repeated tilting 
every 5 min for a total of 30 min. The cells were incubated for 4 hours following the addition of 9 ml 
fresh DG44 growth medium, the medium removed by gentle vacuum aspiration before adding 1ml 
of glycerol shock solution (10% glycerol (v/v) in serum-free medium) and tilting continuously for 4 
min. The cells were then washed twice with 10ml of Ham’s F12 supplemented with 10% FBS, 
Pen/Strep and Glut, before incubating overnight in 10ml DG44 growth medium to recover. 
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The cells were left to recover for no more than 48 hours and the media was replaced with 10ml 
Geneticin® selection medium (Alpha-MEM medium supplemented with Penicillin/Streptomycin 
(100x = 100U/ml and 100µg/ml respectively, Pen/Strep; L-Glutamine (100x = 200mM; Glut); G418 
(Geneticin® sulphate (100mg/ml; Invitrogen) and 10% (v/v) dialysed foetal bovine serum (dFBS; 
Invitrogen)). Cells that had been successfully transfected were resistant to G418 as the plasmids 
expressing the recombinant proteins contained the neomycin gene. Cells that were successfully 
transfected with the pSV2DHFR gene vector were able to synthesize thymidine. In order for a cell to 
survive and proliferate in selection medium, it needs to be successfully transfected with both gene 
vectors. The selection medium was replaced with fresh selection medium twice a week. After 
approximately 10-14 days in selection medium, individual colonies of approximately 2mm in 
diameter were seen and expanded using ring cloning—a technique used to isolate and expanded 
populations of cells from an original clone. The cells were washed with 1x phosphate buffered saline 
(PBS) prior to coating the underside of cloning rings (d=6mm; Bellco Glass, New Jersey, U.S.A) with 
sterile silicon grease creating a seal between the plate and the ring, and then placed to encircle the 
marked colony. 100µl of 2.5% trypsin (v/v) diluted 1:4 in 1x PBS was added to the cells, and 
incubated for 1 min on the bench at room temperature before inactivation with 100µl growth 
medium. Cells were centrifuged (1200 rpm, 3 min) and resuspended in growth medium and seeded 
into wells of 24-well plate (BD Falcon®). The cells were left to recover before expanding and stocks 
generated.  
Gene amplification of the transfected gene of interest was achieved through Methotrexate (MTX; 
Calbiochem, Nottingham, UK) amplification as described elsewhere (Gasser et al., 1982). The cell 
medium was removed and the cells washed once with 1x PBS before adding fresh selective medium 
supplemented with increasing doses of MTX, starting at 12nM followed by 25nM, 50nM and finally 
250nM. The cells were maintained and grown in selective medium supplemented with 250nM MTX 
to maintain selective pressure. 
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 DG44 cells were washed once with 1x PBS when their confluence reached 80%, CD CHO serum-free 
medium (Gibco, Invitrogen) added, and the cells incubated for 48 hours. The supernatant was 
removed, filtered through a 0.45µm filter (Nalgene filters, Fisher Scientific, Leicestershire, UK) to 
remove dead cells and, following the removal of a 1ml aliquot, EDTA was added to a final 
concentration of 20mM to inhibit any endogenous MMP enzyme activity before storage at -80°C. 
HEK-293T cell line expression system 
The Human Embryonic Kidney cell line containing the SV40 large T antigen, HEK-293T, was cultured 
and maintained in HEK-293T growth medium (Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with Pen/Strep, Glut and 10% FBS). HEK-293T cells have a doubling time of 20 hours, 
and were routinely spilt every 3-4 days. Cells were incubated with 5ml trypsin/PBS solution (1:4) at 
37°C for 3–5 min before adding 5ml 10% FBS containing medium to inactivate the trypsin. The cell 
suspension was transferred to a sterile conical tube, centrifuged (800 g, 5 min) and the supernatant 
discarded. The cell pellet was gently resuspended in fresh growth medium before plating 1:10.  
For transient transfection of the HEK-293T cell line with a latent growth factor gene plasmid (20μg), 
1 ml of medium was removed by vacuum from the plates and the calcium phosphate precipitate 
(described in CHO cell line expression system) was added drop wise, followed by occasional tilting 
for 30 min. A further 9ml of growth medium was added and the cells incubated overnight. The 
following day, 1ml glycerol shock solution was added for 4 minutes before washing twice with FBS-
containing medium. The medium was removed by gently aspirated and replaced with fresh HEK-
293T growth medium. The culture supernatant was collected 48 hours later, centrifuged (800g, 5 
min), filtered to remove cell debris, and stored at -80°C until required. 
Freestyle™ CHO-S cell expression system 
Freestyle™ CHO-S cells (Invitrogen) are suspension CHO cells adapted to be used in conjunction with 
the FreeStyle™ MAX CHO Expression System—an optimised system for transient transfection and 
protein production. CHO-S cells are grown in FreeStyle™ CHO Expression Medium and incubated on 
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an orbital shaker rotating at 120-135rpm at 37°C with 8% CO2 humidified atmosphere. Cells are 
passaged the day before transfection at a density of 5–6x105 cells/ml at a volume of 30ml/125ml 
flask. On the day of transfection, the cells are diluted to a density of 1x106 cells/ml and 30ml of this 
cell suspension added to a new flask. pcDNA3(LAP-MMP-mEPO) plasmid DNA (37.5μg) was diluted in  
OptiPro™ SFM before adding to diluted Freestyle MAX Transfection reagent. The solution was 
allowed to develop a precipitate for 10 min at room temperature. The complex solution was added 
gently to the cell suspension whilst gently swirling, and the flask retuned to the orbital shaker 
(135rpm) and incubated for 48 hours. The cell culture was transferred to a sterile conical tube (BD 
Falcon™, Oxford, UK), centrifuged and the supernatant filtered (0.45µm) to remove cell debris 
before storing at -80°C until required. 
Biozzi ABH mouse fibroblast cell expression system  
Our lab previously generated temperature sensitive SV40 large T-antigen immortalised cell lines  
from fibroblast cells taken from the Biozzi ABH mouse (Croxford et al., 2000, Croxford et al., 2001). 
These cells are permanently transduced with a temperature sensitive simian virus 40 (SV40) large T-
antigen that is rapidly degraded at body temperature (in vivo) or when grown at 37°C (in vitro). 
These cells were therefore designated tsF (temperature sensitive fibroblast) cells. They were 
transfected to express the latent growth factors LAP-MMP-mEPO, LAP-MMP-huTGFβ, LAP-MMP-
mIGF1A, LAP-MMP-mIGF1B and the control LAP-MMP (partially engineered by Dr Anne Rigby), and 
were maintained in Geneticin® selection medium (DMEM supplemented with Pen/Strep, Glut, 
Geneticin® sulphate (0.5mg/ml, G418; Invitrogen) and 10% FBS) to maintain selection of the 
neomycin resistant gene present in the retroviral vector expressing the temperature sensitive SV40 
large T antigen for approximately 3 weeks. Following this selection period, the cells were maintained 
rountinely in HEK-293T growth medium (Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with Pen/Strep, Glut and 10% FBS). The cells reached confluency at a similar rate as 
HEK-293T cells (personal observations) and were routinely split 1:10 every 3–4 days as carried out 
for HEK-293T cells. Stable transfection of the tsF cell line was carried out when cells reached a 
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confluency of 50%. After transduction and glycerol shock, the cells were left to recover for 48 hours 
before splitting. Culture supernatants were collected following recovery and stored at -80°C until 
required. 
Production of lentiviral vector packaged particles for Gene Therapy 
HEK-293T cells were seeded at a density of 7x106 cells per 15cm tissue culture plate (BD Falcon) and 
incubated overnight in 15ml HEK-293T growth medium. One hour prior to transfection, 25µl of a 
25mM chloroquine solution was added to the culture medium. 18µg of lentiviral vector DNA, 18µg 
of pCMVR8.2 packaging plasmid and 4µg of pMD.G envelope plasmid (containing the VSVG protein) 
were co-transfected into HEK-293T cells (Naldini et al., 1996). DNA was made up to 900µl with 
distilled water to which 1ml 2x HBS pH 7.1 was added, followed by the drop wise addition of 100µl 
CaCl2 (as for CHO cell transfection) and the solution mixture left for 30 min at room temperature to 
form a precipitate. The mixture was added to the culture medium for 6—8 hours before the medium 
was replaced and the cells left to recover overnight. The medium was replaced the next day (15 ml) 
and the cells left for a further 24 hours. The viral supernatant was removed every 24 hours for the 
next 3 days, filtered to remove cell debris (0.45µm) and ultracentrifuged (30 000 x g, 2 hours, 4°C, 
Beckman XL90 rotor 70Ti) to concentrate. The stock viral pellet was resuspended in 100µl sterile 1x 
PBS and aliquoted (20µl; Nalgene) and stored at -80°C.  
Lentiviral transduction 
tsF cells were seeded at a density of 1.5x104 cells per 15mm well of a 24-well tissue culture plate (BD 
Falcon) and incubated overnight. The cells were transduced the following day with 20µl 
concentrated virus in the presence of 6µg/ml polybrene (Sigma-Aldrich) in a total volume of 200µl 
for 16—18 hours. The medium was replaced and the cells left to recover before expanding and 
generating stocks. Protein production and secretion of recombinant protein was assessed by 
western blot analysis of collected supernatant taken from the stably transduced tsF cells. Cells that 
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failed to express sufficient quantities of recombinant protein were retransduced until sufficient 
quantities were achieved.  
Generation of stably transducted tsF cell stocks 
Once the stably transfected tsF cells reached confluency of 60%, the cells were trypsinised, washed 
with FBS-containing medium, centrifuged (800g, 5 min) and resuspended (0.5x106 cells/ml) in 1ml 
FBS containing 10% DMSO before slow cooling and storing at -80°C until required. 
 PROTEIN ANALYSIS 
Transfected or transduced cells were washed once with 1x PBS when their confluence reached 60% 
and 80% respectively, followed by adding 15ml DMEM supplemented with Pen/Strep and Glut, or 
alternatively for DG44 cells, with CD CHO serum-free medium (Gibco, Invitrogen), and incubated for 
48 hours. The supernatant was removed, filtered through a 0.45µm filter to remove dead cells and, 
following the removal of a 1ml aliquot, EDTA was added to a final concentration of 10mM to inhibit 
any endogenous MMP enzyme activity before storage at -80°C. 
MMP1 Cleavage Assay 
Serial dilutions of EDTA-free supernatant were incubated with 1x MMP1 buffer (50mM Tris-HCl pH 
7.5, 150mM NaCl, 10mM CaCl2, 50µM ZnCl2, 0.05% Brij-35) and 30nM MMP1 ∆C (EC 3.4.24.7 kindly 
provided by Prof. H. Nagase, Imperial College, London) overnight. The reaction was stopped by 
adding EDTA to a final concentration of 20mM. Cleavage was assessed by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blot analysis.  
Western Blotting  
Protein concentration was measured using the bicinchoninic acid assay (BCA; Pierce, Rockford, 
U.S.A), a biochemical assay similar to the Lowry or Bradford assays. All western blots were run under 
reducing conditions. Protein samples for SDS-PAGE were diluted in 1x denaturing buffer (4x = 10% 
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SDS, 40% glycerol, 125mM Tris-HCl pH 6.8, 0.002% bromophenol blue, containing 0.4M DTT or 10% 
final concentration of β-mercaptoethanol) and denatured by boiling in a water bath for 3 min. 
Samples were loaded alongside 8µl–10µl of pre-stained protein marker (Bio-Rad) on either 10% SDS-
PAGE run at 100V (constant) or on a 4%-12% gradient NuPAGE® minigel (Invitrogen) run at 200V 
(constant) following the manufacturer’s protocol, in 1x NuPAGE® MOPS SDS running buffer 
(Invitrogen). Proteins were transferred onto Polyvinylidene Difluoride (PVDF, GE Healthcare, 
Buckinghamshire, UK) membrane for 2 hours using either CAPS transfer buffer (10mM 3-
(Cyclohexylamino) propanesulfonic acid pH 11) at 200mA (constant) or NuPAGE® (Invitrogen) 
transfer buffer and running at 30V (constant) for SDS-PAGE gels or NuPAGE™ Novex Bis-Tris 
(Invitrogen) minigels respectively. The membrane was rinsed three times with 1x PBS before 
incubating for 2 hours at room temperature in blocking buffer (5% (w/v) non-fat reconstituted milk 
in PBS) with agitation, followed by an overnight incubation at 4°C with primary antibody (goat anti-
LAP (R&D systems, Abingdon, UK), goat anti-EPO (R&D systems), goat anti-IGF1 (R&D systems), 
rabbit anti-TGFβ (abcam, Cambridge, UK)) in 0.5x blocking buffer with agitation. The membrane was 
then rinsed with 1x PBS with 0.05% Tween-20 (PBST), followed by five incubations of 5 min each in 
1x PBST with agitation. The membrane was then incubated for 2 hours at room temperature with 
agitation with secondary antibody (mouse anti-goat-IgG-horseradish peroxidase conjugate (Santa 
Cruz Biotechnology, Heidelberg, Germany), goat anti-rabbit-IgG-horseradish peroxidase conjugated 
(DAKO, Cambridge, UK) diluted in 0.25x blocking buffer, before rinsing 3 times in 1x PBST, followed 
by 5 x 5 min incubations in 1x PBST. The membrane was then incubated for 1 min in 10ml 
ChemiLucent™ Plus ECL Detection System solution (Chemicon, Hampshire, UK) before 
autoradiography using Hyperfilm ECL x-rays (Amersham, Buckinghamshire, UK) and developing using 
the AGFA Curix 60™ (AGFA Healthcare). 
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ELISA 
Direct LAP ELISA 
ELISA plates (Immuno 96 Microwell®; Nunc, Thermo Fisher Scientific, UK) were coated with serial 
dilutions of serum or supernatant, or recombinant LAP protein (0—30ng/ml; Sigma-Aldrich) in 
bicarbonate/carbonate coating buffer (100mM, pH 9.6) and incubated overnight at 4°C. The 
following day, the plate was washed 5 times with 200µl/well PBST and blocked with 200µl/well 2% 
casein (w/v) in PBS for 2 hours at room temperature. The plate was washed five times with 
200µl/well PBST and incubated with 50µl/well goat anti-LAP primary antibody (0.4µg/ml, R&D 
Systems, Abingdon, UK) in 1% casein for 2 hours. Following five washes in PBST, the plate was 
incubated with 100µl/well mouse anti-goat HRP conjugated secondary antibody (0.8µg/ml; Santa 
Cruz Biotechnology, Middlesex, UK) in 1% casein for 1 hour. Following five washes, a 1:1 mixture of 
peroxidase B (H2O2) and tetramethylbenzidine (TMB; KLP, Maryland, U.S.A) at 100µl/well was added 
and incubated until the development of adequate colour. The reaction was stopped by adding 
100µl/well 4.5M H2SO4 and the OD read at 450nm on an ELISA plate reader (Bio-kinetics reader; Bio-
Tek instruments, EL3122). 
Sandwich EPO ELISA 
The EPO sandwich ELISA was kindly performed by Dr Anne Rigby using an ELISA kit (Quantikine 
mouse/rat immunoassay, R&D Systems, Oxon, UK). ELISA was carried out on serial dilutions of the 
supernatant from tsF transduced with rEPO (EPO.tsF) or with LAP-MMP-mEPO (LAP-MMP-
mEPO.tsF). Linear regression analysis was performed on the commercial recombinant mouse EPO 
protein standards to derive a linear standard curve. Linear regression analysis was also performed on 
the supernatant sample dilutions to determine the linear portion of the supernatant samples 
dilution curve. Supernatant EPO concentrations were calculated using OD values from the linear 
portion of the supernatant dilutions and applying the protein standards linear regression analysis. An 
R2 value was calculated for each regression performed. 
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Protein deglycosylation 
N-Glycosidase F (PNGase F; NEB) an amidase that cleaves between the innermost GlcNAc and 
asparagine residues of N-linked glycoproteins, was used to deglycosylate the synthesised variants of 
the latent EPO glycoprotein. Denaturation of the protein was carried out in a 10µl reaction using 1—
20µg protein and denaturing buffer (0.5% SDS, 40mM DTT), followed by incubation for 10 min at 
100°C. Deglycosylation was performed in a 20µl reaction volume by adding G7 Reaction Buffer 
(50mM sodium phosphate, pH 7.5), 1% NP-40, PNGase F (500U/µl), followed by incubation for 1 
hour at 37°C. 
Inhibition of protein glycosylation  
The antibacterial and antifungal agent Tunicamycin (MW = 840.0) is an N-linked glycosylation 
inhibitor that blocks dolichol monophosphate-linked oligosaccharide biosynthesis. Asparagine (N) 
linked glycoproteins fail to be synthesised in the ER during treatment with tunicamycin. Lyophilised 
tunicamycin (Sigma-Aldrich) dissolved in DMSO to a concentration of 1mg/ml was filter sterilised 
(0.45µm) and stored at 4°C.  
HEK-293T cells were seeded at a density of 0.5x106 cells per 10cm plate (BD Flacon®) and incubated 
for 16—18 hours. They were transiently transfected with the pcDNA3 (LAP-MMP-mEPO) plasmid 
DNA for 5 hours before the medium was replaced with medium containing tunicamycin (0—5µg/ml). 
The medium was removed after 3 days, centrifuged (1200 rpm, 5 min) and filtered (0.25µm) before 
being aliquoted and stored at -80°C. The cells were lysed (1% NP-40 containing proteinase inhibitors) 
on ice for 15 min and centrifuged (3900 rpm, 10 min, 4°C). The supernatant was filtered (0.25µm), 
aliquoted and stored at -80°C.  
CHO-S cells were seeded at a density of 1x106 cells/ml in a total volume of 20ml per Erlenmeyer flask 
(Sigma-Aldrich), containing 2.5–5µg/ml tunicamycin and left for 16–18 hours. 50µg DNA was diluted 
in polyethyleneimine (1mg/ml, PEI; Sigma-Aldrich) and NaCl (150mM) to a final volume of 1ml and 
left for 10 min at room temperature. An additional 5µg/ml tunicamycin was added before adding the 
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transfection mixture to the cells. The cells were incubated for 3 days at 37°C in an 8% CO2 humidified 
atmosphere on an orbital shaker platform rotating at 135 rpm before the cell suspension was 
centrifuged (1200 rpm, 5 min) and the supernatant stored at -80°C.  
BIOLOGICAL ACTIVITY ANALYSES 
Detection of EPO biological activity using UT-7 cells 
The human megakaryoblastic cell line, UT-7, is dependent on the factors EPO or GM-CSF for survival 
and proliferation as hown by an increase in cell number in response to EPO or GM-CSF, in a dose-
dependent manner. The CellTiter-Glo® assay (Promega; Southampton, UK) is based on the 
measurement of cellular ATP content, which is used as the equivalent of viable cell number because 
ATP content of a given cell type remains constant. All cell cultures were incubated at 37°C in a 5% 
CO2 humidified atmosphere in air unless otherwise stated. 
The UT-7 cell line (kindly donated Dr Julian Kieswich, Queen Mary, UK) was cultured in UT-7 growth 
medium (RPMI medium supplemented with 10% FBS, Pen/Strep, L-glut and human recombinant 
GM-CSF (10ng/ml)) and replaced on alternate days. The cells were collected and centrifuged (800 
rpm, 5 min), resuspended in GM-CSF-free UT-7 growth medium and incubated for 16–24 hours prior 
to assay. The cells were then centrifuged (800 rpm, 5 min), counted and resuspended to 4x105 
cell/ml in the same medium. Each 6mm well of a 96-well plate was seeded with 50μl cell suspension 
corresponding to 2x104 cells. Duplicates of either recombinant mouse EPO (0–10ng/ml; R&D 
systems), or cell culture supernatant (following incubation for 16–18 hours in the presence or 
absence of MMP1 enzyme) were diluted in the same medium to a 2x final concentration. Each of the 
dilutions (50µl) was then added to the cells and incubated for 48–72 hours prior to the CellTiter-Glo® 
assay. The cells were allowed to equilibrate to room temperature for 30 min prior to the addition of 
100µl CellTiter-Glo® reagent. The cells were incubated on a platform rotor for 10 min before the 
samples were transferred to assembly strips of white microtiter plates (Thermo Electron 
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Corporation, Vantaa, Finland) and the luminescence read using the Revelation MLX 4.06 software of 
the MLX Microtiter® Plate Luminometer (Dynex Technologies). 
Detection of TGFβ growth inhibition biological activity using MLEC cells  
huTGFβ has been shown to stimulate the expression of plasminogen activator inhibitor-1 (PAI-1) in 
the mink lung epithelial cell line (MLEC). Abe, Harpel et al. (1994) stably transfected MLEC cells with 
a construct consisting of a truncated PAI-1 promoter fused, at the 5’ flanking region, to the firefly 
luciferase reporter gene (MLEC (PAI/L)). Stimulation of these transfected cells with huTGFβ results in 
a dose-dependent increase in luciferase activity. Using the Luciferase Assay System (Promega, 
Southampton, UK), the luciferase generated by the MLEC (PAI/L) cells in response to huTGFβ 
exposure, catalyses the oxidation of luciferin to oxyluciferin, resulting in a flash of light that can be 
read. All cell cultures were incubated at 37°C in a 10% CO2 humidified atmosphere in air. 
The MLEC (PAI/L) cell line (kindly donated by Dr M. Abe, New York University Medical Centre) was 
cultured in Geneticin® selection medium (DMEM medium supplemented with 10% FBS, Pen/Strep, L-
glut and G418 (1mg/ml)). Following Trypsin/EDTA cell detachment, the cells were centrifuged (1200 
rpm, 5 min), resuspended in MLEC PAI/L selection medium and counted. 1.6 x 104 cells were seeded 
per 6mm well of a 96-well plate and allowed to attach for 3 hours. Duplicates of either recombinant 
human TGFβ (0–350pg/ml; Peprotech, London, UK), or cell culture supernatant (acid activated 
followed by incubation for 16–18 hours in the presence or absence of MMP1 enzyme) were diluted 
in serum-free MLEC PAI/L selection medium containing 0.1% BSA (Sigma-Aldrich). The cells were 
washed twice with 1xPBS and each of the dilutions (100µl) added to the cells and incubated for 14–
16 hours prior to the Luciferase Assay. Cells were washed once with 1x PBS before the addition of 
50µl 1x Passive Lysis Buffer (Promega) and subsequent incubation for 15 min at room temperature 
on a platform rocker. The cells were then placed at -80°C for 30 min prior to thawing at room 
temperature for 10 min. The freeze/thaw procedure was repeated twice more, followed by titration 
before transferring 25µl of the cell lysate to assembly strips of white microtiter plates (Thermo 
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Electron Corporation). The luminescence was read using the Revelation MLX 4.06 software of the 
MLX Microtiter® Plate Luminometer following the addition of 50µl of the Luciferase Assay Reagent. 
Detection of IGF1 biological activity using CG4 cells 
The CG4 cell line contains rat CNS glia precursors derived from bipotential oligodendrocyte-type 2 
astrocyte progenitor cells. Using conditioned medium taken from the neuroblastoma cell line B104, 
CG4 cells can be maintained in culture indefinitely as oligodendrocyte-type 2 astrocyte cells.  
Withdrawal of the mitogens expressed by B104 cells in the conditioned medium, or from the 
additive bFGF and PDGF mitogens in normal growth medium, induces the differentiation of the CG4 
cells into oligodendrocytes. However replacement of the mitogens with 20% FBS results in the 
differentiation of CG4 cells into type-2 astrocytes. Following differentiation, OL or type-2 astrocyte 
cells can be maintained in 5% FBS for several weeks (Louis et al., 1992). 
Cultures of B104 neuroblastoma cells were maintained in B104 growth medium (DMEM 
supplemented with 10% FBS, pen/strep and glut). CG4 cells were maintained in CG4 growth medium 
(Ham’s F12/DMEM [1:1] supplemented with B104 conditioned medium, N1 supplement (100x = 
Progesterone (0.73µg/ml), Putricine (1.6mg/ml), Sodium Selenite (0.5µg/ml), Insulin (0.5mg/ml) and 
Transferrin (0.5mg/ml), 10ng/ml biotin, 5ng/ml bFGF, 1ng/ml PDGF). All cells were maintained at 
37°C in a 5% CO2 humidified atmosphere in air. 
Preparation of B104-conditioned medium for growth of CG4 cells 
Preparation of B104 cells 
B104 cell were grown in B104 growth medium until 70% confluency, washed twice with PBS-without 
Mg2+/Ca2+ (6ml/75 cm flask). The cells were allowed to detach by incubation at room temperature in 
PBS (6ml) with gentle tapping. B104 growth medium (20ml) was added and the cells centrifuged 
(200g, 3 min). The supernatant was gently aspirated, the pellet resuspended in B104 growth medium 
(25ml/75 cm flask) before plating 1:5 and adding B104 growth medium to a final volume of 20ml. 
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Growth of B104 cell depends on the concentration of FCS and cell grown in 10% FCS have a doubling 
time of 27 hours, whereas cells grown in serum-free medium have a doubling time of 51.5 hours 
(Luo and Miller, 1997). Medium was replaced every 3 days with fresh medium and cell routinely 
passaged (1:5) once confluence reached 70%. 
Preparation of N1 conditioned medium 
Once the B104 cells reach confluency, the cells are washed twice in serum-free DMEM and 
incubated for 4 days in N1 medium (15ml/75 cm flask; 1x N1 supplement [5ml 100x, Sigma-Aldrich], 
1x Pen/Strep [5ml 100x, Sigma-Aldrich], to final volume 500ml with DMEM). After 4 days, the 
medium was removed, centrifuged (250 x g, 5 min), sterile filtered (0.25µM) before storing at -80°C 
in aliquots of 15ml labelled N1-conditioned medium.  
Preparation of CG4 cells 
Cultures of the OPC line CG4 (kindly donated by Huseyin Mehmet, Imperial College London, UK) 
were seeded onto poly-L-ornithine coated dishes (10ml of 15µg/ml sterile poly-L-ornithine solution 
added to 100mm tissue culture dishes and incubated for 1—18 hours at 37°C, washed 3x with PBS; 
BD Falcon) and grown in CG4 growth medium until confluent. The medium was replaced initially 
after 3 days and thereafter at alternate days. Cells were harvested by trypsin for 1 min before 
inactivation with soy bean trypsin inhibitor (Sigma-Aldrich). The cell suspension was centrifuged (800 
rpm, 5 min) and resuspended in pre-warmed medium before plating onto pre-coated polyornithine 
dishes.  
CG4 biological response assay 
CG4 proliferation was assessed using cultures established on pre-coated polyornithine 96-well 
plates. Once the cells were at confluence, they were detached by trypsin, and seeded at a density of 
1x104 cells in CG4 growth medium (50µl per well of a 96-well plate). Replicates of cell culture 
supernatant (following incubation for 16–18 hours in the presence or absence of MMP1 enzyme) 
were diluted in DMEM to a 2x final concentration, ranging between 3 two–fold dilutions (2, 4 and 8) 
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and 3 ten–fold dilutions (20, 200, and 2000). Controls included insulin (100nM); DMEM/F12 medium 
alone (1:1) and HEK-293T conditioned DMEM medium. Each of the dilutions (50µl) were added to 
the cells and incubated for 3 days prior to the Cell Titer-Glo® Assay and the luminescence read using 
the Revelation MLX 4.06 software of the MLX Microtiter® Plate Luminometer. 
 IN VIVO STUDIES 
Induction of EAE 
Biozzi AB/H mice (both male and female) were obtained from Harlan UK Ltd. (Oxon, UK) and 
maintained according to UK Home Office and institutional guidelines.  
Preparation of antigen used for immunisation 
Biozzi AB/H spinal cords (age/sex indifferent) were expelled from the lumbar region of the severed 
spinal column by hydraulic pressure using a 20ml syringe fitted with a 20G needle. The spinal cords 
were then homogenised using a glass hand homogeniser and freeze dried at -70°C overnight, before 
being diced into a fine powder and stored at -20°C. A stock solution of Mycobacterium-
supplemented incomplete Freund’s Adjuvant (M-IFA) was prepared by adding 16mg Mycobacterium 
tuberculosis H37Ra and 2mg M.butyicum (8:1) to 4ml incomplete Freund’s Adjuvant (IFA) and stored 
at 4°C for no longer than 1 month. The complete Freund’s adjuvant (CFA) was prepared by adding 
1ml M-IFA to 11.5ml IFA and mixed well. Lyophilised spinal cord homogenate (33mg; SCH) was 
reconstituted in 5ml sterile PBS before being added to 5ml CFA and sonicated in a water bath 
sonicator (Bransonic Ultrasonic cleaner; Sigma-Aldrich) for 10 min at room temperature. The 
solution was emulsified using a 1ml syringe following retraction and replacement of the plunger to 
generate a suspension that was thick enough as not to disperse in water. Sterile 1ml syringes fitted 
with 16mm 25G needles were then loaded with the sonicated emulsion in preparation for 
inoculation. Female Biozzi AB/H mice 6–8 weeks of age were inoculated subcutaneously at two sites 
in the flank with a total volume of 0.3ml sonicated emulsion on days 0 and 7. Each animal received 
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1mg of SCH and 60µg Mycobacterium on each inoculation occasion. All animals were allowed to 
proceed into a spontaneous relapse once the acute phase had resolved.  
The mice were fed on RM1(E) pellets and water ad libitum. When clinical signs were evident, these 
pellets were softened in warm water and placed inside the cage, and longer spouted water bottles 
used.  
Clinical Scoring of EAE 
The animals were weighed and scored daily from day 11 onwards. Clinical signs are evident after an 
initial overnight weight loss of >1.5g. A six point score system was followed: 0 = normal; 1 = limp tail; 
2 = loss of inverted righting reflex; 3 = partial hind limb paralysis; 4 = complete hind limb paralysis; 5 
= moribund or death, at which point the animal was sacrificed. Animals were also sacrificed if the 
weight loss exceeded 35% from the original day 11 weight, or if the animal remained at the graded 
score 4 for more than 4 days during the acute phase, or 10 days during the relapsing phase. All 
clinical signs that were of a lesser degree than the defined graded scores were scored 0.5 lower.  
Blood sampling 
All blood obtained was done so either by tail snipping or by terminal cardiac puncture. Animals were 
warmed for a minimum of 15 min under a heating lamp prior to tail sniping. 1mm off the tip of the 
tail was taken using a clean, sterile scalpel whilst the animals were held in mouse restraints 
(VetTech, UK). The tail was then gently ‘milked’ and the blood collected using a heparinised micro 
haematocrit capillary tubule (d = 1.15mm, l = 75.00mm, GMBH & Co. KG, Wertheim, Germany). One 
end was sealed with a naked flame to prevent sample loss. Terminal cardiac puncture was 
performed at the end of the experiment. Animals were euthanized by CO2 overdose. The sternum 
was exposed using straight surgical scissors. Following puncture of the heart using scissors, the blood 
was collected via sterile disposable pipettes into microfuge tubes and heparinised micro haematocrit 
capillary tubules (GMBH & Co. KG, Wertheim, Germany) 
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Haematocrit measurements 
Samples were centrifuged at 14 000 x g at room temperature for 10 min using a micro haematocrit 
centrifuge (HaematoSpin 1400, 24 place rotor 01971-00; Hawkley, Sussex, UK). Using a metric ruler, 
the ratio between total blood volume and haematocrit volume was determined.  
STATISTICAL ANALYSES 
Statistical analyses were performed using the GraphPad Prism software (version 5.0; GraphPad 
Software, California, U.S.A.).  
Values are presented as mean ± standard error of the mean (SEM). The value of ‘n’ refers to 
animals/group. The differences between groups were determined by ANOVA, followed by Tukey 
post-hoc test for multiple comparisons. Scores and weights are presented as a daily mean ± SEM per 
treatment group and all differences between groups were assessed using the non-parametric test, 
Mann-Whitney, followed by Tukey post-hoc test for multiple comparisons. P values ≤ 0.05% were 
considered statistically significant.  
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INTRODUCTION 
TGFβ is a multifunctional growth factor expressed ubiquitously in normal tissue and cell lines. Gene 
regulation of TGFβ is, as with other growth factors, controlled at the level of gene transcription and 
posttranslational processes that tightly control its expression. One of these processes includes the 
rendering of the growth factor latent by its association with its LAP preventing interaction with 
cellular receptors. Growth factors have demonstrated great potential in treating various diseases but 
have pleiotropic effects, short half-lives, and are administered systemically and often in high doses in 
order to obtain a therapeutic result. The prospect of rendering a therapeutic growth factor latent 
whilst targeting it to specific target areas is extremely appealing as the delivery of a therapeutic 
molecule to a target tissue without substantial toxicity is the cornerstone to successful therapy (Kay 
et al., 2001).  
Adams, Vessillier et al. (2003) first described a latent growth factor that functions at a specific site.  
They demonstrated that the growth factor IFN-β could be rendered latent by the addition of LAP to 
its N terminal end. They also determined that by rendering IFN-β latent, they were able to extend its 
half-life 37 times than that of IFN-β alone (55.02 hrs vs. 1.46 hrs respectively). This was even longer 
than when IFNβ had undergone pegylation (10.82 hrs). The addition of a MMP cleavage site 
(Vessillier et al., 2004) meant that the latent protein could not interact with its cellular receptor/s 
unless in areas where inflammation or tissue remodelling processes involving MMPs was taking 
place. MMPs are found within diseases such as rheumatoid arthritis, atherosclerosis and MS and 
their expression is tightly regulated. 
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CHAPTER HYPOTHESIS AND AIMS 
If the growth factors mEPO, mIGF1A, mIGF1B and huTGFβ were to be linked to the LAP peptide 
linked with a MMP cleavage site, then we hypothesised that they too, should become latent and 
only once incubated with MMP enzymes, should the peptide become biologically active and 
functional.  
The aims of this chapter were to determine first, these peptides could be constructed in vitro; 
second, they were able to be secreted and expressed by a mammalian cell ine; and third, that they 
demonstrated latent biological activity until cleavage occurred using the MMP enzyme, at which 
point the peptide became biologically active.  
RESULTS 
Construction of latent growth factors 
The latent growth factor gene constructs (Figure 3.1) were engineered by fusing the LAP of human 
TGFβ at the N-terminus followed by an MMP site linked to a growth factor, either mouse EPO 
(mEPO), human TGFβ (huTGFβ), mouse IGF1A or mouse IGF1B (mIGF1A or mIGF1B) as described 
previously (Adams et al., 2003). The control plasmid vector LAP-MMP was used previously by our 
group (Adams et al., 2003) and the LAP-MMP-mEPO plasmid vector was previously produced by our 
group (unpublished work).  
Growth factors are interchangeable in a generic expression vector  
Constructs were produced by sequential cloning of different growth factor cDNA into the pcDNA3 
(LAP-MMP) plasmid as illustrated in Figure 3.1. The pcDNA3 (LAP-MMP-mEPO) had previously been 
cloned by Prof. Yuti Chernajovsky and Mrs Gillian Adams (unpublished work). The cDNA from mouse 
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thymus, brain and spleen was kindly provided by Dr Alexander Annenkov. Primers were designed to 
enable in-frame ligation of PCR amplified DNA fragments, and to incorporate specific restriction sites 
at either the 5’ or 3’ ends of the product, into the pcDNA3 plasmid or pHRSIN-CSGW viral vector 
(Chapter 2: Table 2.1). Additionally, the primers were designed to amplify only the mature peptide 
sequence so that the biologically active mature peptide was secreted through the signal domain of 
the LAP to which they are fused. The sequence of the peptide linker (Gly4Ser)3 has been previously 
described (Annenkov and Chernajovsky, 2000) and was produced by oligonucleotide annealing 
(Chapter 2: Table 2.1).  
Following bacterial transformation and plasmid vector purification, all plasmid DNA was 
diagnostically digested with restriction enzymes to confirm sequence insertion and orientation 
before proceeding with further subcloning or recombinant protein expression (Figure 3.2). A 
schematic representation of the recombinant proteins and their respective sizes–as calculated from 
their amino acid sequences–is shown in Figure 3.3. DNA sequence analysis confirmed DNA sequence 
and the annotated sequences can be found in the Appendix. 
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Figure 3.1: A generic gene expression vector map for the construction of a latent growth factor.  
(A) A generic template containing the LAP fused to a growth factor linked to a MMP site. The growth factor is replaced with 
another protein of interest/growth factor between the NotI and XbaI restriction sites. The pcDNA3 plasmid contains 
ampicillin for selection in E.coli and neomycin resistance under the SV40 promoter for selection in mammalian cells. The 
expression vector also includes a cytomegalovirus (CMV) promoter for high efficiency expression of the recombinant 
protein in mammalian cells. (B) Expression of the gene expression vector should result in the secretion of a latent 
recombinant fusion protein that is biologically active when the mature growth factor is released at the MMP site by an 
MMP enzyme. 
 
 
Figure 3.2: Restriction analysis of the latent growth factor constructs.  
The PCR amplified growth factors huTGFβ, mIGF1A, and mIGF1B with NotI and XbaI ends were cloned into the pcDNA3 
plasmid vector cut with NotI and XbaI. Clones with insert were screened by diagnostic digestion using NotI and XbaI 
enzymes. (A) A 358bp huTGFβ fragment is released from pcDNA3(LAP-MMP-huTGFβ); (B) 340bp mIGF1A (lane 1), 346bp 
mIGF1B (lane 2) and 513bp mEPO (lane 3) fragments are released from pcDNA3(LAP-MMP-mIGF1A), pcDNA3(LAP-MMP-
mIGF1B) and pcDNA3(LAP-MMP-mEPO) plasmids respectively.  
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Figure 3.3: A schematic representation of recombinant latent growth factors and mature growth factors.  
(A) Linkage of the growth factors mEPO, huTGFβ, mIGF1A and mIGF1B by a MMP cleavage site with the LAP of huTGFβ 
renders then latent. (B) Cleavage at this site releases the mature peptide from the latent ‘shell’ allowing it to interact with 
its corresponding receptor. The molecular weights as estimated from its amino acid sequence are shown on the right of 
each growth factor. 
 
Expression of latent growth factors 
LAP genetically fused to the sequences of the mature mEPO, huTGFβ, mIGF1A or mIGF1B cDNA via 
an MMP cleavage site, produced four distinct latent growth factor proteins. The control protein LAP-
MMP has been used by our group previously (Adams et al., 2003). The latent growth factor 
constructs were produced by sequential cloning of LAP-MMP and the pertinent growth factor 
fragment, excised by restriction enzyme digestion, into the mammalian expression plasmid vector 
pcDNA3 and the correct orientation verified by DNA sequencing.  
Latent recombinant proteins are secreted from CHO and HEK-293T cells 
Following calcium phosphate transfection of the constructs into the CHO DG44 and HEK-293T cell 
lines, western blot analysis was used to determine if the constructs LAP-MMP-mEPO, LAP-MMP-
huTGFβ, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B or LAP-MMP are expressed and secreted as latent 
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recombinant proteins. A combination of polyclonal LAP antibody and the appropriate primary 
growth factor antibody confirmed the expression and the secretion of the latent growth factors. The 
predicted molecular weight of the LAP-MMP control recombinant protein, according to the amino 
acid sequence, is 32 kDa but due to glycosylation at the amino acid residues Asn82, 136, and 176 (Brunner 
et al., 1992), the detected band is ~ 37-40 kDa when probed with LAP antibody (Figure 3.4). LAP-
MMP-huTGFβ was detected around 45 kDa as calculated by its amino acid sequence when probed 
with anti-TGFβ antibody (Figure 3.5C). The cleaved growth factor mEPO is documented to be highly 
glycosylated with 3 N-glycosylation sites at Asn24, 38, and 83 and an O-glycosylation site at Ser126 (Dube 
et al., 1988) and although LAP-MMP-mEPO is calculated to be 51 kDa based on its amino acid 
sequence, a band is detected at ~70-75 kDa when probed with anti-EPO antibody (Figure 3.5D). The 
molecular weights of the LAP-MMP-mIGF1A and LAP-MMP-mIGF1B recombinant proteins were 
calculated to be 44 kDa and 45 kDa respectively, but were detected at ~50 kDa when probed with 
the anti-IGF1 antibody (Figures 3.5 A and B).  
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Figure 3.4: The CHO cell line DG44 secretes the control recombinant protein LAP-MMP. 
DG44 CHO cells were stably transfected with the pcDNA3(LAP-MMP) plasmid vector and the culture supernatants collected 
after 48 hours, and analyzed by western blotting with antibodies against anti-LAP. The molecular weight is higher than 
expected (an observed ~37-40 kDa vs. the expected 32 kDa as determined by the amino acid sequence) possibly due to 
post-translation modification, e.g glycosylation. Abbreviation: IB=immunoblot, M.W.=molecular weight. 
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Figure 3.5: Latent recombinant proteins are secretable when expressed by CHO DG44 cells.  
CHO DG44 cells were stably transfected with (A) pcDNA3(LAP-MMP-mIGF1A), (B) pcDNA3(LAP-MMP-mIGF1B), (C) 
pcDNA3(LAP-MMP-huTGFβ) and (D) pcDNA3(LAP-MMP-mEPO) plasmid vectors and the culture supernatants collected 
after 48 hours, and analyzed by western blotting with anti-IGF1 (A and B), anti-TGFβ (C) and anti-EPO (D) antibodies. All 
bands ran higher than expected, possibly due to post-translation modifications such as glycosylation. Abbreviation: 
M.W.=molecular weight, IB = immunoblot. 
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MMP cleavage of latent growth factors 
To assess whether the latent recombinant protein releases the cleaved growth factor when 
incubated with recombinant MMP1, culture supernatants were incubated with MMP1 overnight and 
analysed by western blot using the appropriate growth factor antibody and/or the LAP antibody.  
Analysis of cleavage by MMP1 of recobimant proteins secreted by DG44 CHO cells. 
The cleaved mIGF1A and mIGF1B molecules, from LAP-MMP-mIGF1A and LAP-MMP-mIGF1B 
respectively, were detected at ~12 kDa as predicted from their amino acid sequence (Figure 3.6A 
and B, Figure 3.6 C and D respectively). Unexpectedly, two bands smaller than 10kD were also 
observed. The LAP-MMP molecule, when probed with LAP antibody, was detected at approximately 
37 kDa following cleavage by MMP1 (Figure 3.7B). Cleavage of LAP-MMP-huTGFβ by MMP1 releases 
huTGFβ with the resulting LAP peptide seen at approximately 37 kDa (Figure 3.7A). The recombinant 
protein LAP-MMP-mEPO, when secreted by DG44 CHO cells, was also incubated overnight in 30nM 
MMP1 and the supernatant run on SDS-PAGE and analysed by western blot. However, no release of 
mEPO was observed when probed with the anti-LAP antibody (Figure 3.8). This was unexpected as 
the four other ecombinant proteins (LAP-MMP, LAP-MMP-huTGFβ, LAP-MMP-mIGF1A and LAP-
MMP-mIGF1B) all demonstrated cleavage and growth factor release when incubated with MMP1.  
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Figure 3.6: Latent recombinant proteins LAP-MMP-mIGF1A and LAP-MMP-mIGF1B are cleavable by MMP1 when 
expressed by DG44 CHO cells. 
DG44 CHO cells were stably transfected with pcDNA3(LAP-MMP-mIGF1A) (panels A and B) and pcDNA3(LAP-MMP-
mIGF1B) (panels C and D) plasmid vectors and the culture supernatants collected after 48 hours, incubated with and 
without MMP1 for 16–18 hours, and analyzed by western blotting with antibodies against both anti-LAP and anti-IGF1 
antibodies. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – indicates absence of MMP1 during incubation 
overnight; + indicates presence of MMP1 enzyme during incubation overnight. 
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Figure 3.7: The latent recombinant proteins LAP-MMP and LAP-MMP-huTGFβ cleaved by MMP1 when expressed by 
DG44 CHO cells. 
DG44 CHO cells were stably transfected with pcDNA3(LAP-MMP-huTGFβ) (A) and pcDNA3(LAP-MMP) (B) plasmid vectors 
and the culture supernatants collected after 48 hours, incubated with and without MMP1 for 16–18 hours, and analyzed by 
western blotting with antibodies against anti-LAP. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – indicates 
absence of MMP1 during incubation overnight; + indicates presence of MMP1 enzyme during incubation overnight. 
 
Figure 3.8: MMP1 fails to cleave the recombinant protein LAP-MMP-mEPO secreted by DG44 CHO cells. 
DG44 CHO cells were stably transfected with the pcDNA3(LAP-MMP-mEPO) plasmid vector and the culture supernatant 
was collected after 48 hours, incubated with and without 30nM MMP1 for 16–18 hours, and analysed by western blotting 
with antibodies against anti-EPO. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – indicates absence of MMP1 
during incubation overnight; + indicates presence of MMP1 enzyme during incubation overnight. 
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Analysis of cleavage by MMP1 of recobimant proteins secreted by HEK-293T cells. 
Cleavage of the latent recombinant proteins secreted the HEK-293T cell line was observed as with 
DG44 CHO cells. Interestingly, the LAP-MMP-mEPO recombinant protein was able to be cleaved by 
MMP1, and when analysed by western blot and probed with anti-EPO antibody, the growth factor 
mEPO (initially predicted to be 18 kDa as calculated from the amino acid sequence) was detected at 
a higher molecular weight of approximately 70–75 kDa (Figure 3,9). As previously discussed, mEPO 
has several glycosylation sites therefore it is not surprising that, when LAP-MMP-mEPO was 
incubated with MMP1, the size of the cleaved mEPO protein was bigger (~34 kDa) (Figure 3.9). 
 
 
Figure 3.9. When secreted by HEK-293T cells, MMP1 is able to cleave the recombinant protein LAP-MMP-mEPO. 
HEK-293T cells were stably transfected with the pcDNA3(LAP-MMP-mEPO) plasmid vector and the culture supernatant was 
collected after 48 hours, incubated with and without MMP1 for 16–18 hours, and analyzed by western blotting with anti-
EPO antibody. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – indicates absence of MMP1 during incubation 
overnight; + indicates presence of MMP1 enzyme during incubation overnight. 
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In order to determine if the failure of MMP1 to release the cleaved mEPO protein, when secreted 
from the DG44 CHO cell line, was due to protein production from a single CHO clone population, the 
CHO suspension cell line CHO-S, a sub-clone of the parental CHO cell line that has been adapted to 
grow in suspension under serum-free conditions, was transiently transfected with LAP-MMP-mEPO, 
the supernatant collected and incubated overnight in the presence of MMP1. Although the cell line 
expressed and secreted LAP-MMP-mEPO as determined by western blot analysis, it too failed to 
release the cleaved mEPO protein (Figure 3.10, lanes 3 and 4) as compared to LAP-MMP-mEPO 
secreted from HEK-293T cells and incubated with MMP1 (Figure 3.10, lanes 1 and 2). 
 
Figure 3.10: The recombinant protein LAP-MMP-mEPO is cleaved by MMP1 when secreted by HEK-293T cells but not 
from CHO-S cells.  
HEK-293T and CHO-S cells were transiently transfected with LAP-MMP-mEPO and the culture supernatant was collected 
after 48 hours, incubated in the presence of MMP1 enzyme overnight at 37°C, assessed by western blot analysis and 
probed with anti-LAP antibody. The supernatant from HEK-293T cells (lanes 1 and 2) demonstrates cleavage whereas 
supernatant taken from CHO-S cells (lanes 3 and 4) does not. Some degradation of the protein is observed. Arrow indicates 
the released LAP peptide. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – indicates absence of MMP1 during 
incubation overnight; + indicates presence of MMP1 enzyme during incubation overnight. 
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It is possible that this lack of cleavage was due to different glycosylation patterns between the 
human HEK-293T cell line and the hamster CHO cell line. Incubation of CHO-S cells expressing LAP-
MMP-mEPO with the antibiotic Tunicamycin should result in the inhibition of N-glycosylation. 
Tunicamycin interrupts the synthesis of glycoproteins by blocking uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc) and Dol-P, enzymes used by glycosyltransferases to transfer N-
acetylglucosamine to specific sites on a protein molecule. Tunicamycin was added to culture 
medium of CHO-S cells producing LAP-MMP-mEPO at concentrations 5µg/ml and the cells were 
incubated for 48 hours. However, no cleavage of the protein was observed when incubated with 
MMP1 enzyme (data not shown). Importantly, LAP-MMP-mEPO is cleaved by MMP1 when 
expressed in mouse Biozzi/ABH fibroblasts that were used for therapeutic purposes (see below 
Figure 4.3) 
Cleavage of latent mEPO is dependent on the MMP site 
To investigate the latency of the latent mEPO, a glycine-serine flexible linker bridge genetically 
replaced the MMP cleavage site. The glycine-serine linker is a cryptic site that is not sensitive to 
MMP1 cleavage and should not result in cleavage when in the presence of the enzyme, thus 
conferring permanent latency to the recombinant protein. Conditioned medium from HEK-293T cells 
transfected with either the construct LAP-(Gly4Ser)3-mEPO or LAP-MMP-mEPO, was incubated for 6 
hours with increasing dilutions of MMP1, and assessed by western blot analysis for cleavage of the 
LAP as probed using the LAP antibody. Diluting the MMP1 enzyme will rule out the possibility that an 
excess of enzyme, resulting in non-specific opportunistic cleavage, releases any cleaved mEPO 
growth factor. MMP incubation resulted in the cleaved LAP molecule from LAP-MMP-mEPO with an 
expected size of 37 kDa. A faint band corresponding to 37 kDa was seen for LAP-(Gly4Ser)3-mEPO 
(Figure 3.11).  
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Figure 3.11 Cleavage of mEPO by MMP1 from the recombinant protein is dependent on the MMP site.  
HEK-293T cells were transiently transfected either with pcDNA3(LAP-MMP-mEPO) or pcDNA3(LAP-(Gly4Ser)3-mEPO0. 24 
hours after transfection, the conditioned supernatant was collected and incubated for 6 hours with 75pM MMP1, before 
analyses by western blot and probing with anti-LAP antibody. Abbreviation: M.W.=molecular weight, IB = immunoblot.  – 
indicates absence of MMP1 during incubation overnight; + indicates presence of MMP1 enzyme during incubation 
overnight. 
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Biological activity of the latent growth factors 
LAP-MMP-huTGFβ 
Using MLEC cells the biological activity of latent huTGFβ, before and after MMP1 cleavage, was 
tested. huTGF can stimulate the expression of plasminogen activator inhibitor-1 (PAI-1) in MLEC 
cells (Abe et al., 1994). Stimulation of MLEC cells stably transfected with a construct consisting of a 
truncated PAI-1 promoter fused to the Firefly luciferase reporter gene (MLEC (PAI/L)), with huTGFβ 
resulted in a dose-dependent increase in luciferase activity.  
TGFβ is secreted as a latent protein comprising the disulphide linked homodimer of mature TGFβ 
that is associated via non-covalent bonds to LAP and LTBP, associations that are required for 
localisation and binding to the extracellular matrix (Miyazono et al., 1988, Wakefield et al., 1988, 
Lyons and Moses, 1990). Several activation mechanisms release the biologically active TGFβ from 
the SLTC and the LLTC including the dissociation of the LTBP from LAP via acid activation, and the 
proteolytic cleavage of LAP via proteases such as plasmin (Lyons et al., 1988, Lyons et al., 1990).  
Conditioned medium collected from HEK-293T cells transiently transfected with pcDNA3(LAP-MMP-
huTGFβ) was acid treated following incubation with MMP1 enzyme, releasing the mature 
homodimer huTGFβ required for biological assessment. The experimental conditions tested were 
cleaved and uncleaved LAP-MMP-huTGFβ, with or without acid activation (Figure 3.12). Without acid 
activation, the cleaved huTGFβ protein elicited a luciferase output that was significantly higher than 
that of uncleaved LAP-MMP-huTGFβ (p < 0.0001). Interestingly, uncleaved LAP-MMP-huTGFβ still 
exhibited a small degree of luciferase activity. When activated by acid, the luciferase output of 
cleaved huTGFβ was significantly enhanced (p < 0.0001) in comparison to the uncleaved LAP-MMP-
huTGFβ. Additionally, the luciferase output of acid-activated uncleaved LAP-MMP-huTGFβ was of a 
similar intensity as that of the cleaved huTGFβ protein that did not undergo acid activation (Figure 
3.12), possibly due to endogenous MMPs found in the medium of the transfected or the MLEC cells.  
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Figure 3.12: Latent huTGFβ remains biologically inactive until cleaved with MMP1 enzyme.  
MLEC (PAI/L) cells were transiently transfected with pcDNA3(LAP-MMP-huTGFβ) and the supernatant collected after 48 
hours. Following incubation of the supernatant with or without MMP1, the sample were either activated or not by acid. 
The luciferase output was read, and translated into relative light units (RLU). A significant increase in RLU was detected 
following MMP1 cleavage between uncleaved LAP-MMP-huTGFβ and cleaved huTGFβ, as well as between the samples 
with and without acid activation. Statistical analysis was performed using a one-way ANOVA followed by Tukeys post-hoc 
test for multiple comparrisons.  
LAP-MMP-mIGF1A 
To test the biological activity of the LAP-MMP-mIGF1A and cleaved mIGF1A proteins, I used the OPC 
line CG4. CG4 cells proliferate in response to growth factors and mitogens secreted from the 
neuronal cell line B104. Withdrawal of this conditioned medium and replacement with a serum-free 
medium supplemented with IGF1 results in cell proliferation and survival, rather than differentiation. 
Supernatant taken from HEK-293T cells transfected with pcDNA3(LAP-MMP-mIGF1A) was incubated 
with MMP1 and the biological activity of cleaved mIGF1A assessed. When incubated with cleaved 
mIGF1A protein, a significant number of cells survived as compared to those incubated with the LAP-
MMP-mIGF1A (p < 0.001) (Figure 3.13).  
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Figure 3.13. Incubation of CG4 cells with LAP-MMP-mIGF1A after MMP1 cleavage significantly increases cell 
proliferation.  
HEK-293T cells were transiently transfected with pcDNA3(LAP-MMP-mIGF1A). After 48 hours, the supernatant was 
collected and incubated with 30 nM MMP1 overnight prior to assaying with Cell-Titer Glo (Promega). Statistical significance 
was determined by paired t-test. 
LAP-MMP-mEPO 
To test the biological activity of the latent mEPO protein before and after MMP1 cleavage, the 
human megakaryoblastic leukaemia cell line UT-7 was used. UT-7 cells are able to proliferate in the 
presence of IL-3, GM-CSF or EPO (Komatsu et al., 1991). HEK-293T cells were transiently transfected 
with pcDNA3(LAP-MMP-mEPO), and after 48 hours the supernatant was collected and incubated 
overnight with 30nM MMP1. The supernatant was added to the UT-7 cells and then assayed using 
the Cell Titer Glo assay (Promega). The LAP-MMP-mEPO (without MMP1) demonstrated a small 
amount of UT-7 proliferation but when cleaved with MMP1, proliferation doubled (p < 0.0001) 
(Figure 3.14A).  
To determine if the increase in cell number observed in Figure 3.14A for LAP-MMP-mEPO was due to 
endogenous MMP activity found either within the HEK-293T conditioned medium or from the UT-7 
cells themselves, the UT-7 cells were incubated with conditioned medium from HEK-293T cells 
transfected with pcDNA3(LAP-(Gly4Ser)3-mEPO) with or without MMP1 incubation, and with 
supernatant collected from HEK-293T cells transfected with pcDNA3(LAP-MMP-mEPO). Similar levels 
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of stimulation of UT7 cells was observed when the UT7 cells were exposed to supernatant collected 
from HEK-293T cells transfected with pcDNA3(LAP-(Gly4Ser)3-mEPO) (with and without MMP1 
incubation) and supernatant collected from HEK-293T cells transfected with pcDNA3(LAP-MMP-
mEPO) but without MMP1 incubation. Background levels from UT-7 cells incubated with MMP 
enzyme only (no recombinant protein) were negligible and subtracted from the values of the assay. 
These results indicate that the inferred ‘background’ level of cell proliferation seen when exposed to 
the latent recombinant protein, LAP-MMP-mEPO, is unlikely to be due to release of cleaved EPO at 
the MMP site (Figure 3.14B).  
To test whether this background level of activity could be abolished, a broad-spectrum MMP 
inhibitor TAPI-2 was used. Incubation of the latent mEPO protein with TAPI-2 resulted in a significant 
decrease in background activity (p < 0.05) but failed to completely eliminate it, possibly indicating an 
additional pathway for protein cleavage that results in the exposure of the mEPO protein to its 
receptor on the UT-7 cell. Unsurprisingly, a significant reduction in cell proliferation (p < 0.0001) 
occurred when the cleaved mEPO protein was incubated with TAPI-2 (Figure 3.14B).  
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Figure 3.14: Incubation of UT-7 cells with broad-spectrum MMP inhibitor significantly reduces endogenous MMP activity 
on latent EPO.  
(A) Supernatant taken from HEK-293T cells transiently transfected with pcDNA3(LAP-MMP-mEPO) were incubated with 
and without MMP1, and with or without the broad spectrum MMP inhibitor TAPI-2 prior to proliferation assay. Initial 
results without TAPI-2 and without MMP1 incubation show a degree of proliferation. In the presence of TAPI-2, the 
background is reduced as are the samples incubated with MMP1. Significance was determined by one-way ANOVA with 
Tukey post-hoc tests. (B) Latency was investigated using a control containing a glycine serine linker in place of the MMP 
cleavage site and the latent recombinant EPO protein. Protein quantiy was determined by direct LAP elisa and equal 
amounts used for the assay. Both sample supernatants were incubated in the presence of 30nM MMP1 overnight before 
assaying. Significance was determined by one-way ANOVA with Tukey post-hoc tests. 
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DISCUSSION 
The results presented here describe the design, genetic construction and in vitro characterisation of 
the latent growth factors mEPO, huTGFβ, mIGF1A and mIGF1B. Adams et al. (2003) originally 
described this latency platform technology. They ascertained that the growth factor IFN-β could be 
made latent through fusion with the LAP of TGFβ. Activation of IFN-β occurred through cleavage of 
the cleaved protein from the LAP protective ‘shell’ at an engineered MMP site incorporated between 
the two molecules. The latent growth factor demonstrated a lack of biological activity until the 
cleaved protein was released. Interestingly, they also noted that the cleaved protein was released 
when incubated with the CSF taken from patients suffering from neurological diseases such as 
multiple sclerosis. By exploiting this technology, these modular building blocks, the LAP shell fused 
to the MMP cleavage site, and growth factors can be cloned into expression plasmids that are able 
to express recombinant proteins (with a longer half-life and the ability to become active in areas of 
increased MMP activity) in a variety of cell lines, for use as therapeutic agents in MS. Growth factors 
such as mEPO, mIGF1 and huTGFβ target more the neurodegenerative component of the disease 
rather than the immune-mediated component that the approved therapies do. 
Expression and secretion of all four latent growth factors and the control (LAP-MMP) was 
investigated in both the CHO and the HEK-293T mammalian cell lines and analysed using western 
blotting. Methotrexate amplification of the CHO cell clones led to several clonal populations to 
secrete high concentrations of latent growth factor protein that were isolated and expanded in 
order to generate a stable, continuous and consistent production of the latent growth factor protein. 
The expression, secretion and cleavage of the latent growth factors from the CHO cell line were 
successful for all but one latent protein (LAP-MMP-mEPO). The producer of the latent LAP-MMP-
mEPO protein in the CHO cell line was a population of an original clone obtained through ring 
cloning techniques. Therefore, it was hypothesised that the failure of the MMP enzyme to cleave 
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LAP-MMP-mEPO was due to a cellular defect with that particular clone. However, MMP once again 
failed to cleave LAP-MMP-mEPO produced by a suspension-based CHO cell population. As cleavage 
was obtained in the HEK-293T cell line, the inability for MMP to cleave latent EPO was theorised to 
be down to the cell-specific post-translational modifications (such as glycosylation, Raju et al., 2000) 
resulting in altered protein structure or conformation through the interaction of the glycosylation 
sites of EPO and LAP.  
The EPO and LAP proteins are highly glycosylated with 4 N-linked glycosylation sites (Asn24, Asn38 and 
Asn83) and 1 O-linked glycosylation site (Ser126) on the EPO molecule, and 3 N-linked glycosylation 
sites (Asn82, Asn136 and Asn176) on the LAP molecule (Wasley et al., 1991, Purchio et al., 1988). 
Tunicamycin is an antibiotic that interrupts the synthesis of glycoproteins by blocking UDP-GlcNAc 
and Dol-P, enzymes used by glycosyltransferases to transfer N-acetylglycosamine to specific sites on 
a protein molecule. To determine whether the glycosylation pattern of the proteins generated by 
the CHO cells may be the inhibitory factor in the ability of the MMP1 enzyme to cleave LAP-MMP-
mEPO, pcDNA3(LAP-MMP-mEPO) transfected CHO-S were cultured in the presence of tunicamycin 
before the conditioned supernatant was incubated with MMP1. Although the CHO-S cells were able 
to express and secrete unglycosylated LAP-MMP-mEPO, they failed to release mEPO when incubated 
with MMP1. Surprisingly, our lab has demonstrated that when human EPO (huEPO) is fused to LAP 
and expressed by CHO DG44 cells, MMP1 is able to cleave the protein and release huEPO 
(unpublished data, Dr. Sandrine Vessilier). As to the reason MMP1 fails to cleave mEPO when fused 
to LAP is, at present, unclear. Further studies on the recombinant protein structure and composition 
(such as mass spectrometry) may be able to shed some light onto a possible reason for MMP1 
failure. 
CHO cells are the dominant cell line for the production of glycoprotein therapeutics, although other 
cell lines such as HEK-293T cells are being engineered to produce high-expression cell lines (Hossler 
et al., 2009). This addition of oligosaccharides to either the side chain of asparagine (N-linked 
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glycans) or to the side chain of serine/threonine (O-linked glycans) plays a crucial role in protein 
function and half-life and therefore in the pharmacokinetics of the protein. For example, brain 
derived EPO is smaller in size than serum EPO but is more active in vitro at low concentrations, 
factors all pertaining to the degree of sialylation (i.e. glycosylation)  (Genc et al., 2004). This was best 
demonstrated in the recombinant protein asialylated EPO (Erbayraktar et al., 2003). The plasma half-
life of rEPO, usually 5–6 hours, is reduced to 2 min when asialylated. Moreover, the addition of two 
N-linked glycosylation sites into the recombinant protein darbopoetin-α increased the protein half-
life (and ultimately its in vivo activity) significantly, even when given at a ten-fold higher dose of 
rEPO to darbopoeitic-α (Elliott et al., 2003). Methotrexate amplification is a widely used method of 
gene amplification in CHO cells for the large-scale production of recombinant protein, and an 
increase in gene copy number increases the specific productivity of recombinant proteins from the 
CHO cell line (Kim et al., 1998). However, even after methotrexate amplification, the CHO cell line 
stably transfected with the recombinant protein vectors produced significantly smaller levels of 
latent protein than that found from the conditioned medium collected from HEK-293T cells 
transfected with those same recombinant vectors. The purification of latent proteins is problematic 
due to the adherence of the LAP protein to the purification filters (unpublished data, Dr Sandrine 
Vessillier) coupled with small initial concentrations, this method of protein production was 
abandoned in favour of transient transfection of the HEK-293T cell line for these studies.  
The HEK-293T cell line correctly expressed and secreted the latent growth factors and the MMP1 
enzyme successfully released the cleaved protein. Interestingly, the latent mIGF1 proteins, when 
incubated with MMP1, released three protein molecules rather than the expected single cleaved 
protein. This may be due to a MMP enzyme cleaving the mature IGF1 peptide at amino acids Pro63 
and Leu64, which correspond to amino acids found within the engineered MMP cleavage recognition 
site (PLGLWA) resulting in a peptide fragment around 8 kDa. Another possibility may be cleavage of 
the amino acids Gln15, Phe16 and Val17 within the IGF1 protein, which are found within the self-
activation site of MMP1 (GVPDVAQFVLTE) resulting in a peptide fragment around 5 kDa (Vessillier et 
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al., 2004). The mutation of the amino acids Pro63 and Leu64, or of Gln15, Phe16 and Val17 within LAP-
MMP-mIGF1 to ones that do not constitute a recognition site may enable us to confirm this theory. 
Within our biological assay, a significant increase in cell proliferation was observed when 
supernatant containing secreted LAP-MMP-mIGF1 was incubated with MMP and applied to CG4 
cells. It may be that although the MMP enzyme cleaves the mature protein into three fragments, 
each of these fragments is biologically active. Alternatively, only a small amount of IGF1 may be 
required to stimulate proliferation of the CG4 cells and that, although the MMP enzyme has cleaved 
the mature protein into three peptides, the amount of biologically active protein is sufficient to 
induce proliferation. The protein fragments would initially require purification in order to separate 
them into their individual sizes. This can be achieved by running the cleaved proteins through SDS-
PAGE, the gel silver stained to identify the relevant bands, followed by excision and electroelution of 
the protein bands. Once the bands have been isolated, they can be used individually in the CG4 
biological assays to determine whether they are all biologically active; or if not all are biologically 
active, those that are can be titered to determine the minimum concentration required to initiate 
proliferation of CG4 cells.  
By engineering the latent control peptide (LAP-(Gly4Ser)3-mEPO), through the replacement of the 
MMP cleavage site with a flexible glycine-serine linker, the ability of LAP-MMP-mEPO to be cleaved 
by the MMP1 enzyme could be investigated. When incubated with MMP1, a faint band 
corresponding to the LAP fragment of this control is present; however, it is negligible in comparison 
to that of the LAP protein cleaved from the LAP-MMP-mEPO protein. A recent study has 
demonstrated the ability of the proteinase MMP2 to cleave the LAP peptide in vitro in mouse 
embryo fibroblasts (Ge and Greenspan, 2006). It is therefore possible that the latent LAP-MMP-
mEPO peptide contains a cleavage site for both MMP2 and MMP1 in the absence of the preferential 
engineered MMP site resulting in the faint band observed when the MMP site is absent. 
Alternatively, it may be that the addition of MMP1 to the conditioned medium collected from 
transfected cells activates other MMPs found within the supernatant and secreted by the cell, such 
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as MMPs secreted by CHO cells (Adams et al., 2003). This substantiates the finding that cleavage is 
dependent on an MMP site. 
The human megakaryoblastic leukaemia cell line UT-7 proliferates in the presence of EPO and was 
used to assess the biological activity of LAP-MMP-mEPO before and after cleavage by MMP1. A 
significant increase in cell proliferation following MMP1 cleavage confirmed its latency; although in 
the absence of MMP1 incubation the latent protein did exert a notable increase in cell number. The 
MMP cleavage site incorporated into the latent recombinant proteins (LAP-MMP-mEPO, LAP-MMP-
huTGFβ, LAP-MMP-mIGF1A and LAP-MMP-mIGF1B) is a consensus sequence and is not exclusive for 
cleavage by MMP1, but has been found to be cleaved by other MMPs such as MMP2, -3, -7 and -9 
(Adams et al., 2003). Inclusion of LAP-(Gly4Ser)3-mEPO demonstrated similar levels of proliferation 
that was substantially reduced when the broad-spectrum MMP inhibitor TAPI-2 to added to the 
sample. One theory is that other proteases may play a part in the release of cleaved mEPO; another 
is that (as seen from the lack of MMP1 cleavage in CHO generated LAP-MMP-mEPO protein) the 
tertiary structure is somewhat altered allowing the EPO peptide access to its receptor on the cell 
surface even without release in the cleaved form by a proteinase such as MMP1.  
An assay assessing the biological activity of LAP-MMP-mIGF1A before and after incubation with 
MMP1 demonstrated a significant increase in the proliferation of CG4 cells in response to cleaved 
mIGF1A indicating that the LAP-MMP-mIGF1A recombinant protein is cleaved by MMP1 and the 
cleaved mIGF1A peptide is biologically active and able to induce proliferation of CG4 cells and not 
their differentiation in type-2 astrocytes. Once again, a small degree of background level of cell 
proliferation proliferation was observed without MMP cleavage. This is more than likely due to the 
release of cleaved mIGF1A from LAP-MMP-mIGF1A by endogenous MMPs secreted by the producing 
cell line, HEK-293T.  
Utilisation of the MLEC cell line integrated with a luciferase reporter gene demonstrated a significant 
increase in luciferase output when incubated with cleaved huTGFβ as compared to LAP-MMP-
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huTGFβ. Human TGFβ is secreted as a latent protein where the TGFβ homodimer—bound by 
disulphide bonds—is attached by non-covalent bonds to LAP (Miyazono et al., 1988, Wakefield et al., 
1988, Lyons et al., 1990, Shi et al., 2011). The in vitro application of acid activation commissions the 
dissociation of these non-covalent bonds allowing for the release of huTGFβ bound by non-covalent 
bonding to the LAP, visualized by a significant increase in luciferase output. Unsurprisingly, the 
amount of luciferase output for acid activated LAP-MMP-huTGFβ without exposure to MMP1 
enzyme appeared to be similar in intensity to that of inactivated but cleaved huTGFβ. This is because 
although acid activation allows the TGFβ peptide to be exposed, it is still unable to access its 
receptor. Similarly although cleaved TGFβ is released from the LAP, LAP still provides latency to it 
through its association by non-covalent bonds.  
In vitro experiments confirmed the expression, secretion, latency and cleavability of the engineered 
latent growth factors mEPO, huTGFβ, mIGF1A and mIGF1B and their biological activities confirmed 
when cleaved with MMP1. These characteristics demonstrate the appeal of this technology as a 
therapeutic avenue for growth factors as it aims to circumvent the issues of the growth factors 
pleiotropism and toxicity typically observed following systemic administration. The next chapter 
discusses the method of protein delivery.  
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INTRODUCTION 
Treatment of MS, gained from studies performed in the mouse model EAE, with the growth factors 
TGFβ, EPO and IGF1 shows promise. However, the limited access of growth factors to the CNS, and 
their pleiotropic nature when administered systemically hampers their development as therapeutic 
molecules. In animal studies, delivery of these growth factors has been through either direct 
intracerebral injection into the CNS, or via direct gene transfer for example using the Herpes Simplex 
Virus vector. The administration of a therapeutic agent directly into the human brain is obviously not 
possible and as such, alternative delivery methods must be devised. Delivery via a lentiviral vector 
system is extremely attractive due to its natural proficiency to evade the host immune system and 
integrate within a host cell genome. Viruses are highly evolved biological machines that gain access 
to a host cell and exploit the cellular machinery to facilitate their propagation and replication. The 
introduction into, and the replication of the proviral genome within the host cell, is the key to 
utilizing lentiviral vectors as therapeutic delivery vehicles. 
The Lentivirus Life Cycle 
The lentivirus life cycle consists of two phases: the early phase involving the entry and integration of 
the virus into the host cell; and the late phase involving the expression of the proviral genome, and 
all its processes up to and including viral budding and maturation (Coffin et al., 1997). 
The Early Phase 
During the early phase, the virus gains access to the host by binding to a specific receptor on the cell 
surface. The binding of the viral surface glycoproteins (SU, also known as gp120) with the 
transmembrane proteins (TM, also known as gp41),  followed by the binding of that complex with 
CD4 and then CXCR4 or CCR5, thus triggering a conformational change that results in the fusion of 
the two membranes (the viral and the host cell’s membrane) and the generation of a “fusion-pore” 
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(Coffin et al., 1997, Turner and Summers, 1999). It is through this pore that the virus injects its 
genetic material into the host cell’s cytoplasm.  
The Late Phase 
The late phase begins with the injection of the viral genome into the cytoplasm of the host cell. An 
infectious virus has a pseudodiploid RNA genome (two identical copies of which one is a backup in 
case the template is damaged) which enters the cytoplasm as a nucleoprotein complex that is 
uncoated and reverse transcribed before translocating to the nucleus via the preintegration complex 
(PIC) for integration into the host genome. The ability of a virus to reverse transcribe its RNA into 
DNA for integration into the hosts genome is a fundamental and crucial step in the viral life cycle. 
Transcription results in a single linear DNA duplex (co-linear with the RNA template) containing 
coding genes, cis-acting genes and LTR required for the transcription of the viral DNA to RNA for 
packaging (Coffin et al., 1997, Lever et al., 2004).  
The cis-acting elements are the unique 3’ LTR (U3), the unique 5’ LTR (U5), the R, the primer binding 
site (PBS), the polypurine tract (PPT) and the LTR’s including the ψ (Psi) packaging sequence or 
encapsidation sequence (E). The R is the ‘Repeat’ at both ends of the viral RNA found within U3 and 
U5 and containing the polyadenylation signal sequence (AAUAAA). The PBS is a tRNA primer for 
reverse transcriptase binding site situated adjacent to U5. The PPT is a purine rich sequence situated 
immediately upstream of the 5’ U3 that is cleaved during reverse transcription to generate the RNA 
primer for the synthesis of the positive strand of viral DNA. The PPT, PBS and R sequences enable 
efficient reverse transcription to occur. This transcription begins at the 5’ LTR promoter/enhancer 
U3 region and ends at the 3’ LTR transcription termination and polyA tail U5 region (Coffin et al., 
1997, Lever et al., 2004).  
There are three principal groups of viral proteins, translated from the coding genes, which are 
required for efficient and effective infection and replication: Gag, Gag-Pro-Pol, and Env. The Env 
proteins (encoded by the env gene) are responsible for the infection and interaction of the virus with 
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the cell surface receptors. Processing of the Env polypeptide generates the SU and TM proteins 
responsible for the fusion of the viral and host cell membranes and in defining the tropism of the 
virus through the host-cell receptor interaction. The Gag proteins (encoded by the gag gene) are 
nonglycosylated structural proteins of the matrix (MA), capsid (CA) and nucleocapsid (NC). The Pro-
Pol proteins (encoded by the pro and pol genes) are polymerase proteins responsible for reverse 
transcription and integration. They include reverse transcriptase (RT) and RNase H (responsible for 
RNA/DNA hybrid degradation), integrase (IN) and protease (PR) and, in addition to the NC, are 
essential for viral replication. The Gag proteins are responsible for directing viral budding at the 
plasma membrane. The incorporation of the Pro-Pol proteins into the viral bud occurs through 
linkage with the Gag proteins. The viral bud then undergoes a metamorphosis into a mature, 
infectious virus with a core shaped like a truncated cone (Lever et al., 2004).  
Lentiviruses are members of the retrovirus family of which HIV-1 is an example. In addition to the 
gag, pro, pol and env genes, lentiviruses also contain additional regulatory genes (tat and rev) that 
are essential for the expression of the genome. Tat, a low molecular weight protein, activates 
transcription by binding to a highly structured stem-loop region of R that is Tat-responsive (Tar). Rev 
is a protein that binds to the Rev Response Element (RRE), a highly structured sequence found within 
the lentiviral genome, to aid in the transportation of partially spliced and unspliced RNA from the 
cell nucleus to the cytoplasm (Coffin et al., 1997). 
Primate lentiviruses also produce other accessory proteins (Nef, Vpr, Vpu, Vpx and Vif) that are not 
required for viral growth but are crucial for replication and pathogenesis. Negative factor (Nef) is an 
intracellular protein that acts on the signal transduction pathways leading directly to the loss of CD4 
receptors on the cell surface. It increases the infectivity of viral particles and may activate RT either 
directly or indirectly. It also stimulates infected cells to divide. The Vpr protein (Viral protein r) is 
required for the targeting of viral DNA to the nucleus via its connection to the cellular import 
machinery. The karyophilic nature of the PIC (pre-integration complex) allows it to utilise the nuclear 
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import machinery of the host cell to gain access to its cytoplasm. This allows the virus to infect non-
dividing cells as well as those undergoing mitosis making them a very attractive option for gene 
therapy. Vpr is crucial for efficient replication as it causes infected cells to arrest in the G2 phase of 
the cell cycle. It may also promote transport of the PIC into the nucleus after reverse transcription. 
The PIC consists of the viral DNA, the IN and RT enzymes, the MA and Vpr proteins and the cellular 
protein HMG-I(Y) which markedly enhances the integration activity of the PIC. Vpu, a small integral 
membrane protein, indirectly decreases the levels of the CD4 receptor by binding to them and 
signalling their degradation. It also promotes the release of the viral bud at the plasma membrane 
(Turner and Summers, 1999, Kay et al., 2001, Coffin et al., 1997). Vif (Virion infectivity factor) is a 
largely intracellular protein that affects the infectivity of the mature viral particles and is required for 
the efficient viral replication (Figure 4.1). 
. 
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Figure 4.1: Organisation of the HIV-1 genome.  
The long terminal repeat (LTR) regions, the genes and proteins encoded by the viral genome are indicated. The three 
principal viral protein groups Gag, Env and Pol are originally translated as polypeptides and are essential for the infection, 
integration and replication of the virus. The Gag peptide is cleaved into its relative protein subunits by the viral protease 
(PR) into the matrix (MA), capsid (CA) and nucleocapsid (MC) proteins. The Gag-Pol precursor peptide undergoes 
processing to generate the Gag protein subunits MS, CA and NC as well as the viral protease PR, and the enzymes reverse 
transcriptase (RT) and integrase (IN). The Env glycoprotein is processed by a cellular enzyme to generate the surface 
glycoprotein (SU, gp120) and the transmembrane glycoprotein (TM, gp41). The lentiviral accessory proteins (Nef, Vpr, Vpu 
and Vif) are also indicated and are crucial for the replication and pathogenesis of the virus. A lentivirus also contains 
additional regulatory genes (Tat and Rev) that are essential for the expression of the viral genome. The protein and gene 
sizes are not to scale.(Adapted from Freed, 2004 with permission). 
 
HIV-1 
HIV-1 binds to the CD4 receptors amino-terminal immunoglobulin domain expressed on Mø, TH cells, 
monocytes and other phagocytic cells. It undergoes reverse transcription before utilizing nuclear 
localisation signals to move through the nucleopores of the intact nuclear membrane and 
replicating. HIV-derived lentiviral vectors were the first recombinant lentiviral vector system to be 
developed and have been extensively modified from their wild-type counterparts in an attempt to 
improve their performance and their biosafety (Escors and Breckpot, 2010). They have since 
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expanded to include non-human lentiviruses (such as simian, equine, feline, and bovine) in an 
attempt to circumvent the issue regarding the human immune response as they (the non-human 
lentiviruses) are not infectious to humans (Shibata et al., 2009, Grinshpun et al., 2010, Kachi et al., 
2009, Mitomo et al., 2010). These vectors may be advantageous in human treatments. For example, 
the feline immunodeficiency-virus is able to effeciently and stably transduce several human cell lines 
(such as hepatocytes), but has inefficient replication capabilities due to the negligible transcriptional 
activity of the FIV LTR (Grinshpun et al., 2010).  
Lentiviral Vectors for Gene Therapy 
The advantages of a lentiviral vector system in gene therapy include a wide tropism as the viral 
envelope is pseudotyped with the VSV-G envelope protein, the lack of viral protein production after 
infection, integration of the therapeutic gene into the host genome and the long-term expression of 
the transgene at high levels. The use of a lentiviral vector has the additional advantage of genomic 
integration without mitosis. However, the genetic sequences inserted into the viral vector must be 
compatible to the viral life cycle i.e. must not contain introns (Coffin et al., 1997, Cockrell and Kafri, 
2007).  
The design of the lentiviral vector exploits the spatial segregation of the coding genes and the cis-
acting genes by placing them into different plasmids. This enables researchers to manipulate and 
control the performance and biosafety of the virus depending on the application required. For 
example the replacement of the wild-type env gene with that of another virus—a process known as 
pseudotyping—can either broaden or narrow the range of host cells that a recombinant virus can 
infect; by modifying the integrase gene through directional mutagenesis within the packaging 
vector, one can generate non-integrating lentiviral vectors (NILVs) (Escors and Breckpot, 2010). The 
generation of self-inactivating (SIN) lentiviral vectors, the removal of non-essential viral proteins and 
the separation of the coding and cis-acting genes onto isolated plasmids have facilitated the increase 
in biosafety by increasing the number of recombinational events required to generate a replicative-
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competent virus. The expression of the rev gene on a separate plasmid further enhances the safety 
of the lentiviral vector (Coffin et al., 1997).  
The transgene vector contains all the cis-acting elements, such as the ψ packaging sequence, a 
promoter and polyadenylation signal, the PBS, R and LTR’s, required for packaging, reverse 
transcription, and integration. Modifications such as the inclusion of the PPT and the addition of the 
woodchuck hepatitis B posttranscriptional regulatory element (WPRE) enhance the expression and 
stability of the transgene. The addition of cell-specific or tissue-specific promoters are also 
advantageous in that they can target that particular cell-type of tissue type and are less sensitive to 
promoter inactivation. By removing the four accessory proteins, deleting the tat gene and using a 
strong tat-independent constitutive promoter such as the cytomegalovirus (CMV) promoter (Dull et 
al., 1998) no negative effects on vector expression were noted (Gruber et al., 2000, Zufferey et al., 
1997) adding to the safety profile of the developing lentiviral vector, however some target cells can 
silence the CMV promoter (Loser et al., 1998).  
Implementing the assembly and packaging of a virus within a packaging cell line is followed by 
transduction. A lentiviral vector is a replication deficient virus which infects a target cell but which 
cannot replicate and produce viral particles. The envelope-encoding plasmid contains the Env 
proteins that determine the tropism of the virus. Pseudotyping of the HIV-1 lentiviral vector with the 
G protein of the vesicular stomatitis virus (VSV-G) allows for a wider host cell range. Additionally it 
results in a more stable vector that can generate viral titers exceeding 1x1010 t.u/ml (transducing 
units/ml) and which can endure concentration by ultracentrifugation (Kay et al., 2001, Coffin et al., 
1997, Naldini et al., 1996). The number of transducing units (or infectious viral particles) as well as 
the total viral particle number (particle titer) is important as impurities and variations in infectious 
activity can lead to toxicity and can influence infectivity and immunogenicity.  
HIV vectors stably integrate into the host genome in a random manner. This can result in the 
insertional activation of oncogenes by the random integration of the proviral genome, the 
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interruption and inactivation of an important gene due to this insertion and the possibility of 
generating a replication-competent virus through recombinational events (Miyoshi et al., 1998, 
Hanawa et al., 2005, Hacein-Bey-Abina et al., 2003). A SIN vector overcomes these problems as it is 
generated through the deletion of the transcriptional enhancers or the enhancers and promoters 
found within the U3 region or the 3’ LTR, or by placing direct repeats on either side of the ψ 
packaging sequences such that the packaging sequence is deleted during reverse transcription 
(Hanawa et al., 2005, Coffin et al., 1997, Kay et al., 2001). The use of a SIN vector significantly 
increases the biosafety of the virus as activation of neighbouring genes cannot occur due to the 
removal of the enhancer elements.  
Cells as transgene carriers 
Gene therapy requires the delivery of an appropriate amount of a therapeutic gene into the target 
tissue without substantial toxicity to be successful. The use of syngeneic cells has the benefit of not 
eliciting an immune response. Autologous skin fibroblasts are ideal as ex vivo gene therapy as they 
are easy to obtain through biopsy, are easy to propagate and engineer in vitro, are able to be 
transplanted in vivo using simple procedures such as intraperitoneal injection, and once transduced 
are able to express the therapeutic protein at appropriate amounts. Many studies utilizing this 
approach have demonstrated the efficiency and effectiveness of transplanting genetically 
engineered cells in treating diseases concerning the CNS such as Parkinson’s, Alzheimer’s and MS; 
and for diseases involving inflammation such as arthritis (Fisher et al., 1993, Triantaphyllopoulos et 
al., 1999, Croxford et al., 2001, Levivier et al., 1995).  
CHAPTER HYPOTHESIS AND AIMS 
If these latent proteins could be manufactured from the transfection of mammalian cells with a DNA 
plasmid containing the latent protein DNA, then we hypothesised that the latent protein DNA could 
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also be incorporated into a lentiviral vector. Moreover, we hypothesised that this lentivirus could 
infect a mammalian cell line and cause it to manufacture, express and secrete latent proteins that 
are only biologically active once incubated with MMP enzyme.  
The aim of this study was to determine if lentiviral vectors containing our transgenes of interest are 
able to transduce syngeneic cells that were conditionally immortalised and permanently transduced 
(tsF cells) in vitro. Once transduced and the ability of the expressed latent recombinant proteins to 
be cleaved by MMP1 in vitro, the in vivo biological activity was assessed following ex vivo gene 
delivery.  
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RESULTS 
Lentiviral vector production and transduction of syngeneic fibroblasts 
Dr Anne Rigby carried out the creation of the LAP-MMP lentiviral control vector, the production of 
the lentiviral particles LAP-MMP-mEPO, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B and LAP-MMP and 
the transduction of the tsF cells during my maternity leave. 
Lentiviral vector production and transduction of AB/H Biozzi tsF cells 
The HIV-1-derived lentiviral vector pHRSIN-CSGW (Figure 4.2A) has been previously described 
(Demaison et al., 2002). Deletion of the TATA box and the 3’ LTR U3 region (LTR/ΔU3) rendered the 
lentiviral vector SIN. The addition of a strong spleen focus forming virus (SFFV) promoter upstream 
and a WPRE downstream of the enhanced green fluorescent protein (eGFP) drives efficient 
transgene expression originally described by Zufferey et al. (1999).  
To transduce the conditionally (SV40 large T) immortalised Biozzi/ABH fibroblast (tsF) cell line with 
the different transgenes including the original eGFP vector, HEK-293T cells were co-transfected with 
the transgene of interest within the self-inactivating transfer lentiviral vector, along with the 
pCMVR8.2 packaging plasmid and the VSVG envelope plasmid (Figure 4.2). The supernatant was 
collected, cleared by filtration and centrifugation before concentrating by ultracentrifugation.  
Transduction of the tsF cell line was done in the presence of polybrene for 4 days—polybrene has 
been shown to improve the transduction efficiency of lentiviruses in a wide range of cells although 
its mechanism of enhancement is, as yet, unclear (Davis et al., 2002). Transduction with each of the 
lentiviral constructs resulted in stable permanently transduced cells designated LAP-MMP-mEPO.tsF, 
LAP-MMP-huTGFβ.tsF, LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF, LAP-MMP.tsF (acting as a 
negative control) and mEPO.tsF (acting as a positive growth factor control). The transduction 
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efficiency has previously been shown to be approximately 100% as all cells seen were eGFP-positive 
(Rigby, 2009). 
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Figure 4.2: DNA lentiviral vector constructs.  
(A) The HIV- 1 derived lentiviral vector pHRSIN-CSGW was originally described by Demaison (2002), is rendered self-
inactivating (SIN) through the deletion of the TATA box and the 3’ LTR U3 region (LTR/ΔU3). The addition of a strong spleen 
focus-forming virus (SFFV) promoter upstream and a WPRE downstream of the enhanced green fluorescent protein (eGFP) 
drives efficient transgene expression. 1-7| pHRSIN-CSGW-eGFP (1), EPO with its native signal peptide (2), LAP-MMP-mEPO 
(3), LAP-MMP-huTGFβ (4), LAP-MMP-mIGF1A (5), LAP-MMP-mIGF1B (6), LAP-MMP (7). (B) Packaging construct 
(pCMVΔ8.2). (C) Envelope construct (pMD.G). 
 
 
High levels of in vitro expression following stable lentiviral transduction 
In order to determine whether transduction of the tsF cell line with the various lentiviruses resulted 
in stable expression and secretion of each latent fusion protein, ELISAs were done using the 
supernatant taken 24 hours after transduction of tsF cells with the various constructs.  
A sandwich ELISA for EPO quantified the protein concentration for both the growth factor control 
protein mEPO secreted by the mEPO.tsF transduced cells, and the LAP-MMP-mEPO proteins 
secreted by the LAP-MMP-mEPO.tsF transduced cells (Figure 4.3). The transduced mEPO.tsF cells 
acting as the control, produced approximately 2400ng mEPO/mL/106 cells/24hours whereas the 
LAP-MMP-mEPO.tsF transduced cells produced approximately 330ng mEPO/mL/106 cells/24hours 
(Figure 4.3B), a 7-fold difference in expression levels. However, using a direct LAP ELISA the 
concentration of LAP from the LAP-MMP-mEPO.tsF transduced cells produced approximately 
2329ng LAP/ml/106 cells/24hours (Figure 4.4). When testing the relative therapeutic efficacy of 
these proteins, this variation in expression was taken into account.  
The protein concentration for the latent fusion proteins LAP-MMP-huTGFβ, LAP-MMP-mIGF1A, LAP-
MMP-mIGF1B, or the LAP-MMP control was quantified using a direct LAP ELISA (Figure 4.4). The 
transduced cells LAP-MMP-huTGFβ.tsF, LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF and the 
control LAP-MMP.tsF produced approximately 1679ng, 79ng, 48ng and 68ng LAP/mL/106 
cells/24hour respectively. A second infection of the LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF 
and LAP-MMP.tsF transduced cells led to a significant increase in protein production for LAP-MMP-
mIGF1A and LAP-MMP control, with no increase in LAP-MMP-mIGF1B expression: 132, 170 and 43 
ng LAP/mL/106 cells/24hour respectively (Figure 4.5). This may be due to a lack of viable lentiviral 
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vector particles able to infect the cells to express a greater concentration of recombinant protein as 
no titration of viral particles was done, only a set volume of viral particle supernatant used to infect 
the relevant cells(20μl). It is important to note that the levels shown here are the levels of LAP 
protein as determined by the direct LAP ELISA. It is possible, indeed plausible, that a small amount of 
the latent fusion protein is cleaved immediately after secretion from the cell due to endogenous 
MMP enzymes. Therefore some LAP proteins quantified by the ELISA may no longer be a latent 
fusion protein, but only the LAP portion of the fusion protein.  
 
Figure 4.3: Quantification of EPO and LAP-MMP-mEPO production by tsF transduced cells.  
The tsF cell line was infected with the pHRSIN-CSGW-(LAP-MMP-mEPO) or pHRSIN-CSGW-EPO lentiviral vectors producing 
the LAP-MMP-mEPO.tsF and EPO.tsF transduced cells respectively. (A) After 24 hours, the culture supernatant was 
collected to measure expression of the LAP-MMP-mEPO or the native EPO molecule with an EPO-specific sandwich ELISA 
assay standardised with recombinant EPO protein. The results are expressed as a function of protein concentration 
(ng/ml). (B) Mean of two replicate OD interpolated from the standard curve for concentrations of LAP-MMP-mEPO and 
mEPO protein production by LAP-MMP-mEPO.tsF and mEPO.tsF transduced cells respectively and expressed in ng/ml EPO. 
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Figure 4.4. Quantification of latent protein production by tsF transduced cells.  
The tsF cell line was infected with the pHRSIN-CSGW-(LAP-MMP-mEPO), pHRSIN-CSGW-(LAP-MMP-huTGFβ), pHRSIN-
CSGW-(LAP-MMP-mIGF1A), pHRSIN-CSGW-(LAP-MMP-mIGF1B) or pHRSIN-CSGW-(LAP-MMP) lentiviral vectors. After 24 
hours, the culture supernatant was collected to measure expression of the recombinant proteins LAP-MMP-mEPO, LAP-
MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-MMP-huTGFβ, or LAP-MMP with a direct LAP ELISA assay standardised with 
recombinant LAP protein. (A) Standard curve generated through duplicate samples of recombinant LAP ranging in 
concentration from 250ng/ml–0ng/ml. Linear regression analysis was performed and the r2 displayed. Values falling within 
the linear range have been refit in a second standard curve (blue insert) and used to interpolate protein values. Results are 
expressed as a function of recombinant LAP protein concentration (ng/ml).  (B) Mean of two replicate OD measurements 
interpolated from the standard curve for concentrations of LAP-MMP-mEPO, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-
MMP-huTGFβ, and LAP-MMP protein production by LAP-MMP-mEPO.tsF, LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF, 
LAP-MMP-huTGFβ.tsF and LAP-MMP.tsF cells respectively and expressed in ng/ml/106 cells/24 hrs recombinant LAP. 
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Figure 4.5. Quantification of latent protein production by tsF transduced cells following a second round of transduction. 
The LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF and LAP-MMP.tsF transduced cells were infected for a second time 
following low expression levels after initial infection. After 24 hours, the culture supernatant was collected to measure 
expression of the recombinant proteins LAP-MMP-mEPO, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-MMP-huTGFβ, or 
LAP-MMP with a direct LAP ELISA assay standardised with recombinant LAP protein. (A) Standard curve generated through 
duplicate samples of recombinant LAP. Linear regression analysis was performed and r2 displayed. (B) Mean of two 
replicate OD measurements interpolated from the standard curve for concentrations of LAP-MMP-mIGF1A, LAP-MMP-
mIGF1B, and LAP-MMP protein production by LAP-MMP-mIGF1A.tsF, LAP-MMP-mIGF1B.tsF and LAP-MMP.tsF cells 
respectively and expressed in ng/ml/106 cells/24 hrs recombinant LAP. 
 
Growth factor release is achieved following MMP cleavage 
Cleavage of the latent fusion proteins at the MMP site by a MMP enzyme is imperative for the 
release of the growth factor from the LAP. This was demonstrated by incubating the supernatant 
taken from the transduced tsF cell lines with 30nM MMP1, and the presence of the cleaved growth 
factor assessed by western blotting analysis using the anti-LAP antibody (Figure 4.6). The fusion 
proteins LAP-MMP-mEPO, LAP-MMP-huTGFβ and LAP-MMP were detected around 50 kDa and 40 
kDa respectively, consistent with the data seen from 239T and CHO protein production (Figure 4.6 A, 
D and E). The latent fusion proteins LAP-MMP-mIGF1A and B exhibited several forms of the 
glycosylated protein with the dominant protein size at 50 kDa (Figure 4.6 B and C). Cleavage of the 
latent proteins with the MMP enzyme releases the LAP peptide, which was detected at 37 kDa as 
expected (Figure 4.6). 
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Figure 4.6: MMP Cleavage of supernatant taken from transduced tsF cell lines.  
The tsF cell line was infected once with lentiviral vector particles for LAP-MMP-mEPO, and LAP-MMP-huTGFβ, and three 
times for the lentiviral vector particles for LAP-MMP-mIGF1A, LAP-MMP-mIGF1B, and LAP-MMP. The supernatant was 
collected after 24 hours and incubated overnight with 30nM MMP1 enzyme. 35μl supernatant samples for (A) LAP-MMP-
mEPO (diluted 1:2), (B) LAP-MMP-mIGF1A, (C) LAP-MMP-mIGF1B, (D) LAP-MMP-huTGFβ (diluted 1:3), (E) LAP-MMP 
control were electrophoresed down a reducing SDS-PAGE gel and probed with anti-LAP antibody. The protein molecular 
weights are represented in kDa on the left hand side of the Figure. The LAP element of the LAP-MMP-huTGFβ appers to be 
running higher than expected and as previously visualised. This is suspected to be a combination of two factors. First, the 
edge of the gel was not buffered properly as loading dye was not added to the end and unused wells, causing a distortion 
in  the running of the protein through the gel; and second overloading of the lane with excess protein has compound this 
distortion.  
 
In vivo biological activity is achieved following ex vivo gene delivery 
In order to validate that the delivery of a biologically active growth factor occurs in vivo following the 
transplantation of permanently transduced cells expressing our latent fusion protein, tsF cells 
(transduced or untransduced) were injected i.p into AB/H CREAE mice (107 cells/mouse) 27 days 
after EAE innoculation (after the acute phase but one day before a third inoculation was given to 
induce a relapse) and the haematocrit measured after 7, 14 and 21 days post-injection (Figure 4.7). 
Haematocrit levels were significantly elevated following exposure to transduced tsF cells expressing 
LAP-MMP-mEPO (56.7% ± 1.1) or mEPO (57.27% ± 3.2) as compared to untransduced cells (47.1% 
A B C D E 
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±1.65, P ≤ 0.05) on day 7. During the course of the next 7 days, the level of haematocrit of the 
untransduced tsF group decreased slightly representing the slight anaemia the mice undergo during 
a relapse. The haematocrit levels of the treated groups mEPO.tsF and LAP-MMP-mEPO.tsF however 
remained unchanged demonstrating the ability of the mEPO and LAP-MMP-mEPO transduced tsF 
cells to secrete biologically functional EPO that is involved in haematopoiesis. As expected, these 
observations demonstrate that the delivery of permanently transduced, fusion protein expressing 
tsF cells can induce and sustain in vivo expression and biological activity of the fusion proteins 
corroborating the in vitro data.  
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Figure 4.7 Haematocrit levels following ex vivo gene delivery.  
AB/H Biozzi CREAE mice were injected i.p. 27 days after initial innoculation with a syngeneic fibroblast cell line (10
7
 
cells/mouse), which was either untransduced (tsF), transduced with mEPO (mEPO.tsF) or transduced with LAP-MMP-mEPO 
(LAP-MMP-mEPO.tsF). The number of transduced cells injected was adjusted to EPO expression level and compensated 
with untransduced cells to obtain both equivalent EPO expression and equal total number of cells injected. Haematocrit 
levels were measured 7, 14 and 21 days after injection of the cells. The results represent mean haematocrit levels ± SEM of 
all animals within the group (n= 2-4, **p ≤ 0.05 compared with control mice, 1-way Anova followed by Tukeys post-hoc 
test). 
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DISCUSSION 
The aim of this study was to determine if an ex vivo approach to the delivery of LAP-MMP-mEPO, 
LAP-MMP-huTGFβ, LAP-MMP-mIGF1A and LAP-MMP-IGF1B in vivo was feasible. Syngeneic 
fibroblasts taken from the AB/H mouse strain were immortalised and sustained in culture (Croxford 
et al., 2000) before transduction using the lentiviral vector pHRSIN-CSGW. The use of a lentiviral 
vector is advantageous over the use of a retroviral vector due to its ability to integrate into the host 
genome of even non–dividing cells, whereas a retroviral system requires the cells to be actively 
dividing in order to access its nucleus. Previous in vitro experiments using LAP-MMP-mEPO, LAP-
MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-MMP-huTGFβ and LAP-MMP secreted by the HEK-293T cell 
line demonstrated the ability of the enzyme MMP1 to release the mEPO, mIGF1A, mIGF1B, huTGFβ 
proteins from LAP-MMP-mEPO, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B and LAP-MMP-huTGFβ 
respectively following incubation overnight, and that the released growth factor proteins retained 
their biological activities when assessed using the appropriate biological assays. Additionally, 
incubation of LAP-MMP-mEPO, LAP-MMP-mIGF1A, LAP-MMP-mIGF1B, LAP-MMP-huTGFβ and LAP-
MMP (secreted from transduced tsF cells) with the MMP1 enzyme, released the growth factor 
protein in vitro as measured using ELISA. Levels of expression of the latent fusion proteins ranged 
from 48—2400ng/ml/106 cells/24 hours depending on the fusion protein. Although the levels of 
expression differed between proteins, they were still significantly higher than the expression levels 
achieved (1.7 and 3.3ng/ml/106 cells/24 hours for dTNFR.tsF and IL-10.tsF respectively) using the 
retroviral vector system described elsewhere (Croxford et al., 2001, Croxford et al., 2000). The same 
ELISA protocol quantified these levels therefore allowing direct comparisons. The rationale for 
utilizing an ex vivo approach as the delivery method for our therapeutic proteins is to address the 
question as to whether our therapeutic gene can be delivered in vivo. Measurements of the 
haematocrit of AB/H mice injected with mEPO.tsF and LAP-MMP-mEPO.tsF cells showed a significant 
increase in the haematocrit levels corresponding to biologically active EPO as compared to tsF cells 
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alone. The difference in the haematocrit levels was no longer observed 14 days after cell injection 
and the animals exhibited no observable side effects. This was, at the time of the experiment, 
unexpected. However, another study (Rigby, 2009) later found that when serum taken from naïve 
mice or mice injected with transduced tsF cells, was probed for binding antibodies using an ELISA 
and flow cytometry, a notable increase of binding was observed from the serum of the mice injected 
with the transduced tsF cells. Further experiments determined that the inciting antigen was that of 
the BSA used in the growth medium of the tsF cells. It is therefore thought that the lack of increase 
in haematocrit levels after 14 days is due to the gradual destruction of the cells. Although the author 
tried to grow the transduced tsF cells in a serum-free medium for 48 hours prior to intra-peritoneal 
transplantation, loss of expression and immunogenicity agianst the BSA antigen was still observed. It 
should be possible to adapt these cells to serum-free conditions by sequential adaptation or 
weaning where cells are switched to from serum-containing medium to serum-free medium in 
several steps, however this was not attempted during this study. 
As previously discussed, the erythropoietic effects of EPO require a mere 15 units of EPO to increase 
erythropoiesis [where one unit elicits the same erythropoiesis-response in fasted rats as five μmoles 
of cobaltous chloride (Jelkman 2009)] and these effects are mediated through the homodimer 
(EPOR)2 to which EPO has a high affinity. Although the fusion of EPO to the LAP peptide confers 
latency, endogenous MMPs (such as those found within the kidney where endogenous EPO is 
produced) may cleave the protein thus releasing a small amount of biologically active mEPO from 
LAP-MMP-mEPO. Therefore an increase in the haematocrit of healthy AB/H Biozzi mice transplanted 
with LAP-MMP-mEPO.tsF cells would be a reflection of the release of mEPO from LAP-MMP-mEPO. 
This data validates in vivo what was demonstrated in vitro as discussed in the previous chapter i.e. 
that our recombinant protein is secreted by the tsF cells and the peptide released is biologically 
active. The fact that the release of the mEPO protein from LAP-MMP-mEPO was observed after the 
injection of LAP-MMP-mEPO.tsF cells into healthy mice is not unexpected as endogenous EPO (used 
for the generation of new red blood cells) is produced mainly in the kidney, an organ known to 
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express a variety of MMPs such as MMP1, -2, -3, -9, -13, -14, -24, 25, -27, and -28 (Catania et al., 
2007). Thus this cell-based gene-vector approach is ideal for testing our fusion proteins into the EAE 
mouse model. 
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EAE 
EAE Origins and Development 
In 1885 Louis Pasteur developed the first rabies vaccine comprising an emulsion of dried spinal cords 
of rabbits inoculated intracranially with the rabies virus. Treatment was generally accepted and 
consisted of 10-day courses of the vaccine. However, in around 30% of the vaccinated patients 
sporadic paralysis occurred followed by mortality. Histological analysis confirmed that they had 
developed post–vaccinal encephalomyelitis (PVE) which was easily distinguishable from rabies by 
the lymphoid infiltrates and demyelination around the blood vessels of the CNS, and the relative 
sparing of the nerve fibres and nerve cell bodies.  
In the 1930’s, Thomas Rivers investigated those cases of paralysis by the Pasteur vaccine as the 
neurological symptoms resembled those shown by patients infected with smallpox, vaccinia and 
measles. In his experiments on monkeys and rabbits that had received repeated injections of rabbit 
brain (Schwentker and Rivers, 1934, Rivers et al., 1933, Rivers and Schwentker, 1935), he discovered 
varying titers of brain-specific antibodies and the number of affected animals varied according to the 
antigenicity of the emulsion given. The disease was therefore caused by factors in the spinal cord 
and not by the inactivated virus (Rivers et al., 1933, Wisniewski and Bloom, 1975, Kabat et al., 1946). 
By including the bacterium Mycobacterium tuberculosis in the emulsion—utilizing an adjuvant 
strategy—the production of antibodies was boosted and the number of injections required to induce 
the disease in the animals was reduced. The results were an autoimmune encephalomyelitis, now 
known as EAE.  
The dominant characteristic of EAE was that of a relapsing remitting course of the illness. An animal 
would become blind, followed by recovery of its vision only to return to blindness several days later. 
Paralysis of one limb would subside followed by paralysis of another appendage. Histological studies 
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found acute lesions adjacent to blood vessels, and infiltration of the vessel walls with leukocytes, 
and chronic lesions demonstrating an increasing number of lymphocytes and proliferation of 
microglia (Baxter, 2007).  
EAE As We Know It 
EAE is one of the most studied models for autoimmune-mediated diseases. It was initially termed 
experimental allergic encephalomyelitis as its autoimmune origins were still under debate. This 
debate was resolved with the development of EAE by the adoptive transfer of sensitised T cells into 
naïve syngeneic rats and the term changed to ‘experimental autoimmune encephalomyelitis’ 
(Schluesener and Wekerle, 1985, Ben-Nun and Cohen, 1981). EAE has since been replicated in 
several species including guinea pigs, rabbits, pigs, goats, mice, hamsters, dogs, sheep, marmosets 
and even chickens (Gold et al., 2000). A number of variations of EAE have been developed by 
altering the species and strain and what type of antigen was used for its induction, for example 
models for optic neuritis, and relapsing–remitting MS and progressive MS.  
The EAE Mouse Model 
No single animal model exists that mimics all the features of the human demyelinating diseases 
especially for MS but EAE is not one single model rather a collection of models that vary in their 
disease course, animal species and strain, antigen used for induction and in the type of adjuvant 
employed. Mice are the preferred animal for the development of an animal model of human disease 
due to the vast diversity of molecular biology techniques and reagents available. Mice are easy to 
genetically manipulate and generate transgenics and gene knock-outs, and there is a wealth of 
genetic information that is available especially regarding their immune system.  
The immunisation of mice to actively induce EAE is either by the injection of CNS tissue such as brain 
or spinal cord homogenates, of purified components of the CNS myelin – such as MBP (Bernard and 
Carnegie, 1975), PLP, MOG, and myelin-associated glycoprotein (MAG), with the exception of S-100 
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which is a component of glial cells (Gold et al., 2000), or through the adoptive transfer of sensitised 
CD4+ T-cells (Kennedy et al., 1990, Schluesener et al., 1988, Bernard et al., 1976).  
Initially only a monophasic acute form of EAE could be induced in which most animals experienced 
perivascular inflammation and minimal demyelination with spontaneous recovery. Monophasic EAE 
is best suited for studying the mechanisms involved in down-regulation of the immune response 
evident in the vast perivascular accumulation of monocytes, lymphocytes and Mø (Lublin et al., 
1981). By adapting the right induction protocol or strain a relapsing-remitting disease or a chronic 
relapsing EAE (CREAE) model could be induced (Kozlowski et al., 1987, Lublin et al., 1981, Brown and 
McFarlin (1981) cited in Amor et al., 2005). Chronic EAE models have persistent paralytic disease 
that consists of an acute phase followed by spontaneous remittance, then further relapses and are 
characterised by inflammation, demyelination and axonal damage (Lublin et al., 1981, Kozlowski et 
al., 1987). Animals often do not fully recover and remain with some degree of permanent neurologic 
deficit (Lublin et al., 1981, Ben-Hur, 2010). The CREAE model is best suited for studying the 
mechanisms involved in inflammation mediated neuronal degeneration such as MS as both the EAE 
mouse model and MS are “inflammatory demyelinating diseases of the CNS whose development and 
course varies according to several genetic and environmental determinants” (Arredondo, 2003) 
EAE vs. MS 
Multiple Sclerosis is a disease characterised by neuroinflammation, demyelination, astrogliosis, 
remyelination, and neuronal injury, whose clinical history follows a pattern of relapses with periods 
of complete recovery. However, over time these periods of relapses are marked by recovery periods 
that are incomplete and residual disabilities persist and accumulate, until the disease progresses 
without remission. Unlike the multiphasic nature of MS, EAE on the other hand is mostly 
monophasic, with few models demonstrating the secondary progressive characteristics of MS such 
as progressive disability following relapses and remissions, demyelination, gliosis, remyelination and 
neuronal injury. Dependant on the type of species, strain, and immunising agent, the EAE model has 
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the ability to resemble MS in many respects, leading to it being the sole model for the study of MS. It 
displays several features that are found in MS such as demyelination of nerve fibres, axonal sparing, 
lesions of the CNS that differ in both space and time, the maturation of these lesions from 
inflammation to demyelination through to remyelination and gliosis, and the presence of 
immunoglobulin in both the CNS and cerebrospinal fluid (CSF) (Baxter, 2007), making EAE an 
extremely informative and invaluable animal model for the disease. Indeed, the drugs used in the 
treatment of MS (e.g.  Copaxone, mitoxantrone and Natalizumab) were originally founded through 
their ability to improve the clinical symptoms of EAE (Lisak et al., 1983, Ridge et al., 1985, Mauch et 
al., 1992, Yednock et al., 1992, Aharoni et al., 1999). And although some clinical trials emerging from 
studies done on EAE models have failed (such as Inflixima, Sulfasalazine and Linomide (Ziemssen, 
2008)), it still remains an excellent model for studying MS.   
It is precisely the ability of the model to be flexible and adaptive that enables it to be the 
‘prototypical autoimmune model’ (Sriram and Steiner, 2005). For example CD4+ T lymphocytes were 
originally thought to play a pivotal role in the pathogenesis of MS but recent evidence suggests that 
CD8+ T lymphocytes play an equally crucial role (Mars et al., 2011). If the model is induced with MBP 
or PLP, then the role of CD4+ lymphocytes and their putative role in the pathology of EAE can be 
elucidated, similarly if induced with MOG, then the role of CD8+ lymphocytes can be investigated.  
EAE has the ability to mimic the phases associated with MS depending on the strain of mouse or 
species and the type of antigen used to induce EAE. The acute phase can be induced in SJL, PL/J, 
C57BL/6 and the Biozzi AB/H mouse strains, to name a few, using the CNS antigens previously 
mentioned. The relapsing phase can be induced in the Lewis rat model using monoclonal antibodies 
specific for MOG (Linington et al., 1992). The CREAE model can be induced in the Biozzi AB/H mouse 
using spinal cord homogenate without the need for pertussis vaccine usually given to induce reliable 
relapses. The monophasic model is best suited for studying the mechanisms involved in down-
regulation of the immune response; the relapsing model is best suited for studying the mechanisms 
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involved in relapses; and the chronic progressive model is best suited for studying the mechanisms 
involved in inflammation mediated neuronal degeneration (Voskuhl, 2010). 
Biozzi Mice  
The AB mouse was originally engineered through selection of outbred random populations of the 
Swiss Albino mouse by Guido Biozzi giving two stains of high (AB/H) and low (AB/L) antibody lines 
(Biozzi et al., 1972). AB/H mice have high titre antibody responses to certain antigens such as sheep 
erythrocytes and are able to be induced with a number of experimental diseases such as 
autoimmune collagen-induced arthritis and EAE (Biozzi et al., 1972, Amor et al., 2005).  
Baker and Colleagues (1990) first described the induction of EAE in the Biozzi mouse through an 
increase of mycobacterium levels in the spinal cord homogenate leading to the development of a 
reproducible and predictable form of CREAE with high incidence and virtually no mortality. Onset of 
the disease occurs between 15 and 20 days following inoculation with relapses occurring between 
33 and 39 days following inoculation. Mice are induced either with an additional inoculation 
generating synchronised relapses, or left to undergo spontaneous relapses. Young and old, male and 
female mice are equally susceptible. This high degree of susceptibility may be due to the large 
numbers of antigen specific T cells capable of inducing delayed–type hypersensitivity (Biozzi 1985 
cited in Baker et al., 1990) and why once the disease has been initiated, it is able to trigger further 
autoimmune relapses (Figure 5.1).  
As mentioned before, the majority of EAE models tend to follow a monophasic display of acute 
inflammation without subsequent relapse-remission leading to irreversible disability, a characteristic 
of chronic MS. They inadequately model the sequence of events that occurs pathologically in time 
and clinical outcome (Baker et al., 1990, Hampton et al., 2008). The AB/H CREAE model however, 
demonstrates little demyelination within the CNS during the acute phase of the disease, with 
inflammation and demyelination being major pathological features within the relapsing phase, a 
pattern that closely mimics secondary progressive MS (Hampton et al., 2008). Additionally, it 
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behaves in a predictable relapse-remission pattern, with a period of relapse that progressively 
results in disability. The accumulation of these disabilities is known to include tremors and spasticity, 
characteristics that are found in secondary progressive MS (Baker et al., 2000). Inflammation is 
characterised by the infiltration of mononuclear cells such as Mø containing myelin debris and lipid 
deposits and CD4+ T cells expressing αβ receptors and low levels of IL-2 in areas of pro-inflammatory 
growth factors as seen in MS (Hofman et al., 1986, Allen et al., 1993, Baker et al., 1990, Baker et al., 
1991). The expression of adhesion molecules such as ICAM-1 on CNS endothelial cells provides 
evidence for cellular infiltration (Baker et al., 1991). Another pathological characteristic of MS is that 
of demyelinating and inflammatory lesions developing within the optic nerves. EAE induced in the 
Biozzi AB/H mouse exhibits similar demyelinating lesions (O'Neill et al., 1998). During the chronic 
phase, the AB/H mouse induced with EAE follows a predictable course of relapse-remission, 
followed by progressive disability (such as tremors and spasticity) without remission that is 
accumulative (Baker et al., 1990, Hampton et al., 2008). The Biozzi AB/H CREAE model also 
demonstrates significant demyelination and remyelination, hypercellularity, a marked increase in 
the astrocytic marker glial fibrillary acidic protein (GFAP) relating to astrocytic gliosis, axonal and 
neuronal loss—distinctive characteristics found within MS, therefore making the Biozzi AB/H CREAE 
the preferred model for this study. 
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Figure 5.1. Induction and clinical course in an EAE model. Taken from (Baker and Jackson, 2007). 
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CHAPTER HYPOTHESIS AND AIMS 
The previous chapter showed that a lentiviral vector could be constructed to contain the DNA of the 
latent protein mEPO and that this protein remained latent until the MMP cleavage site was cleaved 
by MMP enzymes. The following experiments tested the hypothesis that when permanently 
transduced LAP-MMP-mEPO.tsF cells are injected into mice affected by CREAE, the latent peptide 
LAP-MMP-mEPO is cleaved and becomes biologically active. Moreover, that this biologically active 
mEPO does not cause any of the unwanted side effects noted with high-dose systemic peptide 
exposure. Additionally, it is able to reduce the progression of the disease and its clinical score.  
The aim of this study was to assess the therapeutic potential for the in vivo delivery of ex vivo-
transduced fibroblasts in the CREAE mouse model. Following the injection of permanently 
transduced tsF cells expressing LAP-MMP-mEPO and mEPO proteins into AB/H with CREAE, the 
progression and/or remission of disease and its effect on weight loss/gain were assessed. The 
biological activity of EPO released from the latent fusion protein secreted from the transplanted 
LAP-MMP-mEPO.tsF transduced cells, was assessed indirectly through measurements of the 
haematocrit.  
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RESULTS 
After establishing that the in vivo delivery of LAP-MMP-mEPO.tsF transduced cells resulted in the 
biological activity of EPO as seen in the increase in haematocrit levels (see Chapter 4), and that 
expression of luciferase in the biological assay for TGFβ using MLEC cells was detected using LAP-
MMP-huTGFβ, the therapeutic potential of LAP-MMP-huTGFβ and LAP-MMP-mEPO in the CREAE 
model was investigated.  
Preliminary LAP-MMP-huTGFβ and LAP-MMP-mEPO Response in AB/H CREAE Model 
Dr Anne Rigby performed these preliminary experiments using LAP-MMP-huTGFβ.tsF and LAP-MMP-
mEPO.tsF cells during my maternity leave and includes the figures 5.2 and 5.3.  
Induction of the AB/H CREAE mouse model occurred on days 0 and 7 with spinal cord homogenate 
and Freund’s Complete Adjuvant by s.c injection. Five groups, each consisting of eight mice, were 
injected with a total of 107 tsF cells/mouse on day 11 post-inoculation. Three treatment groups were 
injected i.p. with 1x106 cells/mouse of LAP-MMP-mEPO.tsF transduced cells (Figure 5.2), or either 1- 
or 3x106 cells/mouse LAP-MMP-huTGFβ.tsF transduced cells (Figure 5.3) expressing ~2330ng/ml 
mEPO/106 cells/24 hours or ~1700ng/ml huTGFβ/106 cells/24 hours respectively, or 5000IU/kg bw 
rhEPO, made up to a total of 107 cells with untransduced tsF cells. The control group consisted of 
CREAE induced mice that received an i.p. injection of 107 LAP-MMP.tsF cells. In this particular model 
of EAE, the mice can be made to undergo synchronised relapses through additional inoculations of 
1mg syngeneic spinal cord homogenate and 60µg of mycobacteria, however these mice were 
allowed to undergo spontaneous relapse.  
The scoring of the groups followed the system used by Baker et al (1990): The treatment groups 
(1x106 LAP-MMP-mEPO.tsf, 1x106 LAP-MMP-huTGFβ.tsF and 3x106 LAP-MMP-huTGFβ.tsF 
transplanted cells) entered the acute phase from day 15 with clinical symptoms peaking to 3.9±0.7, 
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3.3±0.9 and 3.7±0.6 respectively, and dropping to 0.5±0.0 during remission. The rhEPO control group 
entered the acute phase on day 15 with a disease severity peaking at a clinical score of 3.2±0.8, 
falling to 0.5±0.0 during remission.  
Although no significant difference between the treatment groups was observed, the LAP-MMP-
mEPO.tsF group displayed lower clinical scores as compared to the LAP-MMP.tsF control group, 
albeit not at levels coinciding with rhEPO. Conversely, in the LAP-MMP-huTGFβ.tsF treatment group 
injected with 1x106 cells/mouse, a significant difference (P≤ 0.001) in clinical score was observed as 
compared to the LAP-MMP.tsF control group. However, when the number of cells injected was 
increased to 3x106 cells/mouse this significance was lost.   
Figure 5.2. Therapeutic effects of LAP-MMP-mEPO.tsF cells in acute EAE.  
AB/H Biozzi mice were immunised by subcutaneous injection of 1mg spinal cord homogenate in complete Freund’s 
adjuvant at day 0 and 7. Animals were injected i.p. on day 10 (arrow) with 1x106 cells/mouse of either LAP-MMP.tsF 
transduced cells (negative control cells)  or LAP-MMP-mEPO.tsF transduced cells (treatment cells). A positive control group 
of mice was injected i.p, 3 times a week, with 5000IU/kg bw of recombinant human EPO (rhuEPO) protein (administration 
of 5000IU/kg bw of rhuEPO has been shown to increase the haematocrit (Agnello et al., 2002). The results represent the 
mean clinical disease score ± SEM of all animals within the group (n=8). (**P ≤ 0.005 compared to LAP-MMP.tsF injected 
mice, 2 way ANOVA followed by Tukeys post-hoc test). 
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Figure 5.3 Therapeutic effects of LAP-MMP-huTGFβ.tsF cells in acute EAE.  
AB/H Biozzi mice were immunised by subcutaneous injection of 1mg spinal cord homogenate in complete Freund’s 
adjuvant at day 0 and 7. Animals were injected i.p. on day 10 (arrow) with a syngeneic fibroblast cell line (either 1- or 3x106 
cells/mouse) which was transduced with either construct: control LAP-MMP (LAP-MMP.tsF) or LAP-MMP-huTGFβ (LAP-
MMP-huTGFβ.tsF). The results represent the mean clinical disease score ± SEM of all animals within the group (n=8). (**P ≤ 
0.005 compared to LAP-MMP.tsF injected mice, 2 way ANOVA followed by Tukeys post-hoc test). 
Latent EPO Dose Response in AB/H CREAE Model 
Induction of the AB/H CREAE mouse model occurred on days 0 and 7 with spinal cord homogenate 
and Freund’s Complete Adjuvant by s.c injection. Four groups, each consisting of ten mice, were 
injected with a total of 107 tsF cells/mouse on day 11 post-inoculation. Three treatment groups were 
injected i.p. with tsF cells permanently transduced with LAP-MMP-mEPO.tsF at concentrations of 
either 1x106, 2x106 or 3x106 cells/mouse, expressing 2µg/ml mEPO/106 cells/24 hours made up to a 
total of 107 cells with untransduced tsF cells. The control group consisted of CREAE induced mice 
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that did not receive an injection of tsF cells. In this particular model of EAE, the mice can be made to 
undergo synchronised relapses through additional inoculations of 1mg syngeneic spinal cord 
homogenate and 60µg of mycobacteria, however these mice were allowed to undergo spontaneous 
relapse.  
Induction of CREAE 
A characteristic of the Biozzi CREAE model is its high incidence of induction. This was consistent in 
this study with 35 out of 40 mice (87.5%) experiencing an acute phase. Of those mice that developed 
acute EAE, 28 (86% of 1x106 group, 70% of 2x106 group, 80% of the 3x106 group and 75% of the EAE 
control group) experienced spontaneous relapses (Table 5.1).  
Clinical symptoms for the treatment groups, 1x106, 2x106, 3x106 and the EAE Control were preceded 
by an initial weight loss of 4.44%±3.04, 6.20%±2.83, 3.74%±5.33 and 3.31%±2.13 respectively and 
continued to decrease as the severity of clinical symptoms increased. This was followed by an 
increase in weight gain and a reduction in the severity of clinical symptoms indicating entering into a 
phase of remission in agreement with the literature (Baker et al., 1990). As expected, the mice 
remitted to a low clinical score demonstrating a small neurological deficit evident in the animals 
inability to raise its tail (grade (1)). The onset of a relapse was indicated by an increase in the severity 
of clinical symptoms and associated weight loss.  
Measurement of Biologically Active EPO in vivo 
The indirect measurement of released, biologically active EPO from the latent EPO expressing tsF 
cells was done through haematocrit measurements on days 10 and 35 post cell transplantation (days 
21 and 46 post-inoculation respectively). The haematocrit values demonstrated a dose response 
following the transplantation of 3x106 LAP-MMP-mEPO.tsF cells, 2x106 LAP-MMP-mEPO.tsF cells, 
and 1x106 LAP-MMP-mEPO.tsF cells when compared to the EAE control (61.2%±3.2, 56.4%±3.2, 
53.5%±5.2 and 42.3%±3.0 respectively) on day 10, following cell transplantation. The values were 
significantly elevated when compared against the EAE control (P ≤ 0.0001 using one-way ANOVA 
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with Tukey post-hoc test) as well as the highest and lowest doses demonstrating a significant 
difference when compared against one another (P ≤ 0.001) (Figure 5.4).  
Figure 5.4: Biological activity of latent EPO is observed 10 days after tsF cell transplantation but is absent after 35 days.  
Following the i.p. injection of LAP-MMP-mEPO.tsf cells expressing up to 6µg/ml latent mEPO/ml/24 hours/mouse, the 
biological activity is assessed by haematocrit measurements taken on days 10 (A) and day 35 (B) following cell 
transplantation. A significant difference is seen as compared to the EAE control (***P≤ 0.0001) and between the highest 
dose of 3x106 cells (6µg latent mEPO/ml/24 hours/mouse) and the lowest dose of 1x106 cells (2µg latent mEPO/ml/24 
hours/mouse) (**P ≤ 0.001). Significance was determined using a one-way ANOVA followed by Tukey post-hoc test.  
 
A 
B 
A 
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Latent EPO Dose Effect on EAE Development 
The scoring of the groups followed the system used by Baker et al (1990): The treatment groups 
(1x106 LAP-MMP-mEPO.tsf, 2x106 LAP-MMP-mEPO.tsF and 3x106 LAP-MMP-mEPO.tsF transplanted 
cells) entered the acute phase from day 11 with clinical symptoms peaking to 3.8±0.3, 3.5±0.4 and 
3.7±0.3 respectively, and dropping to 0.5±0.0 during remission (Table 5.1). The EAE control group 
entered the acute phase on day 13 with a disease severity peaking at a clinical score of 3.7±0.3, 
falling to 0.5±0.0 during remission (Table 5.1).  
The onset of first relapse was sharper in the control group than in the treatment groups (Table 5.1; 
Figure 5.5). Clinical symptoms peaked at 3.6±0.7, 3.3±0.7 and 3.1±0.6 respectively for the first 
relapse with the EAE control peaking at 3.3±1.1. Symptoms fell to 1.0±0.4, 0.8±0.3 and 0.8±0.3 
respectively compared to the control at 0.8±0.3 during first remission. During the second relapse, a 
score of 3.5±0.7 (n=2), 2.7±0.3 (n=3) and 3.1±0.7 (n=5) for the treated groups and a score of 3.3±1.1 
(n=2) for the EAE control was reached (Figure 5.5). Although no statistically significant difference 
between the treatment groups was observed, a delayed but milder relapse was observed for the 
treatment groups. I hypothesize that this delay occurs only because of the distruction of the injected 
tsF cells and that, if the experiment were to be repeated with transduced tsF cells that had been 
adapted to be grown in serum-free conditions, without the immunogenicity (previously determined 
by (Rigby, 2009) the clinical score would remain mild and the relapse would be supressed. The 
treatment groups 1x106 LAP-MMP-mEPO.tsF and 3x106 LAP.MMP.mEPO.tsF each had one mouse 
that had to be euthanized to comply with animal welfare regulations (Table 5.1). 
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Table 5.1: Clinical signs in Biozzi AB/H CREAE mouse model transplanted with EPO-secreting fibroblast cells. 
The mice were injected subcutaneously with spinal cord adjuvant in CFA on days 0 and 7. They were weighed and checked 
daily for a maximum of 60 days post-inoculation for clinical signs. The disease course was divided into different disease 
phases: the acute phase = onset of clinical symptoms (graded (1)–5 and *) occurring after an initial weight loss of >1.5g 
(disease onset day 11); remission phase = decline in clinical symptoms following disease phase and an increase in weight; 
and relapse phase = the reappearance of clinical symptoms (graded (1)–5 and *) following period of remission. Mean 
disease scores were calculated for each disease phase by including all susceptible animals in each group.  
  Number of animals in each disease phase 
  Acute Remission Relapse Remission Relapse Remission 
1x10
6
 LAP-MMP-mEPO.tsF cells 
Complete Paralysis (4)–4 6 - 4 - 1 - 
Partial Paralysis (3)–3 - - 1 - 3 - 
Inverted Righting 
Reflex (IRR) 
(2)–2 - - 1 1 - - 
Limp tail 1 - - - 5 - - 
Limp tail with Tone (1) - 6 - 1 - - 
Normal 0 - - - - - - 
Mean score (n=6)*  3.8±0.3 0.5±0.0 3.6±0.7 1.0±0.4 3.5±0.7 0.0
a
 
2x10
6
 LAP-MMP-mEPO.tsF cells 
Complete Paralysis (4)–4 5 - 3 - - - 
Partial Paralysis (3)–3 2 - 3 - 1 - 
Inverted Righting 
Reflex (IRR) 
(2)–2 - - - - - 1 
Limp tail 1 - - - 1 - 1 
Limp tail with Tone (1) - 7 - 2 - - 
Normal 0 - - - - - - 
Mean score (n=7)  3.5±0.4 0.5±0.0 3.3±0.7 0.8±0.3 2.7±0.3 1.3±0.4 
3x10
6
 LAP-MMP-mEPO.tsF cells 
Complete Paralysis (4)–4 9 - 4 - 2 - 
Partial Paralysis (3)–3 - - 4 - 3 - 
Inverted Righting 
Reflex (IRR) 
(2)–2 - - 1 1 - - 
Limp tail 1 - - - 4 - 2 
Limp tail with Tone (1) - 9 - 4 - - 
Normal 0 - - - - - - 
Mean score (n=9)*  3.7±0.3 0.5±0.0 3.1±0.6 0.8±0.3 3.1±0.7 1.0±0.0 
EAE Control 
Complete Paralysis (4)–4 6 - 3 - 1 - 
Partial Paralysis (3)–3 - - 3 - 1 - 
Inverted Righting 
Reflex (IRR) 
(2)–2 - - - - - - 
Limp tail 1 - - - 4 - 1 
Limp tail with Tone (1) - 6 - 2 - - 
Normal 0 - - - - - - 
Mean score (n=6)  3.7±0.3 0.5±0.0 3.2±0.6 0.8±0.3 3.3±1.1 1.0±0.0 
 
a No mouse had entered remission by end of experiment for this group. 
* Loss of mouse 
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Figure 5.5: A milder, delayed relapse in the AB/H EAE mouse model is observed following dose response of latent EPO expressing tsF cells.  
I.p. injection of 107 tsF cells expressing up to 6µg/ml of latent EPO per day displayed no significant change in disease score and/or weight loss/gain, but rather a milder delayed relapse. The 
number in brackets corresponds to the number of animals that underwent an acute phase with 'n' numbers corresponding to the number of those animals that underwent at least one 
spontaneous relapse. The arrow indicates the day of cell transplantation.  
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Table 5.2: Day of onset for first relapse in the Biozzi AB/H CREAE mouse model.  
Values are for mice with an initial onset of relapse that occurred prior to day 31, during days 31 and 43, or after day 43 
post-inoculation. The percentages are in relation to the number of mice within the individual treatment group (‘n’ in 
brackets).  
Day of Relapse >31 31-43 >43 
1x10
6
 LAP-MMP-mEPO.tsF cells (n=6) 
   
                                                   Number of mice 1 4 1 
                                                    % of group entering relapse 17% 67% 17% 
2x10
6
 LAP-MMP-mEPO.tsF cells (n=7)    
                                                  Number of mice 1 4 2 
                                                   % of group entering relapse 14% 57% 29% 
3x10
6
 LAP-MMP-mEPO.tsF cells (n=9)    
                                                  Number of mice 2 5 2 
                                                   % of group entering relapse 22% 56% 22% 
EAE Control (n=6)    
                                                 Number of mice 0 6 0 
                                                  % of group entering relapse 0% 100% 0% 
 
 
Dose Response of Latent EPO Fails to (Significantly) Ameliorate Disease. 
When comparing groups, no significant difference in day of onset (Table 5.2), disease severity (Table 
5.1) or degree of weight loss was observed within the acute phase in any of the groups as compared 
to the control group (Figure 5.5). 
However, the treatment group that received 2x106 LAP-MMP-mEPO.tsF cells (expressing a total of 
4µg/ml latent mEPO/24 hours/mouse) exhibited better clinical scores during the acute phase and 
second relapse than either of the other groups, with scores comparable to the control during the 
initial relapse and both remissions (Tables 5.1). This experiment was therefore repeated using the 
dosage of 4µg/ml with additional control groups (LAP-MMP.tsF and untransduced tsF cells) (Figure 
5.6).  
The untransduced tsF control group developed acute EAE on day 13, followed by the treatment 
group LAP-MMP-mEPO.tsF and the control groups LAP-MMP.tsF and EAE on day 14. The degree of 
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severity of the clinical score during the acute phase was 3.6±0.5 for the LAP-MMP-mEPO.tsF treated 
group and the EAE control; and 3.6±0.6 and 3.4±0.6 for the LAP-MMP and untransduced tsF cells 
respectively (Table 5.3). All groups demonstrated a low clinical score during remission (0.6±0.2 for 
the treated group, untransduced tsF and LAP-MMP control groups; and 0.8±0.3 for EAE control) and 
fell into first relapse with clinical scores of 3.7±0.7, 3.7±1.0, and 3.1±0.5 for the treated, LAP-MMP 
and EAE control groups respectively. No significant difference between groups was observed. 
However the tsF control showed a lower overall clinical score of 2.9±0.5 reflected in the score and 
weight loss graphs (Table 5.3; Figure 5.6). At the time of experiment end, the group appeared to be 
relapsing and it can be said that this group experienced a delay in first relapse. One mouse control 
group that received 107 LAP-MMP.tsF cells died during relapse as indicated by the asterisk (Figure 
5.6). However, this was the only mouse in the experiment that died as a result and was gaining 
weight in the preceding days. 
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Figure 5.6 Treatment of chronic EAE transplantated with tsF cells.  
I.p. injection of 107 tsF cells expressing 4µg/ml of latent EPO per day displayed no significant change in disease score, weight loss/gain or to day of disease onset. The untransduced tsF control 
group displayed a tendency for reduced clinical score and less weight loss compared to the other groups. The number in brackets corresponds to the number of animals that underwent an 
acute phase with 'n' numbers corresponding to the number of those animals that underwent at least one spontaneous relapse. The day of cell transplantation is indicated by the arrow. 
Asterisk indicates death of a mouse.  
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Table 5.3: Clinical signs in Biozzi AB/H CREAE mouse model transplanted with fibroblast cells secreting 4µg/ml LAP-
MMP-mEPO. 
The mice were injected subcutaneously with spinal cord adjuvant in CFA on days 0 and 7. LAP-MMP-mEPO.tsF cells (107 
cells/mouse) were injected on day 11 post-innoculation. They were weighed and checked daily for a maximum of 60 days 
post-inoculation for clinical signs. The disease course was divided into different disease phases: the acute phase = onset of 
clinical symptoms (graded (1)–5 and *) occurring after an initial weight loss of >1.5g (disease onset day 11); remission 
phase = decline in clinical symptoms following disease phase and an increase in weight; and relapse phase = the 
reappearance of clinical symptoms (graded (1)–5 and *) following period of remission. Mean disease scores were 
calculated for each disease phase by including all susceptible animals in each group. Asterisk indicates death of mouse 
within group.  
  
Number of animals in each disease phase 
  Acute Remission  Relapse  Remission  
2µg/ml LAP-MMP-mEPO/24 hours/mouse 
 Complete Paralysis (4)–4 3 - 4 - 
Partial Paralysis (3)–3 2 - 1 2 
Inverted Righting Reflex 
(IRR) 
(2)–2 - - - - 
Limp tail 1 - 1 - 1 
Limp tail with Tone (1) - 4 - - 
Normal 0 - - - - 
Mean score (n=5)  3.6±0.5 0.6±0.2 3.7±0.7 1.9±1.0 
LAP-MMP Control 
Complete Paralysis (4)–4 5 - 5 - 
Partial Paralysis (3)–3 3 - 1 3 
Inverted Righting Reflex 
(IRR) 
(2)–2 - - 1 1 
Limp tail 1 - 1 - 1 
Limp tail with Tone (1) - 7 - - 
Normal 0 - - - - 
Mean score (n=8)  3.6±0.6 0.6±0.2 3.7±1.0 2.1±0.7 
Untransduced tsF cells 
Complete Paralysis (4)–4 3 - 1 - 
Partial Paralysis (3)–3 4 - 6 1 
Inverted Righting Reflex 
(IRR) 
(2)–2 - - - 2 
Limp tail 1 - 1 - - 
Limp tail with Tone (1) - 6 - 2 
Normal 0 - - - - 
Mean score (n=7)  3.4±0.6 0.6±0.2 2.9±0.5 1.5±0.9 
EAE Control 
Complete Paralysis (4)–4 3 - 1* - 
Partial Paralysis (3)–3 2 - 4 1 
Inverted Righting Reflex 
(IRR) 
(2)–2 - - - - 
Limp tail 1 - 3 - 2 
Limp tail with Tone (1) - 2 - - 
Normal 0 - - - - 
Mean score (n=5)*  3.6±0.5 0.8±0.3 3.1±0.5 1.8±0.5 
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LAP-MMP-mEPO initiates early disease onset  
Although no significant difference was observed for the degree of clinical severity during the relapse 
between groups, a significant difference was observed in the average day of relapse onset between 
the mice transplanted with the LAP-MMP-mEPO.tsF cells (28.4±9.3) and either the untransduced tsF 
cells (43±6.5; P ≤ 0.001) or the LAP-MMP control (40.9±6.7; P ≤ 0.05) (Figure 5.7). No difference in 
day of onset was observed when comparing the treatment group LAP-MMP-mEPO.tsF, LAP-MMP.tsF 
or the untransduced tsF cells with the EAE control group (37.4±3.8).  
 
 
Figure 5.7: Disease onset in CREAE mice 
transplanted with LAP-MMP-mEPO.tsF 
cells.  
The i.p. injection of 107 tsF cells expressing 
4µg/ml of latent EPO per day displayed a 
significant change in day of relapse onset 
when compared to LAP-MMP.tsF cells (P ≤ 
0.05) or untransduced tsF cells (P ≤ 0.001). 
Significance was determined using One-Way 
ANOVA with the Tukey post-hoc test. 
Dashed line indicates the average day of 
onset for the EAE control which displayed 
no significant difference with either 
treatment group.  
 
 
 
 
 
 
Amongst the mice that underwent an acute phase, 72% fell into relapse between day 31 and 43. Of 
the mice that received the transduced LAP-MMP-mEPO.tsF cells, 40% fell into relapse before day 31 
with none relapsing after day 43. However, of those mice that received either the LAP-MMP.tsF 
transduced cells or untransduced cells, none experienced an early onset of relapse compared to the 
EAE control. Furthermore, 75% and 57% respectively fell into relapse between days 31 and 43, with 
25% and 43% respectively falling into relapse after day 43.  
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As observed in the previous experiment, no statistically significant difference in disease day of onset, 
day of relapse onset, weight loss or clinical score was observed when the CREAE model was injected 
with LAP-MMP-mEPO.tsF cells expressing 4µg/ml latent mEPO/24 hours/mouse as compared to the 
EAE, LAP-MMP.tsF and untransduced tsF controls (Figure 5.6). 
Syngeneic untransduced tsF cells may suppress disease. 
When comparing the untransduced tsF groups against the EAE control group, a significant difference 
in the clinical score during relapse (P ≤ 0.05) was seen. This significance was however not reflected in 
its corresponding weight loss (Figure 5.6). Altogether, the mice in the tsF treated group appeared to 
maintain their weight above that in which they began the experiment. 
Latent EPO fails to ameliorate disease or delay onset of relapse. 
When the day of disease onset between all treatment groups and all control groups over both 
experiments were synchronised, no discernable difference was observed between severities of 
clinical scores or delay of relapse onset. It can however be said, that the treatment of mice with LAP-
MMP-mEPO.tsF cells expressing up to 4µg/ml latent mEPO/ 24 hours/mouse displayed a trend 
towards relapse suppression prior to day 30 (Figure 5.5). However, this effect was either reduced or 
removed after day 30 resulting in a delay in relapse peak and remission. This effect will need to be 
investigated further by checking the haematocrit levels on day 30 and every 3 days thereafter. 
Interestingly, the tsF cells alone (untransduced cells) appeared to prolong the onset of the disease. 
Potentially, the amount of endogenously expressed TGFβ from the tsF cells observed by our lab 
(unpublished data), may be in sufficient concentrations to act on the induction of the disease.   
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DISCUSSION 
The aim of this study was to determine if the ex vivo transduction of tsF cells with lentivirus 
engineered to express the latent proteins LAP-MMP-mEPO and LAP-MMP-huTGFβ, would result in a 
biologically active protein that exerts a therapeutic and regulatory effect in vivo in the Biozzi CREAE 
mouse model. The Biozzi ABH mouse has proven itself to be a valuable strain in inducing a relatively 
predictable and reproducible model for relapsing-remitting disease (Baker et al., 1990). Guido Biozzi 
originally selected outbred Swiss albino mice for studies into the susceptibility of infection, due to 
their ability to produce mice with either high antibody (ABH) or low antibody (ABL) titers (Biozzi et 
al., 1972). Inbred strains of these mice allowed researchers to study susceptibility of autoimmunity 
(Baker et al., 1990). Induction of CREAE occurs through the repeated injection of syngeneic spinal 
cord homogenate in CFA in ABH mice without the need for pertussis toxin, but not in the ABL strain. 
Further research found that the myelin oligodendrocyte glycoprotein (MOG) peptide could induce 
similar disease in these animals, but with accentuated demyelination and antibody deposition 
(Morris-Downes et al., 2002). Other studies found that severe relapsing-remitting disease could be 
induced by the myelin protein PLP but not with another myelin protein, MBP (Amor et al., 1993, 
Amor et al., 1996) and so did myelin-associated glycoprotein (MAG). Other non-myelin peptides that 
have been found to induce EAE in this strain include αβ crystallin (Thoua et al., 2000) and glial 
fibrillary acid protein (GFAP) (Amor et al., 2005).  
The growth factor EPO has previously been shown to result in disease amelioration in other models 
of EAE (Agnello et al., 2002, Zhang et al., 2005, Savino et al., 2006), and the use of TGFβ has shown 
both disease amelioration and disease exacerbation in the EAE model (Mirshafiey and 
Mohsenzadegan, 2009). Interestingly, the injection of TGFβ plasmid DNA in the periphery failed in 
ameliorate disease progression, however when TGFβ plasmid DNA was coupled to a cationic-
liposome complex, a reduction in EAE development was observed (Croxford et al., 1998). The 
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increase in efficiency of a therapeutic when injected directly into the CNS has also been observed 
with other molecules such as TNFα (Baker et al., 1994). 
Preliminary experiments injected LAP-MMP-huTGFβ.tsF, LAP-MMP-mEPO.tsF, and LAP-MMP.tsF 
cells i.p. into the CREAE mouse model, along with a group injected with rhEPO (5000IU/kg body 
weight [bw]). Those mice treated with LAP-MMP-huTGFβ.tsF cells demonstrated a lower disease 
score during initial attack when compared to the LAP-MMP.tsF control group. The groups injected 
with LAP-MMP-mEPO or rhEPO demonstrated a trend towards a lower clinical score although this 
was not statistically significant when compared against the LAP-MMP.tsf control group. It has 
recently been shown that the erythropoietic and tissue-protective effects of EPO function through 
two different receptor units and at different concentrations (tissue protection only occurs at high 
concentrations whereas erythropoiesis at low concentrations). It was hypothesized that although a 
trend to lower the clinical score of EAE was observed when CREAE mice were injected with LAP-
MMP-mEPO.tsF, the levels of EPO (once released by MMP cleavage) were not high enough to initiate 
tissue protection. Therefore a subsequent experiment was designed to inject 3 groups of mice with 
either 1-, 2- or 3x106 LAP-MMP-mEPO.tsF cells expressing 2μg/ml mEPO/106 cells/24hrs as these 
levels of mEPO are within the range of tissue-protection. However in the AB/H CREAE model, the 
LAP-MMP-mEPO protein failed to demonstrate disease amelioration or a delay in disease onset or 
relapse. The initial attack began 2 days earlier in those groups treated with the latent EPO expressing 
tsF cells when compared against the EAE control. Interestingly, once the acute phase was resolved, 
the treated groups underwent a milder and presumably delayed relapse compared to the control 
group. It is hypothesised that this relapse is actually the suppression of the original relapse by the 
exogenous EPO generated by tsF cells that secreted the latent EPO protein, but that are destroyed 
by day 32 post–transplantation, as demonstrated by an increase of clinical symptoms; or that the 
relapse was delayed due to the tsF cells themselves. These hypotheses need further investigation.  
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From the haematocrit profiles, biologically active EPO release from the latent protein was in 
circulation when the acute phase resolved but was absent when measured on day 35 post–cell 
transplantation. This infers either the loss of the transplanted tsF cells or the loss of latent EPO 
production by the transplanted tsF cells. It is unlikely that the latter is true as the cells were 
manitained in culture for one month and their expression tested prior to transplantation. A possible 
reason for the former may be in the production of antibodies against either the tsF cells or against 
the fusion protein. A study by Rigby et al. (2009) tested serum taken from EAE mice transplanted 
with untransduced tsF cells, tsF cells expressing fusion proteins and from naïve mice for binding 
antibodies. High levels of antibodies were found in the serum from mice that received the 
transplantation of tsF cells (both transduced and untransduced), but very few were found in the 
serum from naïve mice. This was unexpected as the cells are syngeneic to the mice and should not 
exert an immunological response. As the serum from untransduced tsF cells cultured in vitro 
exhibited antibodies against it, it is unlikely that the neo gene product is responsible for the clearing 
of these cells in vivo. As mentioned earlier, these cells are permanently transduced with a 
temperature sensitive SV40 large T-antigen that is rapidly degraded at body temperature (in vivo) or 
when grown at 37°C (in vitro) and therefore unlikely to be a source of immunogenicity. The growth 
of the tsF cell line in vitro is dependent on the presence of serum in the medium. BSA was therefore 
a likely candidate for the antigenicity demonstrated. Indeed, upon further investigation, it was 
determined that BSA did in fact induce the production of antibodies. The immunological response 
against the BSA present in the transplanted tsF cells may be the cause of the eventual loss of latent 
protein expression through systematic destruction of the cells, possibly by peritoneal Mø found at 
the site of injection. The ability of tsF cells to be grown in vitro in serum-free conditions was 
investigated but the cells failed to survive for longer than 48 hours. The use of an adaptation 
protocol (Sinacore 2000) may allow for tsF cells to be grown in serum–free conditions whilst still 
expressing the latent fusion proteins. A repeat of the study with tsF cells adapted to serum-free 
growth conditions would provide strong evidence that the BSA contained in serum–containing 
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growth medium may have induced the production of the antibodies thus leading to the possible 
destruction of the tsF cells in vivo evident at day 35 post-transplantation.  
Although the disease score did not differ significantly when comparing the controls with the mice 
that received 2x106 LAP-MMP-mEPO.tsF cells (4µg/ml latent mEPO/24 hours), using a One way 
ANOVA with the Tukey post-hoc test to compare the groups, the overall status of the animals was 
improved in the LAP-MMP-mEPO.tsF group, as it is evident from the weight loss curves reported in 
Figure 5.7, where at the end of the experiment on day 54 the body weight loss was observably less in 
mice treated with LAP-MMP-mEPO.  
The low number of mice that underwent an acute phase and experienced a spontaneous relapse in 
the treated groups resulted in high SEM. This was resolved by repeating the experiment using the 
dose of 4µg/ml latent mEPO/24 hours/mouse (equivalent to 2x106 LAP-MMP-mEPO.tsF cells) and 
including additional controls LAP-MMP.tsF cells and untransduced tsF cells, thereby increasing the 
number of mice for statistical analysis. The data generated was synchronised to day of disease onset 
to allow for biological variability. However, no significant difference in disease onset or disease 
amelioration was observed. Once again prior to day 29 following disease onset, the mice treated 
with the latent mEPO protein entered relapse but the clinical severity appeared to be suppressed. 
On day 30 this effect was gone leading to a continued relapse. It is therefore highly plausible that, in 
combination with the haematocrit data stating that the EPO effect was negligible by day 35 post 
transplantation, the cells were destroyed due to the immunogenic effect discovered by Dr Rigby in 
the days leading up to the onset of relapse. The replication of this experiment with transduced tsF 
cells expressing the latent EPO protein that had been grown in serum–free conditions, may 
demonstrate a different outcome. Therefore it cannot be conclusively stated that the latent EPO 
protein does not ameliorate EAE and further studies need to be performed with frequent 
haematocrit readings taken. 
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Surprisingly, the control group injected with untransduced tsF cells showed significant disease 
amelioration when compared with the EAE control, and the LAP-MMP-mEPO.tsF and LAP-MMP.tsF 
treatment groups. Untransduced tsF cells have been found to express low levels of TGFβ 
(2.1ng/ml/106 cells/24hrs (Croxford et al., 2000)) which potentially act to inhibit the onset of EAE. 
Indeed even 3ng/ml active TGFβ has been shown to inhibit the proliferation of over 92% of T cells 
and can inhibit the development of EAE if given prior to disease onset (Racke et al., 1991)  
Conversely, several studies have shown that TGFβ can exacerbate EAE for example, through the 
increase in Th17 production and subsequently the expression of the proinflammatory growth factor 
IL17 (Mirshafiey and Mohsenzadegan, 2009). It would therefore be beneficial if investigations were 
made into whether TGFβ has a ‘therapeutic window’ in which levels over and above a certain 
threshold switch it from having a positive effect in MS to a negative one.  It may be that the low 
levels of TGFβ expressed by the untransduced tsF cells is within the threshold of beneficial effects, 
whereas the higher levels of TGFβ expressed by LAP-MMP-huTGFβ cells may be on the cusp of 
beneficial vs. deleterious effects of the protein, where an increase in expression levels actually lead 
to exacerbation of the disease rather than amelioration. This appears to indeed be the case as 
CREAE mice injected with 3 times as many LAP-MMP-huTGFβ.tsF cells show little difference when 
compared to the LAP-MMP.tsF control group.  
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Growth factors have a multitude of functions and interact with receptors in a diverse number of 
organs and tissues, and as such are able to elicit serious side effects when found in high 
concentrations. For example, the growth factor EPO is produced in the foetal liver and adult kidney 
and interacts with receptors found throughout the body, including the brain. But as it promotes the 
formation of new red blood cells, high concentrations lead to serious complications such as 
thrombosis and heart failure. Interestingly, studies have shown that treatment of EAE with EPO 
leads to a decrease in clinical severity, however the concentrations of EPO required to deliver these 
therapeutic effects are high and therefore unsuitable for human clinical trials. This study utilized the 
LAP technology originally described by Adams et al. (2003) to render EPO latent through its fusion to 
an MMP cleavage site attached to the LAP peptide of human TGFβ. The resulting LAP-MMP-mEPO 
fusion protein was shown to be inactive until incubated with recombinant MMP1, whereby the 
released mEPO protein was found to be biologically active in vitro. This demonstrates the ability of 
the technology to overcome the limitations of most growth factors, the implications of which are 
highly significant. The design and construction of the DNA vectors used to manufacture the latent 
growth factors is modular i.e. the LAP peptide, the MMP cleavage site, and the protein of interest 
site are all easily removable, and the protein of interest can be removed or inserted simply through 
two common restriction sites (NotI and XbaI), making it very attractive to ‘chop-and-change’ 
therapeutic protein targets as the need or research arises. The mere fact that a growth factor can be 
released into the body of an animal and not interact with the multitude of receptors available to it is, 
in itself, a remarkable achievement. It is this versatility to confer latency to a number of other 
growth factors that lends itself to a broad range of clinical applications, such as cancer, 
atherosclerosis and other autoimmune diseases.  
MS is an autoimmune disease that is characterised by lesions in the brain, areas demarcated by 
demyelination and leukocyte infiltrates. Although growth factor therapy has shown therapeutic 
potential in EAE models for MS, the high concentrations needed and the location of where the 
growth factor is required presents serious problems in their future consideration as a therapeutic 
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molecule. The LAP technology has advantages as a targeted drug delivery system. The latent fusion 
protein remains inactive until it is released at sites of inflammation, areas demonstrating high levels 
of MMP activity such as lesions in MS. This technology therefore presents itself as a potential 
solution to overcome the difficulty in accessing the CNS without surgical procedure, or the 
administration of high concentrations of therapeutic drug to elicit the therapeutic effect. This study 
has shown that this modular design can be used to generate lentivirus capable of infecting syngenic 
cells, cells that are able to produce the latent fusion protein in vivo, an extension of the LAP 
technology that has the potential to act as a self-sustaining treatment for a number of clinical 
applications. 
MS is one of the most common neurological diseases affecting the young population today. It is 
defined as an autoimmune demyelinating disease whose aetiology is unknown but both 
environmental and genetic factors influence its susceptibility and/or severity. Pathologically it is 
characterised by an increase in inflammatory cell infiltration, OL loss and demyelination, microglial 
activation and astrocyte scarring within the CNS. The order of destruction is, as yet, unclear as to 
whether it is initially inflammation-driven followed by demyelination, or demyelinating followed by 
inflammation, with the former being the most generally accepted hypothesis. Nevertheless, the 
presence of monocytes, T lymphocytes (both CD4+ and CD8+) and B lymphocytes, and Mø provides a 
diverse and dynamic puzzle board on which to work with, both therapeutically and aetiologically.  
Treatments have been aimed at resolving the disease from the perspective of autoimmunity with 
little success when targeting the demyelinating arm of the disease. The majority of these treatments 
and their failed counterparts were initially investigated for efficacy in the EAE model for MS. This 
model has been called the ‘prototypical autoimmune model’ as it can be manipulated to 
demonstrate specified points of the disease. MS is a disease that progresses through stages of 
relapse and remission to which point EAE can be induced to simulate, dependent on species, strain 
and antigen used for induction. Furthermore, these stages can be somewhat ‘compartmentalised’ in 
CHAPTER 6: GENERAL DISCUSSION  
 
        200 
their inflammatory and demyelinating aspects. For example, the induction of monophasic acute EAE 
in the Lewis rat with CNS proteins or purified myelin components is mainly inflammatory with very 
little demyelination, whereas the CREAE model in Biozzi AB/H mouse, induced with syngeneic spinal 
cord homogenate, demonstrates inflammation during the acute and initial relapsing phases with 
demyelination and remyelination, in addition to inflammation, occurring in the chronic phase 
(Hampton et al., 2008). It is through our research in these models, that we have become adept at 
inhibiting relapsing EAE. However, once the inflammatory component has been eliminated, the 
neurodegenearative component remains and is unresponsive to immunosuppression. The typical 
models of C57BL/6 mice and SJL mice used in the inflammatory studies are inadequate in studying 
the progressive phase of the disease, characterised by the neurodegenerative component. The 
C57BL/6 model is monophasic and primarily inflammatory, whilst the SJL EAE-induced model has a 
clinical course that is aggressive and has a variable frequency of relapses. The AB/H mouse model is 
very robust with a reproducible disease course with easily distinguishable relapses and is amenable 
to disease manipulation. It is easier to handle and the disease slowly evolves into progressive EAE 
with associated neurological damage. It shows persistent demyelination, gliosis and glial cell 
activation, remyelination as well as neuronal and axonal loss. In particular, it is possible to stop 
further relapse autoimmunity at any stage of the disease through immune tolerance induction 
allowing researchers to monitor long-term repair strategies (Pryce et al., 2005, Jackson et al., 2009).    
But EAE is not MS; it does not evolve spontaneously, it requires a strong immunological kick-start 
(i.e. through the use of Freund’s adjuvant) that is unlikely to exist during physiological conditions and 
is studied in thoroughly inbred animals, quite unlike the spontaneously evolving disease that appears 
in the genetically heterogenous human population. Despite these limitations, most of the principle 
processes of brain inflammation have been elucidated through studies on EAE and without them, 
the pathogenesis of MS and future therapies for its treatment could not be developed.    
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The use of growth factors for the treatment of disease is inherently problematic due to the 
pleiotropic nature of the proteins, their short half-life, the systemic administration of high 
concentrations to attain therapeutic levels in the targeted tissue, and their inevitable side effects as 
a result of such high concentrations. The construction of a latent growth factor utilizing the LAP of 
human TGFβ fused via a MMP site to the growth factor (Adams et al., 2003) circumvents many of 
these drawbacks. By encasing the biologically active growth factor IFNβ within LAP, its pleiotropic 
nature was silenced until its release through cleavage by MMP enzymes. The inclusion of the MMP 
site ensures that the release of the growth factor occurs predominantly at sites of elevated MMP 
activity such as areas of inflammation. The inclusion of the growth factor within the LAP allows not 
only for the targeting of growth factor release to these areas, but also attributes a longer half-life, 
for example LAP-MMP-VIP has a half-life of 31 hours as compared to 1.5 min for free VIP (Vessillier 
et al., 2012). Interestingly cleavage of the latent IFNβ occurred when incubated with CSF from rhesus 
monkeys with EAE but not from monkeys with collagen-induced arthritis. As increased MMP activity 
has been found within active lesions of multiple sclerosis and in animal models of EAE, this LAP 
technology presents a novel method for the treatment of MS with growth factors that have 
demonstrated ameliorating effects in the EAE model.  
Three proteins in particular, EPO, TGFβ and IGF1, have demonstrated potential in the treatment of 
MS as elucidated from EAE data. The growth factor EPO has demonstrated neuroprotective and anti-
inflammatory properties in several models of EAE through the suppression of pro-inflammatory 
growth factors and the inhibition of proliferating autoreactive T cells. Treatment of EAE with TGFβ 
has demonstrated anti-inflammatory effects by blocking the expression of growth factor induced 
endothelial adhesion molecules, by inhibiting pro-inflammatory growth factors and through its role 
in preventing the entry of autoreactive T cell into the CNS (Johns et al., 1991, Racke et al., 1991, 
Prehn et al., 1994, Croxford et al., 1998, Ruocco et al., 1999, Zhu et al., 2002). IGF1 is intricately 
involved in the remyelination aspect of the disease with its expression coinciding with the expression 
of IGFBP by OLs and astrocytes. It has also demonstrated an involvement in neural cell proliferation 
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and differentiation during development (McMorris et al., 1986, McMorris and Dubois-Dalcq, 1988, 
Mozell and McMorris, 1991, Shinar and McMorris, 1995, Annenkov, 2009). 
By utilizing engineered latent growth factors mEPO, huTGFβ and isoforms IGF1A and B, I was able to 
determine that they could be made latent whilst still retaining their respective biological activities, 
activities which are only functional following MMP cleavage. The production of therapeutic proteins 
on a large scale by transforming DHFR- CHO cells to DHFR+ transgene expressing CHO clones is 
routinely used and was initially attempted in this study to express the latent proteins. CHO cells are 
currently the “premier workhorse” for the production of therapeutic proteins with over 70% of all 
recombinant therapeutic proteins being produced by CHO cells (Jayapal et al., 2007). The 
therapeutic proteins Aranesp (Amgen) and Epogen/Procrit (Amgen/Ortho Biosci) used in the 
treatment of anaemia are recombinant EPO proteins produced by CHO cells. Mammalian cell are 
mainly used for the production of therapeutic proteins as they are able to produce biologically active 
forms that are correctly folded with appropriate post-translational modifications, predominantly 
glycosylation, unlike microbial hosts like E.coli. Interestingly, when coupled to the LAP shell 
containing the MMP cleavage site, latent EPO produced by CHO cells was not cleaved by MMP1. LAP 
and EPO are both highly glycosylated with N-linked glycosylation sites (3 and 4 sites respectively) 
that play pivotal roles in their production, secretion and biological activities. It may be that the 
pattern of carbohydrate moieties of EPO, coupled with the LAP shell, interferes with the folding of 
the latent protein in such a way that either the MMP enzyme cannot access its binding site or that 
the binding site is structurally hidden. The failure of MMP to cleave latent EPO was unexpected and 
the role of glycosylation was investigated. Unglycosylated latent EPO, expressed by CHO-S cells 
exposed to tunicamycin, succeeded in releasing the mature EPO molecule following MMP cleavage. 
Nonetheless, for latent EPO to be biologically active and therefore therapeutic, it would have to be 
glycosylated that, if produced by CHO cells, would render it uncleavable and therefore useless. 
Interestingly, the use of human EPO fused to the cleavable LAP-MMP shell has demonstrated 
cleavage when expressed by CHO DG44 cells (unpublished data, Dr. Sandrine Vessillier). Why MMP is 
CHAPTER 6: GENERAL DISCUSSION  
 
        203 
able to cleave EPO when it is the human homologue but not the mouse homologue is unclear. 
Further experiments mutating the EPO molecule should shed some light in this regard. Additionally, 
proteins rendered latent through the addition of the LAP shell are unable to reach a degree of purity 
that would allow in vivo testing. Therefore an alternative method of protein production was needed. 
Other mammalian cell lines such as those derived from baby hamster kidney, mouse myeloma and 
HEK-293T cells are regulatory approved cells for the production of therapeutic proteins (Wurm, 
2004). The transient transfection of HEK-293T cells with latent growth factor constructs consistently 
produced high concentrations of secreted, cleavable and biologically active latent growth factors 
(including LAP-MMP-mEPO) as assessed by western blot analysis and the appropriate biological 
assays.  
The use of protein therapy has been used extensively for the treatment of various diseases such as 
the treatment of MS with IFNβ. However, the prolonged systemic delivery of therapeutic proteins in 
vivo may be of more benefit than serial injections. Great success has been achieved in ameliorating 
or inhibiting EAE in the mouse model by transplanting ex vivo transduced syngeneic fibroblasts 
expressing TNF inhibitors or IL-10 (Croxford et al., 2000, Croxford et al., 2001). The transplantation of 
tsF cells from the AB/H mouse is an attractive method of cellular gene therapy as fibroblasts are 
easily cultured from skin biopsies thereby minimising any potential allogeneic immune response, 
whilst the cells additionally contain a temperature-sensitive T antigen mutant that is easily degraded 
at body temperature. The transduction of tsF cells with lentiviral vectors expressing our latent 
growth factors resulted in constitutively produced latent proteins that were able to be cleaved by 
MMP1 in vitro.  
During a preliminary study of the tsF response in vivo, LAP-MMP-huTGFβ.tsF cells demonstrated a 
significant reduction in disease score of mice induced with EAE. It is well known and documented 
that TGFβ is a potent anti-inflammatory growth factor. It has demonstrated disease amelioration in 
previous studies of EAE. The reason as to why LAP-MMP-huTGFβ appeared to work less effectively at 
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higher does is unclear at this moment; no paper to date has been published stating the TGFβ 
produceses a dose-dependent bell curve. However these cells are not inert, they secrete various 
other factors that may interact with TGFβ such as BMP7 that could regulate TGFβ signalling.  
When transplanted into AB/H CREAE mice, the LAP-MMP-mEPO protein demonstrated biological 
activity as seen by an increase in haematocrit values comparable to the literature (Agnello et al., 
2002). However these values had subsided by day 35 after transplantation, presumably through the 
systematic destruction of the LAP-MMP-mEPO.tsF cells. Previous studies have shown that both the 
AB/H mouse and the DBA/1 mouse do not mount an immune response to these transduced tsF cells 
(Dr Anne Rigby, Dr Marinela Mendez-Pertuz, unpublished data). However it was determined that 
they were initiating an immune response to the BSA that had been absorbed on the cell membrane 
leading to there distruction (Rigby, 2009). The cells were transplanted on day 11 to coincide with the 
onset of clinical symptoms. The group treated with LAP-MMP-mEPO.tsF cells displayed no significant 
amelioration of disease or delay of onset compared to that of the control. Current literature has 
shown that amelioration of disease occurs when EPO is injected preventatively but not 
therapeutically (Savino et al., 2006). Additionally, onset of relapse appears to be expedited when 
treated with LAP-MMP-mEPO whilst demonstrating a reduction, albeit not a significant one, in 
clinical score that increased after a period of apparent suppression. It is plausible that the 
destruction of the tsF cells initiated the end of this period of suppression resulting in a consistent 
decrease in LAP-MMP-mEPO production, and that this effect is be due to the molecular and cellular 
environment (i.e. the types of cells surrounding them and their interactions with them, as well as the 
proteins and other molecules secreted through these interactions) surrounding the transplanted 
cells as the tsF control group demonstrated a similar delay in relapse.  
However, the levels of serum EPO in the mice were not tested and therefore it cannot be said that 
the levels of recombinant EPO were sufficient to engage the tissue-protective receptor (EPOR)2/βcR 
necessary for sustained tissue-protection. Additionally, the expression of (EPOR)2/βcR during the 
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course of EAE has not yet been assessed. It may be expressed at very low levels, or may even be 
absent within lesions thereby interacting with the classical (EPOR)2 receptor. Nonetheless, the 
worsening of clinical symptoms was not reflected in the weight of the mice suggesting an 
improvement in the overall status of the mice treated with latent EPO.  
Interestingly, the group treated with untransduced tsF cells demonstrated significant disease 
amelioration during relapse as compared to the EAE control that was not seen when treated with 
latent EPO. It is known that the transduced fibroblasts secrete small endogenous levels of TGFβ 
which may account for the reduction in disease score. Furthermore, clinical symptoms appear to 
escalate following the surmised period of tsF cell destruction further substantiating the theory that it 
is the loss of the tsF cells that results in the return of clinical symptoms. Further experiments will 
need to be done in order to verify this.  
Although fibroblasts were transduced with LAP-MMP-mIGF1A and LAP-MMP-mIGF1B, time and 
funding were critical and therefore only a limited amount of in vivo experiments could be 
performed. Futher funding would allow another researcher to continue this work, to determine 
whether IGF1A or IGF1B ameliorate EAE and provide neuroprotection during the relapse phase.  
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FURTHER EXPERIMENTS 
The Biozzi AB/H CREAE model is the best representative of progressive MS available to date. It 
displays spontaneous relapses, a high degree of incidence and an acute phase that is predominantly 
inflammatory followed by periods of remission and relapse with inflammation and demyelination. 
Additionally, it displays demyelinating lesions within the optic nerves, a pathological characteristic of 
MS (O'Neill et al., 1998).  
This study was undertaken using the AB/H CREAE model based on these characteristics, utilizing the 
general scoring system currently used for the majority of EAE murine models, with statistically 
acceptable numbers and additional control groups to account for untreated EAE, delivery of 
untransduced tsF cells, vehicle delivery (LAP-MMP) and dosage.  
With these elements in place, the study was scientifically sound and corroborated the data 
generated from different rodent strains and induction protocols. Systemic administration of EPO has 
demonstrated a delay in disease onset with a reduction in clinical score, a reduction in disease 
severity and duration and in reduced body weight loss (Agnello et al., 2002, Savino et al., 2006, Li et 
al., 2004). This study demonstrated a tendency to increase the relapse rate albeit with reduced 
clinical score and severity that was reflected in a reduction in body weight loss when treated with 
latent EPO expressed by ex vivo transduced tsF cells. It can be suggested that should the transduced 
tsF cells be grown in serum-free conditions and a repeat of the study done whilst giving consistent 
results, that the data generated could translate into human MS subjects.  
The tissue-protective properties of EPO are only initiated when EPO expression is at high levels as 
the tissue-protective receptor unit (EPOR)2/βcR has a low affinity for the ligand. Therefore any LAP-
MMP-mEPO induced neuroprotection would need to occur at high levels locally. Therefore the 
inferred latency given by the fusion of LAP to EPO is ideal for the delivery of a high level of EPO 
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without the activation of the erythropoietic receptor (EPOR)2 systemically, prior to receptor 
initiation within the CNS. However, at these levels the appearance of unwanted side effects such as 
thrombosis are possible as the EPO protein is not contained within the CNS, and the CNS does 
express (EPOR)2 able to initiate erythropoiesis. Therefore the next step in utilizing this latency 
technology, would be to add LAP fused to the MMP cleavage site to the nonerythropoietic, EPO-
mimicking peptide ARA290, thus creating a latent peptide that has no possibility of these 
aforementioned side-effects, but which is neuroprotective and only engages the (EPOR)2/βcR unit 
resulting in a high efficiency of neuroprotective signalling. 
Modifications in the experimental design 
This study could not conclusively demonstrate any therapeutic benefit of latent EPO in the 
treatment of MS. However, if the study were to be repeated utilizing the following modifications in 
its design, a conclusive outcome may be obtained. The modified experimental design should include 
weekly tail vein blood sampling under anaesthesia for determining a change in the haematocrit 
ratios, and three different ‘therapeutic windows’—preventative, therapeutic and late therapeutic 
schedule—where the transduced EPO.tsF cells are transplanted on day of induction (day 0), day 10 
and day 25 respectively to determine if the latent protein is most beneficial on a preventative basis 
as demonstrated by Savino (2006). Additionally, as tsF cells are grown under serum-containing 
conditions, it should be investigated as to whether these cells can be adapted for serum-free 
culturing conditions to avoid the targeted destruction of these cells due to their BSA antigens (Rigby, 
2009). Should this prove to be unachievable, the direct infection of the mice with the lentivirus 
encoding latent EPO expression should be considered. It was identified that the transplantation of 
untransduced tsF cells ameliorated EAE. This was very unexpected and should be investigated and a 
growth factor/protein profile generated using protein array (chip) technology (capture array). This 
will enable us to quantify the growth factors expressed by the conditionally immortalised fibroblasts 
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and detect any that differ in their expression levels from control fibroblasts that have not been 
immortalised i.e. fibroblasts that have not been immortalised.  
Alternatively, another attractive technology for the introduction of the tsf cells (transduced to 
secrete our therapeutic latent growth factor) into the CREAE mouse model, is the encapsulation of 
the cells. The encapsulation of the cells in a hydrogel, a cross-linking polymer, creates a physical 
barrier for transplanted cells against the host immune response through the prevention of immune 
cell and antibody infiltration. The cells are immobilized in a polymer matrix surrounded by a 
semipermeable membrane. The mesh structure is small enough to prevent immune cells and 
antibodies from entering, but large enough to allow the diffusion of oxygen, nutrients and other 
molecules. The choice of polymer used to encapsulate the cells needs to be biocompatible as it 
influences the rate of biodegradation (http://cdn.intechopen.com/pdfs/19720/InTech-
The_therapeutic_potential_of_cell_encapsulation_technology_for_drug_delivery_in_neurological_d
isorders.pdf; 
http://homepages.cae.wisc.edu/~bme200/microencapsulation_fall05/reports/BME_400_Microenca
psulation_Final_Report.pdf). Additionally the mesh structure created by the polymer determines the 
molecular weight cut-off. By generating a mesh structure with a molecular weight cut-off of 100kDa, 
antibodies (at around 150kDa) and the larger leukocytes are excluded from entering, offering the 
encapsulated cells immunoprotection, whilst allowing the cell secretions (such as the latent growth 
factors) to diffuse out of the capsule, and target the sites of inflammation. A problem encountered 
with cell encapsulation is cell necrosis brought about by large diffusion distances. Small diffusion 
distances of 100µm can avoid hypoxia of the cells. Additionally, the site of injection of the 
encapsulated cells can play an important part in the avoidance of cell necrosis for example 
subcutaneous injection, as it presents a better oxygen supply than peritoneal injection. Through the 
use of a hydrogel polymer, the encapsulation of the transduced tsF cells would allow for their 
immunoprotection whilst still allowing the secretion of the latent growth factors for diffusion to sites 
of inflammation within the brain. The cost of protein therapies becomes increasingly more with 
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inceased treatments. The continuous and sustained production of the latent growth factors in vivo 
afforded by the low rate of biodegradation may dramatically reduce the therapeutic costs involved 
(http://cdn.intechopen.com/pdfs/19720/InTech-
The_therapeutic_potential_of_cell_encapsulation_technology_for_drug_delivery_in_neurological_d
isorders.pdf; 
http://homepages.cae.wisc.edu/~bme200/microencapsulation_fall05/reports/BME_400_Microenca
psulation_Final_Report.pdf).    
Quantification of in vivo protein production and clearance rate 
The expression and secretion of the latent therapeutic EPO protein has been confirmed directly in 
vitro and indirectly in vivo in the haematocrit ratios. However, the precise concentration of protein 
produced is highly variable dependent on the number of surviving and viable tsF cells. It is 
imperative that the dose of latent protein produced in vivo in the EAE mouse model be determined. 
Assuming the levels of protein released within the CREAE model are within the detection range, a 
standard direct or sandwich ELISA can be performed. With a sandwich ELISA, two different 
antibodies of different species recognising two different epitopes of the growth factor protein can 
be used to identify the released growth factor with a high degree of specificity. However, if the 
levels of MMP expression within the CREAE model are not sufficient as to release a concentration of 
the growth factor detectable by ELISA or that the protein is degraded swiftly in vivo such that the 
serum levels are below the detection threshold of an ELISA (i.e. protein levels in the fentomol range) 
than an alternative method of protein detection is required, such as stable isotope labelling tandem 
mass spectrometry (SILT) (Bateman et al., 2007). This technique utilises the incorporation of the 
naturally occurring isotope carbon-13 into the amino acid leucine. Following immunoprecipitation of 
the protein from the CSF, blood and/or urine, the protein is digested with trypsin and the tryptic 
peptides quantified using tandem mass spectrometry. It is reproducible, robust, can be used in vitro 
or in vivo, and has the advantage of being able to correctly identify the protein analysed through 
CHAPTER 6: GENERAL DISCUSSION – FUTURE DIRECTIONS 
 
        210 
tandem mass spectrometry ions. Most importantly, it is able to quantify low abundance protein 
levels and clearance rates, as would be the case with our latent protein, that are beyond the 
detection limits of other established in vivo analytical approaches such as Gas 
Chromatography/Mass Spectrometry or Gas Isotope Ratio Mass Spectrometry.  
Clinical Trials 
The recent results of a clinical trial using EPO in the early treatment of acute ischemic stroke have 
highlighted an alarming increase in the risk of death and of further complications such as 
intracerebral haemorrhage, brain oedema and other thromboembolic events when combined with 
recombinant tissue plasminogen activator (rtPA) (Ehrenreich et al., 2009). It is possible that these 
effects are due to a dysfunction in the endothelium of vessels (Dame, 2010). Endothelial 
microparticles (EMP) are “submicron particles that are shed from plasma membranes in response to 
cell activation, injury and/or apoptosis” found in increasing circulatory levels during a worsening of 
endothelium-dependent vasodilation making them useful markers of endothelial dysfunction 
(Chironi et al., 2009). They are also the main carriers of circulating tissue factor (see below) 
(Horstman et al., 2009).  
Currently, clinical trials of recombinant EPO (48000 IU i.v) in conjunction with methylprednisolone 
(1g i.v) in two stages (weekly administration for 12 weeks and bi-weekly for 12 weeks) are underway 
at the Rigshospitalet in Denmark (The Danish MS Research Centre; Rigshospitalet. The Effects of 
Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple 
Sclerosis (EPO-ProgMS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine 
(US). 2000- [cited 2010 Oct 16]. Available from: http://clinicaltrials.gov/ct2/show/NCT01144117 
NLM Identifier: NCT01144117). The side effects noted in the Acute Stroke Trial may occur during the 
EPO trial in Denmark as increased circulatory levels of EMP, associated with endothelial dysfunction, 
have been found in MS during exacerbations but not during remission (Minagar et al., 2001). EPO 
has been found to increase the expression of tissue factor on the extracellular matrix of endothelial 
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cells, leading to an increase in platelet adherence and therefore its thrombogenecity (Fuste et al., 
2002). The neuroprotective properties of EPO occur through the interaction of the (EPOR)2/βcR, 
similarly demonstrated by the neuroprotective action of EPO in tissue repair after stroke (Sautina et 
al., 2010). It may be that the side effects highlighted in the stroke trial are modulated through the 
homodimer EPOR, rather than (EPOR)2/βcR (Brines et al., 2004, Brines and Cerami, 2008, Tufekci and 
Genc, 2010). Furthermore, non-erythropoietic EPO derivatives such as asialoEPO or CEPO may 
circumvent those side effects as they have different procoagulant and vasoactive activities, however 
it has been found that derivatives of recombinant proteins may elicit an immunogenic response 
(Sauerborn et al., 2010, Coleman et al., 2006). Latent EPO is expected to be therapeutically useful at 
concentrations considerably lower than that required if delivered systemically as a fully active 
therapeutic molecule. Therefore it is unlikely that the increased side-effect profile or immunogenic 
response would pertain to latent EPO, however a small safety study should be done to verify this.  
The potential benefit of EPO in the treatment of progressive MS cannot be conclusively drawn. 
Although there is a tendency to suppress the clinical severity of symptoms in the mice that 
underwent EPO treatment by ex vivo transduced tsF cells, it cannot be said that it is the role of EPO 
that affords this benefit as the relapse eventually does occur. 
The multimodal protein TGFβ has been shown to have paradoxical effects in MS (Mirshafiey and 
Mohsenzadegan, 2009). Whether these effects are triggered through different ligand threshold 
concentrations is, as yet, unknown. When LAP-MMP-huTGFβ.tsF cells are injected into the CREAE 
mouse model of MS, the low (1x106 cells/mouse) but not the high (3x106 cells/mouse) dose resulted 
in disease amelioration. However it remains to be determined what levels of TGFβ are required to 
transfer the balance of positive effects in EAE (for example the generation of TH3 cells) to one of 
negative effects.  
The remyelinating properties of IGF1 have highlighted this protein as a promising therapeutic 
molecule for MS.  Although treatment with IGF1 has demonstrated both positive (the lack of 
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demyelination and an improvement in clinical score in EAE (Genoud et al., 2005, Cannella et al., 
2000)) and negative results (such as unwanted side effects (Lovett-Racke et al., 1998)), the latency 
inferred by LAP would allow the protein to be released in small amounts that are specifically 
released at sites of increased MMP activity such as within the CNS. Additionally, as with EPO, IGF1 
may act within a particular therapeutic window where outside those threshold levels its effects are 
negative. Unfortunately, due to time and monetary constraints, further experiments utilising LAP-
MMP-mIGF1A and LAP-MMP-mIGF1B in the CREAE could not be done. Additionally, there have been 
no studies done (at the time of writing) investigating the functionality of the different isoforms 
IGF1A and IGF1B within EAE, or even within the CNS. This information would help us understand the 
further molecular versatility of this protein within the CNS and within MS. 
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APPENDIX 1 
Annotated sequence of LAP-MMP-huTGFβ in pcDNA3. 
>CMV Promoter (3’ end)                                    >T7                                 HindIII >LAP 
|                                                         |                                   |       | 
G TCT ATA TAA GCA GAG CTC TCT GGC TAA CTA GAG AAC CCA CTG CTT ACT GGC TTA TCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCC Aag ctT ATG CCG  < 900 
M   P 
>AarI 
| 
CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG CCT GGC CGG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT A  < 1000 
P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T   P   G   R   P   A   A   G   L   S   T   C   K   T   I 
 
tc gac atg gag ctg gtg aag cgg aag cgc atc gag gcc atc cgc ggc cag atc ctg tcc aag ctg cgg ctc gcc agc ccc ccg agc cag ggg gag gtg cc  < 1100 
D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P   S   Q   G   E   V   P 
Bsu36I 
| 
G CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC  < 1200 
P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D 
AleI                           >RleAI 
|                              | 
TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC A  < 1300 
Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N 
KpnI 
Acc65I                                                                                        PmlI 
|                                                                                             | 
AC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GA  < 1400 
T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L   R   L   K   L   K   V   E   Q   H   V   E 
 
G CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA  < 1500 
L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F   D   V   T   G 
 
GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC A  < 1600 
V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I 
BstXI 
| 
TC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CA  < 1700 
N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q 
EcoRI   >MMP site                                             BlpI   NotI       >huTGFB         <AjuI 
|       |                                                     |      |          |             | 
G CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA GCC CTG GAC ACC AAC TAT TGC TTC AGC  < 1800 
H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   A   L   D   T   N   Y   C   F   S 
<BarI 
| 
TCC ACG GAG AAG AAC TGC TGC GTG CGG CAG CTG TAC ATT GAC TTC CGC AAG GAC CTC GGC TGG AAG TGG ATC CAC GAG CCC AAG GGC TAC CAT GCC AAC T  < 1900 
S   T   E   K   N   C   C   V   R   Q   L   Y   I   D   F   R   K   D   L   G   W   K   W   I   H   E   P   K   G   Y   H   A   N   F 
 
TC TGC CTC GGG CCC TGC CCC TAC ATT TGG AGC CTG GAC ACG CAG TAC AGC AAG GTC CTG GCC CTG TAC AAC CAG CAT AAC CCG GGC GCC TCG GCG GCG CC  < 2000 
C   L   G   P   C   P   Y   I   W   S   L   D   T   Q   Y   S   K   V   L   A   L   Y   N   Q   H   N   P   G   A   S   A   A   P 
 
G TGC TGC GTG CCG CAG GCG CTG GAG CCG CTG CCC ATC GTG TAC TAC GTG GGC CGC AAG CCC AAG GTG GAG CAG CTG TCC AAC ATG ATC GTG CGC TCC TGC  < 2100 
C   C   V   P   Q   A   L   E   P   L   P   I   V   Y   Y   V   G   R   K   P   K   V   E   Q   L   S   N   M   I   V   R   S   C 
XbaI                   <SP6               >BGH polyadenylation signal 
|                      |         | 
AAG TGC AGC TGA CTC TAG AGG GCC CTA TTC TAT AGT GTC ACC TAA ATG CTA GAG CTC GCT GAT CAG CCT CGA CTG TGC CTT CTA GTT GCC AGC CAT CTG T  < 2200 
K   C   S   * 
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Annotated sequence of LAP-MMP-mEPO in pcDNA3. 
>CMV Promoter (3’ end)                                    >T7                                 HindIII 
|                                                         |                                   | 
G TCT ATA TAA GCA GAG CTC TCT GGC TAA CTA GAG AAC CCA CTG CTT ACT GGC TTA TCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT ATG CCG  < 900 
>LAP 
| 
CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG CCT GGC CGG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT A  < 1000 
L   S   T   C   K   T   I 
TC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CC  < 1100 
D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P   S   Q   G   E   V   P 
Bsu36I 
| 
G CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC  < 1200 
P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D 
AleI 
| 
TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC A  < 1300 
Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N 
KpnI 
Acc65I                                                                                        PmlI 
|                                                                                             | 
AC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GA  < 1400 
T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L   R   L   K   L   K   V   E   Q   H   V   E 
G CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA  < 1500 
L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F   D   V   T   G 
GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC A  < 1600 
V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I 
BstXI 
| 
TC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CA  < 1700 
N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A   Q 
EcoRI   >MMMP Site                                             BlpI   NotI      >mEPO 
|       |                                                      |      |     | 
G CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CTC TGT GCT CCC CCA CGC CTC ATC TGC  < 1800 
H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   L   C   A   P   P   R   L   I   C 
PpumI 
| 
GAC AGT CGA GTT CTG GAG AGG TAC ATC TTA GAG GCC AAG GAG GCA GAA AAT GTC ACG ATG GGT TGT GCA GAA GGT CCC AGA CTG AGT GAA AAT ATT ACA G  < 1900 
D   S   R   V   L   E   R   Y   I   L   E   A   K   E   A   E   N   V   T   M   G   C   A   E   G   P   R   L   S   E   N   I   T   V 
<AjuI 
<BaeI 
|    | 
TC CCA GAT ACC AAA GTC AAC TTC TAT GCT TGG AAA AGA ATG GAG GTG GAA GAA CAG GCC ATA GAA GTT TGG CAA GGC CTG TCC CTG CTC TCA GAA GCC AT  < 2000 
P   D   T   K   V   N   F   Y   A   W   K   R   M   E   V   E   E   Q   A   I   E   V   W   Q   G   L   S   L   L   S   E   A   I 
BmtI 
SbfI                    NheI                                                                                      <BarI 
|                       |                                                                                          | 
C CTG CAG GCC CAG GCC CTG CTA GCC AAT TCC TCC CAG CCA CCA GAG ACC CTT CAG CTT CAT ATA GAC AAA GCC ATC AGT GGT CTA CGT AGC CTC ACT TCA  < 2100 
L   Q   A   Q   A   L   L   A   N   S   S   Q   P   P   E   T   L   Q   L   H   I   D   K   A   I   S   G   L   R   S   L   T   S 
 
CTG CTT CGG GTA CTG GGA GCT CAG AAG GAA TTG ATG TCG CCT CCA GAT ACC ACC CCA CCT GCT CCA CTC CGA ACA CTC ACA GTG GAT ACT TTC TGC AAG C  < 2200 
L   L   R   V   L   G   A   Q   K   E   L   M   S   P   P   D   T   T   P   P   A   P   L   R   T   L   T   V   D   T   F   C   K   L 
XbaI       <SP6 
|                     | 
TC TTC CGG GTC TAC GCC AAC TTC CTC CGG GGG AAA CTG AAG CTG TAC ACG GGA GAG GTC TGC AGG AGA GGG GAC AGG TGA GGT CTA GAG GGC CCT ATT CT  < 2300 
F   R   V   Y   A   N   F   L   R   G   K   L   K   L   Y   T   G   E   V   C   R   R   G   D   R   * 
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Annotated sequence of LAP-MMP-mIGF1A in pcDNA3. 
>CMV Promoter (3’ end)                                    >T7                                 HindIII >LAP 
|                                                         |                                   |       | 
G TCT ATA TAA GCA GAG CTC TCT GGC TAA CTA GAG AAC CCA CTG CTT ACT GGC TTA TCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT ATG CCG  < 900 
M   P 
>AarI 
| 
CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT A  < 1000 
P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I 
TC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CC  < 1100 
D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P   S   Q   G   E   V   P 
BsrGI                                                                      Bsu36I 
|                                                                          | 
G CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC  < 1200 
P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D 
AleI 
| 
TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC A  < 1300 
Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N 
Acc65I 
>LAP                KpnI                                                                                              PmlI 
|                   |                                                                                                 | 
AC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC GT  < 1400 
T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H   V 
G GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC  < 1500 
E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F   D   V   T 
GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG G  < 1600 
G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D 
BstXI 
| 
AC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GC  < 1700 
I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A 
EcoRI   >MMP site   BamHI                                            NotI       >mIGF1A 
|       |           |                                                |          | 
C CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCg gcc gca gga cca gag acc ctt tgc ggg gct  < 1800 
Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   G   P   E   T   L   C   G   A 
EcoNI 
| 
gag ctg gtg gat gct ctt cag ttc gtg tgt gga ccg agg ggc ttt tac ttc aac aag ccc aca ggc tat ggc tcc agc att cgg agg gca cct cag aca g  < 1900 
E   L   V   D   A   L   Q   F   V   C   G   P   R   G   F   Y   F   N   K   P   T   G   Y   G   S   S   I   R   R   A   P   Q   T   G 
BspEI 
| 
gc att gtg gat gag tgt tgc ttc cgg agc tgt gat ctg agg aga ctg gag atg tac tgt gcc cca ctg aag cct aca aaa gca gcc cgc tct atc cgt gc  < 2000 
         I   V   D   E   C   C   F   R   S   C   D   L   R   R   L   E   M   Y   C   A   P   L   K   P   T   K   A   A   R   S   I   R   A 
c cag cgc cac act gac atg ccc aag act cag aag gaa gta cat ttg aag aac aca agt aga gga agt gca gga aac aag acc tac aga atg tag AGG AAG  < 2100 
Q   R   H   T   D   M   P   K   T   Q   K   E   V   H   L   K   N   T   S   R   G   S   A   G   N   K   T   Y   R   M   * 
XbaI                   <SP6                                                >bGH PA 
|                      |                                                   | 
TGC AGG AAA CAA GAC CTA CAG AAT GTA GTc tag AGG GCC CTA TTC TAT AGT GTC ACC TAA ATG CTA GAG CTC GCT GAT CAG CCT CGA CTG TGC CTT CTA G  < 2200 
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Annotated sequence of LAP-MMP-mIGF1B in pcDNA3. 
>CMV Promoter (3’ end)                                    >T7                                 HindIII >LAP 
|                                                         |                                   |       | 
G TCT ATA TAA GCA GAG CTC TCT GGC TAA CTA GAG AAC CCA CTG CTT ACT GGC TTA TCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT ATG CCG  < 900 
       M   P 
>AarI  <BcgI 
|      | 
CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT A  < 1000 
P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I 
TC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CC  < 1100 
D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R   L   A   S   P   P   S   Q   G   E   V   P 
BsrGI                                                                      Bsu36I 
|                                                                          | 
G CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC  < 1200 
P G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E   P   E   A   D 
AleI 
| 
TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC A  < 1300 
Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N 
KpnI 
Acc65I                                                                                            PmlI 
|                                                                                                 | 
AC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC GT  < 1400 
T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L   R   R   L   K   L   K   V   E   Q   H   V 
G GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC  < 1500 
E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F   D   V   T 
GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG G  < 1600 
G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D 
BstXI 
| 
AC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GC  < 1700 
I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L   L   L   M   A   T   P   L   E   R   A 
EcoRI   >MMP site   BamHI                                           NotI        >mIGF1B 
|       |            |                                               |          | 
C CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCg gcc gca GGA CCA GAG ACC CTT TGC ggg gct  < 1800 
Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   G   P   E   T   L   C   G   A 
EcoNI 
| 
gag ctg gtg gat gct ctt cag ttc gtg tgt gga ccg agg ggc ttt tac ttc aac aag ccc aca ggc tat ggc tcc agc att cgg agg gca cct cag aca g  < 1900 
E   L   V   D   A   L   Q   F   V   C   G   P   R   G   F   Y   F   N   K   P   T   G   Y   G   S   S   I   R   R   A   P   Q   T   G 
BspEI 
| 
gc att gtg gat gag tgt tgc ttc cgg agc tgt gat ctg agg aga ctg gag atg tac tgt gcc cca ctg aag cct aca aaa gca gcc cgc tct atc cgt gc  < 2000 
I   V   D   E   C   C   F   R   S   C   D   L   R   R   L   E   M   Y   C   A   P   L   K   P   T   K   A   A   R   S   I   R   A 
<RpaB5I 
| 
c cag cgc cac act gac atg ccc aag act cag aag tcc ccg tcc cta tcg aca aac aag aaa acg aag ctg caa agg aga agg aaa gga aGT ACA TTT GAA  < 2100 
Q   R   H   T   D   M   P   K   T   Q   K   S   P   S   L   S   T   N   K   K   T   K   L   Q   R   R   R   K   G   S   T   F   E 
XbaI                   <SP6 
|                      | 
GAA CAC AAG TAG AGG AAG TGC AGG AAA CAA GAC CTA CAG AAT GTA GTc tag AGG GCC CTA TTC TAT AGT GTC ACC TAA ATG CTA GAG CTC GCT GAT CAG C  < 2200 
E   H   K   *   R   K   C   R   K   Q   D   L   Q   N   V   V   *   R   A   L   F   Y   S   V   T   *   M   L   E   L   A   D   Q   P 
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Annotated sequence of LAP-MMP-huTGFβ 
>LAP 
| 
C TCC GAC AGA CTG AGT CGC CCG GGG GGG ATC TCC ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG  < 600 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T 
>AarI             >ApyPI 
|                 | 
CCT GGC CGG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC A  < 700 
P   G   R   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K 
AG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GC  < 800 
L   R   L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A 
Bsu36I                                AleI                           >RleAI 
|                                     |                              | 
C GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC  < 900 
G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D 
Acc65I 
KpnI 
| 
AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG C  < 1000 
K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R 
<BpuEI                      PmlI                                                             >AlfI 
|                           |                                                                | 
GT CTG CTG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CC  < 1100 
L   L   R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P 
C AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC  < 1200 
S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H 
TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG C  < 1300 
C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P 
>MMP site 
>EciI       >BsrBI        <PspOMII           BlpI 
|       |           |             |                  | 
CT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GG  < 1400 
F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G 
>MaqI 
<AjuI        <AcuI         >TspGWI                               <BarI 
|            |             |                                     |   | 
C TCA GCG GCC GCA GCC CTG GAC ACC AAC TAT TGC TTC AGC TCC ACG GAG AAG AAC TGC TGC GTG CGG CAG CTG TAC ATT GAC TTC CGC AAG GAC CTC GGC  < 1500 
S   A   A   A   A   L   D   T   N   Y   C   F   S   S   T   E   K   N   C   C   V   R   Q   L   Y   I   D   F   R   K   D   L   G 
>BssSI                                                                                       >huTGFB 
|                                                                                            | 
TGG AAG TGG ATC CAC GAG CCC AAG GGC TAC CAT GCC AAC TTC TGC CTC GGG CCC TGC CCC TAC ATT TGG AGC CTG GAC ACG CAG TAC AGC AAG GTC CTG G  < 1600 
W   K   W   I   H   E   P   K   G   Y   H   A   N   F   C   L   G   P   C   P   Y   I   W   S   L   D   T   Q   Y   S   K   V   L   A 
CC CTG TAC AAC CAG CAT AAC CCG GGC GCC TCG GCG GCG CCG TGC TGC GTG CCG CAG GCG CTG GAG CCG CTG CCC ATC GTG TAC TAC GTG GGC CGC AAG CC  < 1700 
L   Y   N   Q   H   N   P   G   A   S   A   A   P   C   C   V   P   Q   A   L   E   P   L   P   I   V   Y   Y   V   G   R   K   P 
MreI 
<BsaXI                                                            SgrAI                             BsaBI   >NlaCI 
|                                                                 |                                 |       | 
C AAG GTG GAG CAG CTG TCC AAC ATG ATC GTG CGC TCC TGC AAG TGC AGC TGA TGA CGC CGG CGT CCA AGC CGA ATT CTG CAG ATA TCC ATC ACA CTG GCG  < 1800 
K   V   E   Q   L   S   N   M   I   V   R   S   C   K   C   S   *   * 
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Annotated sequence of LAP-MMP-mEPO  
>LAP 
| 
C TCC GAC AGA CTG AGT CGC CCG GGG GGG ATC TCC ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG  < 600 
S   D   R   L   S   R   P   G   G   I   S   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T 
<BcgI      >ApyPI 
|          | 
CCT GGC CGG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC A  < 700 
P   G   R   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K 
AG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GC  < 800 
L   R   L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A 
Bsu36I                                AleI                           >RleAI 
|                                     |                              | 
C GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC  < 900 
G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D 
Acc65I 
KpnI 
| 
AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG C  < 1000 
K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R 
<BpuEI                      PmlI                                                             >AlfI 
|                           |                                                                | 
GT CTG CTG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CC  < 1100 
L   L   R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A   P 
LpnI 
HaeII 
| 
C AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC CAC  < 1200 
S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A   H 
TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG C  < 1300 
C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P 
PspOMI 
ApaI                               >MMP site   BamHI 
BaeGI                                      >EciI       >BsrBI        <PspOMII           BlpI 
|                                  |       |   |       |             |                  | 
CT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GG  < 1400 
F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G   G 
DraIII     >mEPO 
|          | 
C TCA GCG GCC GCA CTC TGT GCT CCC CCA CGC CTC ATC TGC GAC AGT CGA GTT CTG GAG AGG TAC ATC TTA GAG GCC AAG GAG GCA GAA AAT GTC ACG ATG  < 1500 
S   A   A   A   L   C   A   P   P   R   L   I   C   D   S   R   V   L   E   R   Y   I   L   E   A   K   E   A   E   N   V   T   M 
<AjuI 
SspI                <BaeI 
|                   |    | 
GGT TGT GCA GAA GGT CCC AGA CTG AGT GAA AAT ATT ACA GTC CCA GAT ACC AAA GTC AAC TTC TAT GCT TGG AAA AGA ATG GAG GTG GAA GAA CAG GCC A  < 1600 
G   C   A   E   G   P   R   L   S   E   N   I   T   V   P   D   T   K   V   N   F   Y   A   W   K   R   M   E   V   E   E   Q   A   I 
BmtI 
StuI                                                        NheI                              <BsaI 
|                                                           |                                 | 
TA GAA GTT TGG CAA GGC CTG TCC CTG CTC TCA GAA GCC ATC CTG CAG GCC CAG GCC CTG CTA GCC AAT TCC TCC CAG CCA CCA GAG ACC CTT CAG CTT CA  < 1700 
E   V   W   Q   G   L   S   L   L   S   E   A   I   L   Q   A   Q   A   L   L   A   N   S   S   Q   P   P   E   T   L   Q   L   H 
<BarI 
SnaBI                                >BmrI 
|   |                                | 
T ATA GAC AAA GCC ATC AGT GGT CTA CGT AGC CTC ACT TCA CTG CTT CGG GTA CTG GGA GCT CAG AAG GAA TTG ATG TCG CCT CCA GAT ACC ACC CCA CCT  < 1800 
I   D   K   A   I   S   G   L   R   S   L   T   S   L   L   R   V   L   G   A   Q   K   E   L   M   S   P   P   D   T   T   P   P 
>EarI 
>SapI                       <AquIV 
| |                         | 
GCT CCA CTC CGA ACA CTC ACA GTG GAT ACT TTC TGC AAG CTC TTC CGG GTC TAC GCC AAC TTC CTC CGG GGG AAA CTG AAG CTG TAC ACG GGA GAG GTC T  < 1900 
A   P   L   R   T   L   T   V   D   T   F   C   K   L   F   R   V   Y   A   N   F   L   R   G   K   L   K   L   Y   T   G   E   V   C 
GC AGG AGA GGG GAC AGG TGA GGT CTA GTG ACG CCG GCG TCC AAG CCG AAT TCT GCA GAT ATC CAT CAC ACT GGC GGC CGC GAC TCT AGA GTC GAC CTG CA  < 2000 
R   R   G   D   R   * 
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Annotated sequence of LAP-MMP-mIGF1A 
>LAP 
| 
C TCC GAC AGA CTG AGT CGC CCG GGG GGG ATC TCC ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG  < 600 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T 
>AarI             >ApyPI                                >CdiI                   <Bsp24I 
|                 |                                     |                       | 
CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC A  < 700 
P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K 
BsrGI 
| 
AG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GC  < 800 
L   R   L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A 
Bsu36I                                AleI 
|                                     | 
C GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC  < 900 
G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D 
Acc65I 
KpnI 
| 
AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG C  < 1000 
K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R 
HpyCH4IV 
TaiI 
PmlI 
>BdaI      <BpuEI                      BsaAI                                                            >AlfI 
|          |                           ||                                                               | 
GT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GC  < 1100 
L   L   R   R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A 
A CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC  < 1200 
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A 
CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC C  < 1300 
H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R 
ApaI                                           BamHI                 <PspOMII 
PspOMI                         >MMP site   >EciI 
|                              |           |   |                     | 
GG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GG  < 1400 
P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G 
>mIGF1A                                           >EarI 
<BsaI                                   >SapI                    >TaqII 
|       |                                       ||                       | 
G GGC TCA GCG GCC GCA GGA CCA GAG ACC CTT TGC GGG GCT GAG CTG GTG GAT GCT CTT CAG TTC GTG TGT GGA CCG AGG GGC TTT TAC TTC AAC AAG CCC  < 1500 
G   S   A   A   A   G   P   E   T   L   C   G   A   E   L   V   D   A   L   Q   F   V   C   G   P   R   G   F   Y   F   N   K   P 
<BsmI    >BplI     EcoNI                                    BspEI                                       HpyCH4III 
|        |         |                                        |                                           | 
ACA GGC TAT GGC TCC AGC ATT CGG AGG GCA CCT CAG ACA GGC ATT GTG GAT GAG TGT TGC TTC CGG AGC TGT GAT CTG AGG AGA CTG GAG ATG TAC TGT G  < 1600 
T   G   Y   G   S   S   I   R   R   A   P   Q   T   G   I   V   D   E   C   C   F   R   S   C   D   L   R   R   L   E   M   Y   C   A 
<TspGWI                                          <HpyAV                                 >AquIV 
|                                                |                                      | 
CC CCA CTG AAG CCT ACA AAA GCA GCC CGC TCT ATC CGT GCC CAG CGC CAC ACT GAC ATG CCC AAG ACT CAG AAG GAA GTA CAT TTG AAG AAC ACA AGT AG  < 1700 
P   L   K   P   T   K   A   A   R   S   I   R   A   Q   R   H   T   D   M   P   K   T   Q   K   E   V   H   L   K   N   T   S   R 
 
A GGA AGT GCA GGA AAC AAG ACC TAC AGA ATG TAG TGA CGC CGG CGT CCA AGC CGA ATT CTG CAG ATA TCC ATC ACA CTG GCG GCC GCG ACT CTA GAG TCG  < 1800 
G   S   A   G   N   K   T   Y   R   M   * 
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Annotated sequence of LAP-MMP-mIGF1B  
>LAP 
| 
C TCC GAC AGA CTG AGT CGC CCG GGG GGG ATC TCC ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA CTG GTG CTG ACG  < 600 
M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L   L   V   L   T 
>AarI  <BcgI                                            >CdiI                   <Bsp24I 
|      |                                                |                       | 
CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC TGC AAG ACT ATC GAC ATG GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC A  < 700 
P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M   E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K 
BsrGI 
| 
AG CTG CGG CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GC  < 800 
L   R   L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L   A   L   Y   N   S   T   R   D   R   V   A 
>BsgI                      Bsu36I                                AleI 
|                          |                                     | 
C GGG GAG AGT GCA GAA CCG GAG CCC GAG CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC GAA ATC TAT GAC  < 900 
G   E   S   A   E   P   E   P   E   P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N   E   I   Y   D 
Acc65I 
KpnI 
| 
AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG C  < 1000 
K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S   E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R 
TaiI 
BsaAI 
>BdaI      <BpuEI                      PmlI                                                             >AlfI 
|          |                           ||                                                               | 
GT CTG CTG AGG AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC TGG CGA TAC CTC AGC AAC CGG CTG CTG GC  < 1100 
L   L   R   R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S   W   R   Y   L   S   N   R   L   L   A 
A CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC CTT AGC GCC  < 1200 
P   S   D   S   P   E   W   L   S   F   D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R   L   S   A 
CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC C  < 1300 
H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G   F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R 
PspOMI                         >MMP site       BamHI                 <PspOMII 
ApaI                                       >EciI 
|                              |           |   |            |        | 
GG CCT TTC CTG CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC GGA TCC CCG CTC GGG CTT TGG GCG GGA GG  < 1400 
P   F   L   L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G   G   S   P   L   G   L   W   A   G   G 
>mIGF1B                                         >EarI 
<BsaI                                   >SapI                    >TaqII 
|       |                                       ||                       | 
G GGC TCA GCg gcc gca GGA CCA GAG ACC CTT TGC ggg gct gag ctg gtg gat gct ctt cag ttc gtg tgt gga ccg agg ggc ttt tac ttc aac aag ccc  < 1500 
G   S   A   A   A   G   P   E   T   L   C   G   A   E   L   V   D   A   L   Q   F   V   C   G   P   R   G   F   Y   F   N   K   P 
<BsmI    >BplI     EcoNI                                    BspEI                                       HpyCH4III 
|        |         |                                        |                                           | 
aca ggc tat ggc tcc agc att cgg agg gca cct cag aca ggc att gtg gat gag tgt tgc ttc cgg agc tgt gat ctg agg aga ctg gag atg tac tgt g  < 1600 
T   G   Y   G   S   S   I   R   R   A   P   Q   T   G   I   V   D   E   C   C   F   R   S   C   D   L   R   R   L   E   M   Y   C   A 
<TspGWI                                              <RpaB5I 
|                                                    | 
cc cca ctg aag cct aca aaa gca gcc cgc tct atc cgt gcc cag cgc cac act gac atg ccc aag act cag aag tcc ccg tcc cta tcg aca aac aag aa  < 1700 
P   L   K   P   T   K   A   A   R   S   I   R   A   Q   R   H   T   D   M   P   K   T   Q   K   S   P   S   L   S   T   N   K   K 
MreI 
<HpyAV                                             SgrAI                             BsaBI   >NlaCI 
|                                                  |                                 |       | 
a acg aag ctg caa agg aga agg aaa gga agt aca ttT GAA GAA CAC AAG TAG TGA CGC CGG CGT CCA AGC CGA ATT CTG CAG ATA TCC ATC ACA CTG GCG  < 1800 
T   K   L   Q   R   R   R   K   G   S   T   F   E   E   H   K   * 
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APPENDIX 2 
NCBI Accession Numbers 
 
Table A.1: NCBI accession numbers. 
Protein Definition Reference Seq 
(DNA) 
Size Reference Seq 
(Protein) 
Size 
huTGFβ 
transforming growth factor beta-1 precursor [Homo sapiens] 
NM_000660 
 
2217 bp 
 
NP_000651 
 
390 aa 
mEPO 
erythropoietin precursor [Mus musculus] 
NM_007942 
 
715 bp NP_031968 
 
192 aa 
mIGF1A 
insulin-like growth factor I isoform 4 preproprotein [Mus musculus] 
NM_001111275 
 
7069 bp NP_001104745 
 
153 aa 
mIGF1B 
insulin-like growth factor I isoform 1 preproprotein [Mus musculus] 
NM_010512.4 7121 bp NP_034642 
 
159 aa 
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APPENDIX 3 
 
Aggregating cultures of rat brain cells  
Hypothesis 
The in vitro model of aggregating neural cell cultures consists of primary three-dimentional neural 
cells that have spontaneously aggregated following physical dissociation. They are able to 
differentiate and develop specialized structures such as synapes and myelinated neurons when 
cultured under the right conditions. Experiments using this model were anticipated to test the 
hypothesis that the latent recombinant proteins LAP-MMP-mEPO, LAP-MMP-huTGFβ and LAP-MMP-
mIGF1 help prevent myelin loss and/or aid in the process of remyelination following incubation with 
MMP enzyme.  
Analysis of Aggregating Neural Cell Cultures 
Due to the high reproducibility of the cultures, and the possibility of producing numerous replicates 
of the cultures, a wide variety of analysis such as immunocytochemistry, histochemistry, electron 
microscopy, autoradiography, and biochemical analysis is possible. Biochemical analyses in this 
model allows for the testing of enzymatic activities, total protein and DNA content; mitotic activity; 
protein expression; ELISA and radioimmunoassay; and subcellular fractions (e.g. for the quantitative 
extraction of myelin).  
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Materials 
Pucks D1 solution  
NaCL      8g/L 
KCl      400mg/L 
Na2HPO4 ·7H2O     45mg/L 
KH2PO4      30mg/L 
D-Glucose     1g/L 
Sucrose, pH 7.4, 340 mOsm   20g/L 
Store at 4°C until required then add 25mg/L gentamicin-sulfate, pH 7.4 
 
Serum-free culture medium 
The protocol for the preparation of 10L serum-free culture medium is as follows: 
1) Purchase powdered DMEM containing high glucose (4.5g/L) and L-glutamine, without 
bicarbonate and pyruvate for 10L. 
2) Supplement with  choline chloride (1.35g), L-Carnitine (20mg), Lipoic acid (2mg) and Vitamin B12 
(13.6mg). 
3) Add 1ml of each of the following 104-fold concentrated stock solutions (stored frozen at -20°C) 
CdSO4·8H2O   50μM 
CuSO4·5H2O   100μM 
MnCl3·4H2O    50μM 
Na2·SeO3    150 μM 
(NH4)6Mo7O24·4H2O   5μM 
NiSO4·6H2O    2.5μM 
SnCl2·2H2O    2.5μM 
ZnSO4·7H2O    50μM 
4) Adjust the pH close to the final pH with NaOH (1N). 
5) Add sodium bicarbonate (3.7g/L) and gas immediately with 10% CO2 in air until pH is adjusted to 
7.4. 
6) Adjust the osmolarity of the medium to 340 ± 2mOsm by adding water. 
7) Sterilize and store at 4°C in the dark in 500ml bottles.  
8) Prior to use, add the following supplements to complete the medium: 
Basal Medium (Eagle) [BME] vitamins (100x stock) 
Transferrin    1mg/L final concentration 
Triiodothyronine    30nM final concentration 
Insulin    5mg/L final concentration 
Hydrocortisone-21-phosphate  20nM final concentration 
Linoleic acid   3mg/L final concentration 
Gentamicin sulfate   25mg/L final concentration 
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Barbitone buffer 
The protocol for the preparation of barbitol buffer is as follows: 
 
1) Dissolve barbital sodium (12g) in 800ml distilled water. 
2) Dissolve barbital (4.4g) in 150ml distilled water. 
3) Mix both solutions together and adjust pH to 8.2 with NaOH (1N). 
4) Add merthiolate (0.15g) and adjust final volume to 1L.  
Methods 
Embryo’s were removed from pregnant Sprague-Dawley rats on embryonic day 16 following 
decapitation and placed into ice cold Puck’s D1 solution. The brain was removed and the 
telencephalon dissected out and placed into ice-cold sterile D1 solution. The telencephalons were 
progressively dissociated by sequential sieving through 200m nylon mesh fitted with a glass funnel, 
followed by 100m nylon mesh (Nybolt, Zurich Switzerland). 
The filtrates were washed twice with ice-cold D1 solution and centrifuged (300 xg, 15 min, 4C). The 
pellet was resuspended by trituration in cold serum-free culture medium and cell viability 
determined by 0.1% Trypan Blue exclusion before diluting to a density of 2.5x107 cells per 25 ml 
flask. The cultures were incubated at 37C at a 10% CO2 humidified atmosphere under constant 
rotation (68rpm to 70rpm; Kuhner Shaker, Philip Harris Scientific). The rotation speed was increased 
during the first week to a maximum rotation of 80rpm to ensure optimum cell aggregation. The 
initial day of seeding is termed day in vitro 0 (DIV=0). The culture was transferred to 50ml culture 
flasks on DIV=2 and the total culture medium volume doubled to 8ml.  
Regular replenishment of the culture medium was done every third day from DIV=5 to DIV=14, and 
every other day thereafter. The cell cultures were subdivided on DIV=20 due to the increase in 
metabolic activity of the maturing aggregates. An equivalent number of culture flasks were placed 
into the incubator 1 hour prior to subculturing. The aggregates were resuspended by gentle 
aspiration using a pipette before being placed into new prewarmed flasks and the total volume 
doubled to 8ml.  
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Either Z12 derived anti-MOG antibody in PBS (31.3g/ml) plus complement (25g/ml guinea pig 
serum [GPS]) were added to cultures on DIV=26 for 4 days with a medium feed and fresh addition of 
anti-MOG antibody after 48 hours, or lentivirus (20μl/8ml; LAP-MMP-mEPO or LAP-MMP) was added 
once and the culture left for 4 days before replacing with fresh medium. The demyelinating agents 
were removed by replacing the culture medium twice with fresh prewarmed culture medium. 
Control cultures received subclass specific IgG2a (Sigma-Aldrich) plus GPS. Samples of aggregates 
were taken at DIV=26, 28 and 48 and washed in sterile barbitone buffer before being stored at -
20C. Prior to analyses by ELISA, the aggregates were resuspended in 500l Tissue Protein Extraction 
Reagent (T-PER; Pierbio Science UK, Northumberland, UK) containing HALT® Protein Inhibitor 
Cocktail (Pierbio Science UK, Northumberland, UK) and homogenised for 30sec. The total protein 
concentration was assayed using the BCA protein concentration assay as described previously.  
Results   
Unfortunately the samples were lost before performing the ELISA during the move of laboratories. 
The cost involved in performing this experiment and the time required prevented me from repeating 
this experiment.  
